var title_f16_28_16832="Adhesive small bowel obstruction on computed tomography";
var content_f16_28_16832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adhesive small bowel obstruction on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 203px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) of the abdomen&nbsp;demonstrates small bowel obstruction due to adhesive disease. The transition point is shown (white arrow).&nbsp;&nbsp;",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Imaging. Copyright &copy; British Institute of Radiology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16832=[""].join("\n");
var outline_f16_28_16832=null;
var title_f16_28_16833="Patient information: Tourette syndrome (The Basics)";
var content_f16_28_16833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Tourette syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/tourette-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10195103\">",
"      <span class=\"h1\">",
"       What is Tourette syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Tourette syndrome is a rare disorder that causes people to make unusual movements or sounds, called &ldquo;tics.&rdquo; Common examples of tics include blinking and throat clearing. People with the disorder have little or no control over their tics. Many people with Tourette syndrome have mild symptoms, but some have more severe ones.",
"     </p>",
"     <p>",
"      Most people with Tourette syndrome start showing signs of the disorder before they are 11 years old. In about half of children with Tourette syndrome, the tics go away by the time they turn 18. But in some people, the tics return later in life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195118\">",
"      <span class=\"h1\">",
"       What are the symptoms of Tourette syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Motor tics &ndash; These are tics that involve unusual movements. They can be mild (called &ldquo;simple motor tics&rdquo;) or more extreme (called &ldquo;complex motor tics&rdquo;). Examples of motor tics include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Blinking",
"       </li>",
"       <li>",
"        Briefly making a face as if angry or in pain (called a &ldquo;grimace&rdquo;)",
"       </li>",
"       <li>",
"        Shrugging the shoulders",
"       </li>",
"       <li>",
"        Jerking the head",
"       </li>",
"       <li>",
"        Walking in a strange way",
"       </li>",
"       <li>",
"        Kicking, jumping, or moving the body in odd ways",
"       </li>",
"       <li>",
"        Scratching",
"       </li>",
"       <li>",
"        Making obscene gestures",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Vocal tics &ndash; These are tics that involve unusual sounds or words, or phrases that don&rsquo;t make sense or seem odd. Examples include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Throat-clearing, grunting, or other noises",
"       </li>",
"       <li>",
"        Swearing",
"       </li>",
"       <li>",
"        Repeating words or phrases (including echoing what other people say)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with Tourette syndrome often know that they are going to have a tic before it happens.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195133\">",
"      <span class=\"h1\">",
"       Is there a test for Tourette syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But your doctor or nurse should be able to tell if you or your child has it by learning about the symptoms. Most people with Tourette syndrome have a normal physical exam. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195148\">",
"      <span class=\"h1\">",
"       How is Tourette syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Children and adults with Tourette syndrome don&rsquo;t need medical treatment unless their tics are severe. A person with Tourette syndrome might need treatment if he or she is having problems:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Talking with other people",
"       </li>",
"       <li>",
"        Attending school or working at a job",
"       </li>",
"       <li>",
"        Doing everyday things such as bathing, dressing, and eating",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &ndash; Certain medicines used to treat different mental health conditions can lower the number of tics a person has.",
"       </li>",
"       <li>",
"        Botulinum toxin (brand name: Botox&reg;) &ndash; This is a medicine that is given by injection. It works by blocking or calming the nerve signals that make the muscles jerk or twitch.",
"       </li>",
"       <li>",
"        Habit reversal training &ndash; This treatment involves working with a therapist, who teaches people with Tourette syndrome to recognize when they are about to have a tic. Then, the people train themselves to do a different movement that makes it hard to do the tic. This treatment is not available everywhere.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10195163\">",
"      <span class=\"h1\">",
"       How can I learn more about Tourette syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;More information is available online from the Tourette Syndrome Association at",
"      <a class=\"external\" href=\"file://www.tsa-usa.org/\">",
"       www.tsa-usa.org",
"      </a>",
"      . It&rsquo;s also important to make sure that family, friends, teachers, and co-workers of people with Tourette syndrome learn about the disorder.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/28/16833?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83754 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16833=[""].join("\n");
var outline_f16_28_16833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195103\">",
"      What is Tourette syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195118\">",
"      What are the symptoms of Tourette syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195133\">",
"      Is there a test for Tourette syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195148\">",
"      How is Tourette syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10195163\">",
"      How can I learn more about Tourette syndrome?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_28_16834="PIV seasonality";
var content_f16_28_16834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Reported percentages of positive parainfluenza virus tests in the United States, July 1990-June 2004",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 451px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The percentage of tests positive for parainfluenza virus (PIV) serotypes 1, 3, 2, and 4 reported to the National Respiratory and Enteric Viruses Surveillance System (NREVSS) in the United States, by week, July 1990-June 2004. The percentage of antigen detection tests positive for respiratory syncytial virus (RSV) reported to NREVSS is shown for comparison. (Note that RSV and PIV-4 have different axis scales than the other PIV serotypes.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fry AM, Curns AT, Harbour K, et al. Seasonal trends of human parainfluenza viral infections: United States, 1990-2004. Clin Infect Dis 2006; 43:1016-22.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16834=[""].join("\n");
var outline_f16_28_16834=null;
var title_f16_28_16835="CT scan infrarenal aortic aneurysm with eccentric thrombus";
var content_f16_28_16835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    CT scan infrarenal aortic aneurysm with eccentric thrombus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axial CT image shows&nbsp;an infrarenal abdominal aortic aneurysm, which measures&nbsp;&nbsp;3.2 cm. Eccentric mural thrombus is seen adjacent the&nbsp;contrast-enhanced lumen (arrow).",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16835=[""].join("\n");
var outline_f16_28_16835=null;
var title_f16_28_16836="Ca oxalate monohydrate crystals";
var content_f16_28_16836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67694%7ENEPH%2F65169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67694%7ENEPH%2F65169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urinary calcium oxalate monohydrate crystals under polarized light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment viewed under polarized light showing coarse, needle-shaped calcium oxalate monohydrate crystals. These crystals have a similar appearance to hippurate crystals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of W Merrill Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcium oxalate crystals in the urine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing both dumbbell-shaped calcium oxalate monohydrate (long arrow) and envelope-shaped calcium oxalate dihydrate (short arrows) crystals. Although not shown, the monohydrate crystals may also have a needle-shaped appearance. The formation of calcium oxalate crystals is independent of the urine pH.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16836=[""].join("\n");
var outline_f16_28_16836=null;
var title_f16_28_16837="Bismuth subsalicylate, metronidazole, and tetracycline: Patient drug information";
var content_f16_28_16837=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bismuth subsalicylate, metronidazole, and tetracycline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31733?source=see_link\">",
"     see \"Bismuth subsalicylate, metronidazole, and tetracycline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Helidac&reg;;",
"     </li>",
"     <li>",
"      Pylera&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bismuth, metronidazole, salicylates, tetracycline, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Kidney disease or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, calcium, iron, magnesium, zinc, multivitamins with minerals, colestipol, cholestyramine, didanosine, or antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Do not take alcohol for at least 24 hours after the last dose. Drinking alcohol or products that have alcohol, such as cough syrup, may cause cramps, upset stomach, headaches, and flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698374",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in tongue color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Helidac&reg;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chew bismuth tablets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow metronidazole tablets and tetracycline capsules whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705514",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Pylera&trade;:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11210 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16837=[""].join("\n");
var outline_f16_28_16837=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141573\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019728\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019730\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019729\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019734\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019735\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019737\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019732\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019733\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019738\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019739\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31733?source=related_link\">",
"      Bismuth subsalicylate, metronidazole, and tetracycline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_28_16838="Norepinephrine (noradrenaline): Drug information";
var content_f16_28_16838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Norepinephrine (noradrenaline): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/53/10067?source=see_link\">",
"    see \"Norepinephrine (noradrenaline): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"    see \"Norepinephrine (noradrenaline): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levophed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levophed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F202432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F202407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Administration requires the use of an infusion pump.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Norepinephrine dosage is stated in terms of norepinephrine base.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypotension/shock:",
"     </b>",
"     Continuous I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 8-12 mcg/minute; titrate to desired response. Usual maintenance range: 2-4 mcg/minute; dosage range varies greatly depending on clinical situation. If patient remains hypotensive despite large doses, evaluate for occult hypovolemia and provide fluid resuscitation as appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      ACLS dosing range (weight-based dosing):",
"     </i>",
"     Post cardiac arrest care: Initial: 0.1-0.5 mcg/",
"     <b>",
"      kg",
"     </b>",
"     /minute (7-35 mcg/minute in a 70 kg patient); titrate to desired response (AHA, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sepsis and septic shock (weight-based dosing):",
"     </i>",
"     Range from clinical trials: 0.01-3 mcg/",
"     <b>",
"      kg",
"     </b>",
"     /minute (0.7-210 mcg/minute in a 70 kg patient) (Hollenberg, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F202422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"      see \"Norepinephrine (noradrenaline): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Administration requires the use of an infusion pump.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Norepinephrine dosage is stated in terms of norepinephrine base.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypotension/shock:",
"     </b>",
"     Continuous I.V. infusion: Initial: 0.05-0.1 mcg/kg/minute; titrate to desired effect; maximum dose: 2 mcg/kg/minute (AHA, 2010; Kleinman, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F202408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [strength expressed as base]: 1 mg/mL (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levophed&reg;: 1 mg/mL (4 mL) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F202388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Administer as a continuous infusion with the use of an infusion pump.",
"     </b>",
"     Dilute prior to use. Administration via central line recommended; may cause severe ischemic necrosis if extravasated. Do not administer sodium bicarbonate (or any alkaline solution) through an I.V. line containing norepinephrine; inactivation of norepinephrine may occur.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14473011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     4 mg in 250 mL (concentration: 16",
"     <b>",
"      mcg",
"     </b>",
"     /mL)",
"     <b>",
"      or",
"     </b>",
"     8 mg in 250 mL (concentration: 32",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     8",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     16",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F202438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, anidulafungin, argatroban, bivalirudin, caspofungin, cisatracurium, clonidine, dexmedetomidine, diltiazem, dobutamine, dopamine, doripenem, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, furosemide, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, inamrinone, labetalol, lorazepam, meropenem, micafungin, midazolam, milrinone, morphine, mycophenolate, nicardipine, nitroglycerin, nitroprusside, potassium chloride, propofol, ranitidine, remifentanil, telavancin, tigecycline, vasopressin, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Drotrecogin alfa, insulin (regular), thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide, nesiritide, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F202386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of shock which persists after adequate fluid volume replacement; severe hypotension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Levophed&reg; may be confused with levofloxacin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F202430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, bradycardia, peripheral (digital) ischemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, headache (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Skin necrosis (with extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, respiratory difficulty",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F202391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to norepinephrine, bisulfites (contains metabisulfite), or any component of the formulation; hypotension from hypovolemia except as an emergency measure to maintain coronary and cerebral perfusion until volume could be replaced; mesenteric or peripheral vascular thrombosis unless it is a lifesaving procedure; during anesthesia with cyclopropane (not available in U.S.) or halothane (not available in U.S.) anesthesia (risk of ventricular arrhythmias)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F202375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO-Inhibitors; prolong hypertension may result from concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metasulfite: Product may contain sodium metasulfite.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Assure adequate circulatory volume to minimize need for vasoconstrictors. Avoid hypertension; monitor blood pressure closely and adjust infusion rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Avoid extravasation; infuse into a large vein if possible. Avoid infusion into leg veins. Watch I.V. site closely.",
"     <b>",
"      [U.S. Boxed Warning]: If extravasation occurs, infiltrate the area with diluted phentolamine (5-10 mg in 10-15 mL of saline) with a fine hypodermic needle. Phentolamine should be administered as soon as possible after extravasation is noted.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of Norepinephrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Norepinephrine may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13376222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Norepinephrine is an endogenous catecholamine and crosses the placenta (Minzter, 2010; Wang, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F202411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levophed Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (4 mL): $3.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Norepinephrine Bitartrate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (4 mL): $4.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adine (CN);",
"     </li>",
"     <li>",
"      Adrenor (ES, IN);",
"     </li>",
"     <li>",
"      Arespin (ID);",
"     </li>",
"     <li>",
"      Arterenol (DE);",
"     </li>",
"     <li>",
"      Cardiamed (MY);",
"     </li>",
"     <li>",
"      Fioritina (AR);",
"     </li>",
"     <li>",
"      Levonor (PL, PY, UY);",
"     </li>",
"     <li>",
"      Levophed (GB, IE, LU);",
"     </li>",
"     <li>",
"      Levophed Bitartrate (AE, AU, BE, BH, BR, CY, EG, GR, IL, IQ, IR, JO, KP, KW, LB, LY, MY, NZ, OM, PH, QA, SA, SG, SY, TH, YE);",
"     </li>",
"     <li>",
"      N-Epi (ID);",
"     </li>",
"     <li>",
"      Noradrenalina (DO, GT, HN, PA);",
"     </li>",
"     <li>",
"      Noradrenalina Tartrato (IT);",
"     </li>",
"     <li>",
"      Noradrenaline (GB);",
"     </li>",
"     <li>",
"      Noradrenaline Aguettant (FR);",
"     </li>",
"     <li>",
"      Norepin (PH);",
"     </li>",
"     <li>",
"      Norepine (TW);",
"     </li>",
"     <li>",
"      Norphed (PH);",
"     </li>",
"     <li>",
"      Norpin (KP, TH);",
"     </li>",
"     <li>",
"      Rhinopront (LU);",
"     </li>",
"     <li>",
"      Vascon (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F202374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors and alpha-adrenergic receptors causing increased contractility and heart rate as well as vasoconstriction, thereby increasing systemic blood pressure and coronary blood flow; clinically, alpha effects (vasoconstriction) are greater than beta effects (inotropic and chronotropic effects)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F202390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Very rapid-acting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: vasopressor: 1-2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via catechol-o-methyltransferase (COMT) and monoamine oxidase (MAO)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (84% to 96% as inactive metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aron DC, Bravo EL, and Kapcala LP, &ldquo;Erroneous Plasma Norepinephrine Levels With Radioimmunoassay,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1983, 98(6):1023.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer PE, &ldquo;Physiology and Pathophysiology of the Human Sympathoadrenal Neuroendocrine System,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1980, 303(8):436-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/6248784/pubmed\" id=\"6248784\" target=\"_blank\">",
"        6248784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(9):1928-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/15343024/pubmed\" id=\"15343024\" target=\"_blank\">",
"        15343024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martin C, Papazian L, Perrin G, et al, &ldquo;Norepinephrine or Dopamine for the Treatment of Hyperdynamic Septic Shock?&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1993, 103(6):1826-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/8404107/pubmed\" id=\"8404107\" target=\"_blank\">",
"        8404107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Minzter BH, Johnson RF, Paschall RL, et al, \"The Diverse Effects of Vasopressors on the Fetoplacental Circulation of the Dual Perfused Human Placenta,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2010, 110(3):857-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/20032025/pubmed\" id=\"20032025\" target=\"_blank\">",
"        20032025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson Textbook of Pediatrics, 18th ed, Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds, Philadelphia, PA: WB Saunders Co, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peberdy MA, Callaway CW, Neumar RW, et al, &ldquo;Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):768-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/20956225/pubmed\" id=\"20956225\" target=\"_blank\">",
"        20956225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay M, Lessard MR, Tr&eacute;panier CA, et al, &ldquo;Stability of Norepinephrine Infusions Prepared in Dextrose and Normal Saline Solutions,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2008, 55(3):163-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/18310626/pubmed\" id=\"18310626\" target=\"_blank\">",
"        18310626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang L, Zhang W, and Zhao Y, \"The Study of Maternal and Fetal Plasma Catecholamines Levels During Pregnancy and Delivery,\"",
"      <i>",
"       J Perinat Med",
"      </i>",
"      , 1999, 27(3):195-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/28/16838/abstract-text/10503181/pubmed\" id=\"10503181\" target=\"_blank\">",
"        10503181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9709 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16838=[""].join("\n");
var outline_f16_28_16838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709175\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202404\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202432\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202407\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202422\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202408\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202385\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202371\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202388\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473011\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473012\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202438\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202386\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174558\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202430\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202391\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202375\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299773\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202380\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202382\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376222\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202411\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323542\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038708\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202374\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202390\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9709\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9709|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/53/10067?source=related_link\">",
"      Norepinephrine (noradrenaline): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=related_link\">",
"      Norepinephrine (noradrenaline): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_28_16839="Endometrial polyp histology";
var content_f16_28_16839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endometrial polyp: Histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 540px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIcAZYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6OCjI57evX3pgOflBHQ/KewpcsGAKk5HUDge1OBy4HOcelQWHOxc8t1z70cbVIYbO5B60jEBsGRF9MnBzQgwo2g5Ax9aBC54OD83OKG44CnLcdP1NIGUgKDgDoCeSPpQeBkD5v88UAK3OF6YoXpk4PYYH+eaAwyRjHcn0NKp3HKnkjn6UAISeMAYzg+wqONdpcKpxncPQ57VIOSTjr0pe/qaAFPL89B0+tJ0yxOPTnjFDZIxzkHik4xljn2x1oEGAxzkH3pcKDwBk/wA6Q/fXIPHQ44pTkcDOPX0oGJ3BbaCCcd6QZJH90EjFOPHbr046Um7jBKkkZIH+elAgIXBA5yecUvAJH4k+tGDtAOR6kHpSkDvwaAGg/Me59M0hBIxtOwnByO1DAcjdg4646Cl2jguORyT2oGLySeg7+vNNkxjkEc9cenOaYHDB9gY4OD8p4OM/j+FPI3ff59OfvUAIRuG3qSeSBwD6/wAqRY13ZVAH+6SB/nigbgz73yM9MduwzUgI4J79s559KBDASSSwOOACO5HoKccjOSQFOd3XcPSkZQMgk4J6k9M0qqQx7Drx3oAbFEkUax26BEUYCDoB1xRjchJ5z2Izj2pwBwec+3p9KNxYE4I+vH4igBAeWVsEcbRj2pFAWMBBn0XpTjkqRkMfcYpBkgBsn0z2/GgAZeSpdiD3z0/woUMqke+ASe3rSkcfdJPTjik5I3c9B2zigBct1BGz2Hb60EADJXg9TTYsqqiVxJL0LhcZ79KjggZbuWWSTc5UIoA+6vJ59SSfyAoGSkkkheuMgnoaXdkqTwo5znikmZYVIldIj23OF/nVC71nS7MulzqNlFIB/q3lAI+ozQCV9jQIJLZ6Afd6UjAMBhsAdKyh4m0Jn2jWLIkDI/egZqaDWdLndfKv7RyRy4kG0Y7E560x8rW6L7SAAsWAAOOO+KXHJzznHJGOPSsfUPEFjbWlw9pdWd9dR8LbJcxxl2zwu4kKOe5rGPjOSCyL6jot0LkgnyLV1nGM7Rt25yCcZI6daBcrOwyFOSOScY6/SgH5Dt/M81z3h3xKdSf7Pe2Oo2M7swjW9tTAH4+4hJ+Y9c4+tb0SlYBvkMgySSQD1PA49OmaAaJByc9z29qQnJK4yBinHIOBgEdyO1NPIbBKnrk0CEchVbd6559KdwV4xyMUAHaMnLDn0FIV2lmHXuaAFAwOFwMdKgvovPs54RtRnjKhj0GepqwDgDJyfWm5PbJIPQDPNAxm7DRRbXbcDhgM4A6En1p5G4q3XGQOOlIpUY+YnOTnuad1Bznp3oAQEgg7SMjkAd/WimmQByNxJ9AM0U7ASc4I5PPT/Ck+9H1GD/dNAI3AZ4xwe9NiLFcyIFP+ycipAU9ANoLD7o4JojdJFLxyBxkrkeo4I/A05shflI3cYzQCTnHXtnigBCw4z16c8GlzknGc9KCARx9Djmgk7gOeenFABkDkDjk5zSZOM4O49sYP5UYDKeM+o9aXG09ABnigAOec5IPH0pFYHDZPNKPlB6kDtihThupOepoAQjsMqPpxTV83IztUEckHJ69Bx0xTyvI5OAcikY7RnP5ck0ALltvygA+/ShMgk9F/nQfu5yAO9HGc5Xkdc9qBCYHO37p5zmhckcDHP4mkLZXj5h2x9fTvTjxkH7tADT8pLYPHU5pxxzkH6n+VBJAHIPPp2oztXc3Ucn2oAXpy2MdutNyBwODzzj2pv8SqAAHGfT6U5S2O5yetAxo6A4O7HQnOeacQSpyWP4c0jplNoAOO3YCnEHj5m6EdaAEU5QFWZh6+tIy4AWPaPwyAM88UD5AAMnaMZPJOO/uaCSGbA9hnvQIcN2CSD9OtN3DG7IOM9D+YpchgQp2+9IST8zZ4P14oAMgOAWwcZ5HJ59ajiyJpsoQu7r/eP09qlkVSCWAI5PPpUcDAwiQlP3nz8cjDe9AyXIJK/NkEfjSEjOF64/Kg/eyOgGPf8KPmG0IAOuRQIOcAt2GSB3ps0qRxtJNKkUSZLO5CgD6muc1zxfZaa7wWSNf3YJ4V8RoR6t/QZrhtX1i/1gA6lIjRJhlijAEat9O59zVJG0KLlvodrqvjWytn2adbvfyZ5cHy4+v94jJ/AVyWo+L9X1BHT7QltC+VK2o5I/3zk47HGKx1kf53kAUA4GPTtmmGVUb5gFJwoAXP04HaqSOmNKMegyS3hlcvcqZWACh3JckemTUflK5UQW6qc8Nsxt96uRsB3G4Y44A/CmMREGVVVeQfTPvTuaDDBGqBJgHZvlIZScHnp6fWomiQnDRxoiDImCjBPTGPT3p6PKqbmJJOScjaQPQgdaPtPllfNYxhm2RhxzJxn5cdM9s0alJMc8MYhkWRkVe2V+7+FKtvBDJbmOWO1lyACGO8nOTwD6Z596cJGZWxExwAVK9W/wDr0yGRZLxJEeRd0W3YuDHtycE8Zz+NBOp0UGsapb3Zmj1O7bI2iOfEiEdRlSODz1z0711/hnxCmqsYLpFgvcFgEb5JFHUr3B9Qa86MpbYWxleN3T/PFW9On8jVdPmTgRXCEhe+TggfXNTYwlTTR6yCWGBg7Tjn6fzp4Oc5BGaGwpI4HNNAwuFPOc4POO9ScY2QsiErGZCoztUjJPpzTJxIfIWJtrFz83XgAn9elTEgjjByOxqrJ9pGoRspD2rLtZFAyjf3s9e9A0WTn5eg2/jS/dPzHr7YqMSeYoeMBwW5wQNvX5v/AK1OHIKjkZ4wPSgQ585PzYPXI60Fe4PbNIThsYPT7v8AhSjqTkH2BxgUDGlQQA314HFFDEk5BIx68UUwHZAZRjBzgYpEjVEVUVUVfuheMUD3J2kcc9aUgYAxwRjipAbgb9owuOenSnEAAbRnsPagH7zEHB7EencClGQOefTFACOCcgZU44agZDKGHPqOlCcgE4+v/wBal759fWgAyNuecE0MSDkAZyB70AgDBIP4YpTnIxnFACcdCDz+tBOCpzxnH1o6+gb0z1pcnHJH4UAMbAYEkgEHoKXgc5wMcgjp707twe3c0n8XXnFACAZXGRkcZFI7BUzJgR96XjBP/wCrNJMoYJ5m44YED1I5FADiuWIPbt6GkUBQoB4xilHGMDp+lJwSPXGQfSgAZtpxjj36Uqk5OD0PPtSE8YIzntStnIIxxx16UCAD5s7h9KCOpHLHqAcZpGJ2ZTHtzihCCSACCPagBHbAXnYScDjPWl6j5MAE/WgY5J+70NG0BgQACOmKBjWAChlzhT0HApxIzgkAjuOooAOFyee+OBikcZU5IHHOKBAejYGD04Oad/E3I9BjtSEHzNwYCPb0A5z65owAwBAGBgZoAHXehQ5APcGhEVFCgAIvAXHApc4x1yOMAUNnBwv60AIOcZGCePpXO+Ob8Wmji1WRllu/3Z2jny/4j7en410J5OGQ8gZPb6VwPiRINX13UZf7RtrWGyC2zeYwLO4GSVGR8o3AHGTkGqSuaU172pz13Ik12THHHHCoCRoq4AVRtHHrgZ+pqEhc4+X5j+Gf8aZC2cAnBPvU6RPJcR28abpJG2qMdD9eg+vaqOzYpMC0n3SoAzhu57VQ1m3mnCMkjDaTk7mHbAII5ypwfQ9+K6O+0xoZJPMvbUyjkKjE78YBAYgAnkcVQe2k2jejA7d2MdBnGT6c+tNO2pcJrdFCDJQfK4YEEEt8pOOo9KuvGhkRyQp29+nrik8ltyBkyp6nIH86kKrnlMkHuOlFxt3K0ry+YrLH5sDjJ2sA6H6fxA/mPeoormdpl8mL/RyPmYkKwb02/wCNSS2okMtvJIpil4xu2FF7gMOcZHH5VDJpIgik8maKVztyZlYkheg+Y5IA45OeaC1y21Irm6MEMr3DxW4GVXDg7sEZYHsCCBz0rRuZ7ee5zYRTQ2z7X8piTtYDPBz0PbPWsxxFDazRX/72Abi4nAb5M5ww64HT6CrdvAkT+TFM21ZBIsb4fy15yqnsPT0FPQckrXJUHAOxl3AcEcgHtWr4dR7nWomSEssT5Ztu4DjHPb7xA+tUFjlcBYEaSZyAiqpOWPTiu88EaQumRmPUFgW+klaSFWz5hKjDFc9Rz27HPNS2c1SajHzOks4pIbdIZLprmWMAPNJGAzn8OOnHFWRnd+tKDvKgHgjO4Uh+ZSd2OwHYGoOATGSQM9Mk56fSh3VAGyBzzij5s9CGHAPGCM0KGUEFAcn+EcY70DGEO7b1LKASrBcMGHrUnsAoXvUMckbySKs4d923Z1CleDgdamLYYY+UY796AEQhRtA245wRx68UyeGOWPy5hvj3A4yRnHIzjr+PFSYUMV2gAncf8aAQWzkE46j0oAQ89t2eQccUUgAYEknk5yTRTSAeWw2ccdM0o+ZcH6HnpSDjOcEYyB3xS9R1APr6VIBgYBxgDpkdKNwA3HIHv2oPOOozxij5s8DgfrQAHI6jr/Okz1IIB9D60NnZ/tYpT7kY70AA+bv0PBpAoAIAJBYse/PXNJuy7KVfAGd2OD7D3p2ScEED296AEBAJIxu4zQF4GM8HIz3pR7EZ74oGR347+9AB17UhwF5B+o60oyOmASO1IBgnjnr9frTAXPp1PSgcY6YoXkZySD09qAcnjp3xSAX165NNxt3HPJ6ZpcY5OKQ9zngfhQAPk429MdzTuvb8+1IeCcjP40pIztzyaAEHckjilGAcHmkU5we5oJ2lieMckntQAjEhWIBYgH5R3NHJXK8MR91u3saC6jBznJwPenc7vT3oARmPy4x6daYqnzpNwUrgYOTkn37emKf2z0J7/wBaOQnzHc3sOtACKDnjGCcketG7HbGelIw+XK4DE8E9M+/1rN1zWrTR4EkugZblwRDAn3nPc+y+rUIEr6I0weRwcdyahe5txLHF9ojDtIY1TdyzgZK/UDnFcZb+KroLJcapIY7cAuIbGHdIgGOCTknOewzXR2BtJjafZ7LbNbPsKyAlrcv94A9zzz9adinBx3LWtX66Zps10U3lQFVSQMsenX868mis2uH80KGmYlmIUHn1H+e9dT4v1U6lL/Z1qu+0ik/eSFvvsvBH+6M9aq26W9vceS5ESOgAXeMN1IJbsODyOD0prQ2prkXmYSqwBUAu2cDHAJx0z2q9ocq2F/FcXBd4gGhkVVwSjqQWTPcZ/Q0upRO9sJZIJUt512JIGGCD3z2Oc1nz+duUxXOUjH7sqq5HqSSMn0xT3Nd0aF9cWVvIkNnsv1UOoaaHYu1u3XJYevFVZ9RkltjEsMMCYIZlZmdgcZUEnhTgcVSiSfyxiDzIy2VW2ALuT1ymR3z3pbtJYZXjkyoBxt4BB75p2GoocJwq9iM+tRSKWmRgXjCHgBvvZ4JI7+1NYRPuRQwYnq3Sobt7lLghkVIWHyyLwwPHBz0784xzTSNUtdCyVRZQTwWO0M3G3kHPv6fjU7QobgyS26MyrtSUrlsHnC+3WrusSeGX0xV0XTZbfUmKDGG+UZ+cSSNlSvORjJJxjvUCbpomVLd96KeYhh2A/wBk8Z6njk0Mzu3qYev+ZHbafMkaSS3LrCqznCOfmULxzggEZ/pVzSYfs1hEkwaK5ZFkkidw5iJGFTIH3RjA/rWrG0s0zBFSSEfuwAoHT7pVu42njoeTW1oHhn+1JUvNSQJY7sqsbc3YH3WbHRQOPehsqVZKHKyroWiTX2mvqMVwYCXKW6lijOMZBDDnk8cds1s6dpGpw2OlJc2kU9zaXeblpLt0UR8kPEeS+3djB25+gFdVDZ26MhjtYEaPATCAbcZAA9MDvUiOjBtrhhG21x12t3B9etZ3OCU3J3HHA25znO0Hb3NKeTyDkfdJ6UFRgkElunWo1too5XkiTbJIcuwJ5PrjpQQP34DbyBt6npilBwAQckn0oJBJDAY9PX2o6LkkDPYUARTMttG8xVVdsLkLyxJ46dalJZSABu7H/GmMSXCnp1BPr6Cm3M8VrC01zKsUSYLOw45oGSKQqhVwRnsf1pFySGA7denH0pVAA4+71A/z2oBwWbnJOOetAAp5J6dsZxRQAgzjBxwc0UwBRn5WBI9SacDkZHIPpTSw2gq42njI9acy7sD9KkAI+UjJGR0pGYouduR3waUfMoPSj14OaAEDZAKqSWHGKAcqDjPpxil7d85wSKQkkgEfhQA4DH1po64Cjg5zTs4HP6UDBHcjpQA3BAx1PXmlI3Dr14ODQABnaOp5pcYHvQAgwVXP5UdDxke3akwAcZ4HIGOlK3PA4/CgAbn3B5zRtGckdORjufWkyMc429Dx1pf17cGgBT1Jz05+lIOcEAHHH0o4J9h70gOAc/e74oAVevXPpScYJxk/7Xb/AApCAyqdzEHkE8/jTsEDI4HegAUYXG4kj1600HAwFO1eBinZJAI4objO7pxQAgBwc9fTsKdn0xgDrTSAcDnPtSBcnec7sYPJwaAEbeEJRVeUAYBO0Hn/ACae20kjcOmf/r0Y5zWb4h1eLR7H7RIfMmf5YIc/6x8fyHUmgEm3ZFTxT4gj0SFVREnv5cGKFiQAP7zY6D9TXB/bpp7lry8NxJfP8sso2fKOwRR90D61AC89xJc3MglvJnLSSH1PXH6Y9KsaHYS6tqkdom9IWy0kgXIVR1P9KvY64wUEbvgrUoElvReLH9kkIYyzDkc4CnjofX1qtrF/c6Ld6paLM5musFnU5YHOSQccHacYrdj8J6Zb3AnuZWkto0LPHKMZ4+8SOw9K5PxR50mqtfqZHEqCSKOR84Q8AAY44H60lqyY8spaFKG2luoxFbxOzYLso5Yf49qnu5tTg2QtJ5sQCgLuBVFA46D8cevWmeaEjZScOygA4GQMfdHt9arSyEHcztuyFY55PHHP0pmiVw1O/uZY5JHV5t7tMy4Ch36buB7VWt3vGlVZYYUiKAn59+4nsMdAPfmpo8SMpDbevT+IVbTBhKKBsbDbcHkg/pTvbQu9laxTCjZ86xhSCckcmo7os8bCMKrbfkD5Izj+LHNadpp1zfXrWlpDvmQFmDsFCrwMk1bu/CmtWsjstotxHtyXt3BJOO4ODn+dBPMk9WZ/hnQ7jXoplFxYWt3D9+Ml5Ay9nXgHGeMHkVvXfgu2h2RnXoBdyDiK4VUD9hjnI5471z2g3503WUubeLzZIw0bws23IPBB9MHFbGsXml6pImotpTJqaupEr3G6Ibfu528tgjgYHPU4oe4pOXNvp8jndpSTZLCzoGIkJx8hBIJx35FS28d1fCOBbYJK8gaNCN77w3yuAPz9qnlUgIZ97CV8uQwBJOTnPPBOTXeeDbS1k0iSdd3nSsY5D90x4/hU9cdDmhsJ1OVXIdI0GHTZIrzV7kPeSHc0C48qN8dvXjjnv0rZ0XUNMu45YdHaN4LNhAwiTaiHGdq8AHHfHQ1W1Pw/ZX4BuJr4HaFlMd00ZnAOQJCOvPpitKwtbexs4rOxt1gt4eEijXCqPb+ZqdDllJNXe5MR8pDfLuznBoIyB2Oc+1Kw653YHPXrigElckYNSZiKWwdxXb/CQcHHv759KVRyT19D7UdOvQev9KTYCWPIyMdaYDXIUkfeznC9ST3xUmMjBII+nWmr90g8DAAGccUNnD+Xgv8A7R4oAaWCsowdxzgFuT/n1pckZ54A3YHT6UxLdAwdlVpF4EmBnnqB6D2qYsCexzQMZ8pPH8XP4etKTg5IPA7UAhR8wAGeMfp+NL+A+lAAvPBGR1zRTeozxg84/rRRYBUwB2xnORTsBuCFIPJH403HIAIx7dqcRyMk/n1pAA+YfKePalJywGcGmOofaXGHGCD3B/yad0HQ5B6DqaAF7/Tpz1pG4G4nGOtA3ZwccdxR83Uev6UAKePb0o285PX1oyfTnsKYOG6Yz79aAHHOewA/OlPTNJ3wQMY/Gk6EYP4daAFU84wR7ZozkHoaX+fSkBB+oPTuKBCcLkgYwcccUoILHI+YUhySp44Ocg9aXjjqcHIzQMST+8VzjnjrQCBgA5J4AzyTTmHSjv0x70AN3HrxjHU+vajrg8fhxmlwSScj0o54ORQALnPT9aRckDcSDjn60SJvjK7ip4yy8HAOaAw52jj2oAAvzHjA/n+FJk4yBxjgj+VHmr53lHdv27+AcYzjr0/CqeqarZaUiSX1ykQcfInV3/3VHJoBJvRFwn++QoXknPAx1P4V5Tr2ovq+pnUME2hBW0DH/lmpxux6scn8q6iTVJtejZZWi0zQWfyp5XlAnmHTywP4c5AOMnFYniiOQaolmVhWO0hCLtZVZh3yoJ9gM84FUtDopR5Xruc+TyQrAe5PGPevUvDt/b3uiW4t55V8pVhYsQG9Axx69jXnJs5FZfMVcuA6hSDgH19/arulXNzYJNJCXjUp8+BwR6YND1NKi50bviHUhNo8gDeY7ttVhhZHgzzGxx8rH078GuXvzG88jIrRwZ/doXLlR6ZPWrf2tZrKS3SNxDM25vNQCQtnjvx0rPvpw7RRqQ7BOuefx9/ehBCNtBbTdJcqirubrj1rQ1WwiNussY4kYtye46j0yKyLWXbIpAyxYADNTSXckLNBdBo4/MYrmQdPUL+Qp2LabehAfMjYFEHpleQKkvLoRQmWT5QEDOQPugDqKEnAAZFJx904wKjnmBfoMg9+mPpTHY73wBpV3aR3d5eRPC9yVSJZfvbASSxHbJPHtXG+M9avJptWuUuWLG4isdIt4mbY2Ww8khHpgt9AKl0zU5bKCSFZpXsJozFJAJNuFPB2E8K3pil8SQ6bq1rNNpk8NjdG4j8prtsCJVCgoYwDuQgHkc8npRHe7IguWpeRNrmsXNwYIJfsl2qIC85g8uVnwM4YdOmeM56dqzA0Rsg0fySybmKM3LEE5/X0Heor12to0thPFqC2w2x3CMw3oSTtORztJKgjqMVBaW0sBSSZ0kdImAbZg5cktj0H3R74oNFBJaEhD/OIYiUGxdu/lm9s9B6mvQPhr57aXfSXLxmVrnBWPJVdqjjnvXC26hZ4cLjYduDXfeALkPpE8GQBFJujTbtYK3971Oc+9J7GNb4bHUDuMZx2PelzuGR09e1Bz6nI9KJASpCkB8dSMj8RUHGJnOWxnHIANKOgPAOKD3P4U0EHAY5cegxQA7HyjIBI7UhODjJ/HsKX+LHGT60nDfwnGehFMAxlSMDOfTNIecnI9M01nVZFRt2ZCduemRzj8qkABHykbfbigBOnb5T6GkK/LjBA6cd6UDnq2DzjpijlQAQM+q0ANIO0Yznsc8n8aceO3A/Kg9MdvX0piMNvzHB756/jTAcFyecHj0ooLKpyc4zjp3opajA/IOBgcngd6dkDGcAUi9Ce/rjrTu/ofT3pAByF5BJ9KO+D/Pg0mcjgHnrmhuh68dqAELAH/ax6ZpeOoI459KOduCOO+KMAAYwT0570AKc47Y/WkHA6H29aCQOpxzQQcDce/wBKABuvGc9f/wBVGDnnoenrSNyQcEjpS/MCScAHoBQAdD6dqOQnOT6dyaQkrkAFvYUp6ZzQAHn8BR1xjHIoI+bOBn170vOORnPrQAmQG9zSgdxyKFIAAHTsKbjC4yQc9RzmgB34duaTnP8APjtS5O7B6Yz9aQ/3iSB1znigBR1PUjr9aRmCxlnYKqjJYnAH1rJ8Q67p+iQhr+dvMcYjtol3yS/RfT3PFee6nrNzril7ousW791Z4KogHQt/eb3NNI0hSlLXodVrPjKzj/daWi30yN80m4rCpHv1b6DiuAv5Z729lubg+dcTHLPnAHsPQe1XHtZjH+6IUqOSykgdhWo2nWljf3gR5SgIYB5ckAgHAHp149KpWR0xUYbFXw5FC2oyNdXMltbW1ud0iQ+Zlz23EEKcHIxjOBWr4bj0Gz1GO10/QruWWaXZcXUqgMHPO5gTk44zjONwI4pmn6s+mpLHFZ209pcZdreaUKoYAZZTzleBwaqQ6lLJq76jcSxLcNzH5a/LEQm1SM9x03UXE3J37HRX8el6NHdXNpbPHcTsXndMyDrggHkL3yBisBlGo3MbeZAHkT7zfuyVUdcH9PpWh9vtLaxWMXLm/m2TSlUCoH64cj19K5ae5LTO0kobe+8cEDnoRntSSFCLYzVPMWV4bQRbFO0TynIx2O0dfpUdnAyXCrcPcXKFiWcuN5OOMdMD29Kkup0eIAHMm7JOeDTLVGQPJsZV6qSuMn2NV0N1pGxWtbnyAEn2mVpMHbwPbj6elahdn5mX5VyAetYWyRbkNIhYqckrzj8K0GIMJw5cHkcdB2pyQ3G7Iry6gC+VJJhmOAFPPqSPwq0tqLjTbaW1gE3mXTwyuAxKDaDGfl6A/N+NUdOkurK+tr21uAtxbP5ibhuzkEMp9VIJBxWhbXc8V1dXECm2a7Zt0dmSiqD1QAc4J5+p4o2HJcuxVbdCJI9xRslSwxxjj86e8gLssbY4+8OTnH5e9OlgaMiOSN43Xko6kce4PNRxLaTSSJfy3Ucaxu0bwA58zHyggdVz+HrQtRabgZLoRRgXCNKo2tI0QAYfQdKe1y/AYOwUAZ6kfh1qPBC5YAY6gDvURDKwBBwe+aB2TLLA+YByMHg10/gqdrPWYy6jyboeVzx8w5U/XPH41zdkyrIXYBzwMkZ4z6Vo2V0Le9jaNXYxyxsgJwp+cZyO59KlmVRXVj1dDuGQ27k5weM+lL94MD9D2pzAK7DBAP55peQB3FQeeNJ69BQSuMnp0oPJwMjI4xx+tIScYUjcexoAFIBPHJ649PegEBgMg559/wAKdjB4Az6U0hSdrDdgg8/pTATnJPOOpFAywwwHPHsadgY7cdKReDgfXFAAADjBJHagnGOvTr1qOedLdVkuHCozBVHUkngADqT9KWPe53SxiNh91c5IH+12z9KAHAksSSMDJGM9PWkkGTHxllOQP605vm3AqTg9+lIygJgdFOepoAUEh+SoGOvfPpRTWIIwW2d85waKYxwbLBc5yM/hSkhQMnBJwB70DIXuccYzRx2wBnn3qQF6nJGKPqabnAJzz79P/rU4gnIBPSgBmFwSTx3bNOBA4PVs460YGVO0EdiKUkkgAceuaAE6dRz060AAfSkyCTkEkcc0NnoODjrQApHOOo60ufmxz65pFHBGeOKM5AIIx2IoABkDAA4oBBGR+FA98n6UDk7iDkHA5oAXGB60nuOlGcLzRg5PpjAoAHwQf50HJY4wO+aX/wDXmop5oraAy3UiRRKMszHAFAD9ueRkk9Aa47xF4uCK9poLpLcqSJLnG6OL129mb9B71l+I9fuNZLQWwkt9OPBTlXmHqxHQe351R0uxjvr6wtWAS1mlEb44OACSB9QMVSVjohTS96RnpHDbyxXet6nJbLd7ik7I0s9wV67AO3PGeD2FbtjommaykkdhfX0Nym4gTJvXaOPnwBtJPYEmsrWLyaXUU1Bo4i9rMg3LwIFHCrHnuUP681v/AA5ikhuViiO2KOBvPHYuXLDJ9eapvQ2npDmvqc/dW97p95NYXu+GYpliGyrr2IbuOP0xUt1kG1fdl5rWNyep6Fc/Xitv4hOsms2cQO4pasW9svwP0Nc5cZ8jTZAAHaNxt3dAshA/nSCPvJMsyndYmPaWZduC3PHse3/1qxGkdXD7yGDAAGtoyvcRZ2tFGrCMyDIQnHAJ/vHB+tZ06IshYJhs9TQi4abjzJvOdvHXYOBnuazVElzPOsk0spt2W3QyHhUXO0AY7ZPNdb4e0Br8PeXrm20yNS0krHaGA5OM+nrW9Fq1tc2sUFlpMEmnbcxm4OCyf3gMZGffnmjmtsQ6qi9Fc898h2t0Uog2knIGDz2z3HHH1qSG4wUV+dp4H9a7uPR9G1UyW9vHJY3yjICOXX8AeCPYYIrj9W0640u+kt7pMSAZRl5V17EHuP5UXuVCopaFQgLKwAAGenc1X3ckluc/Q0+MnkZyw6elMZWdl44GSTVGiRWa9iS4EZOHJAGEz1qS2vXjRpSJisOxpXiUHyQW2hyc9N3HGaglhVSr7Ar7cFwRgfWooYbyKZ4TEYbG6SPfuXiSOOTcu0+hcc/Q1aSZbSsblxcNNJI7sXJPzM561XG04x/DxmtnwnDAs17qd4qPDZReasbDh5CcID69+KTW786pbRXk9tDBerKY3aEYWRNuRx6jpmszG9nypGam8r1BHTae9RtjAGOas6XbreatZWshKRTzLEzL1APpXUa/4b0iKbybC8NrqBUGK3lcssnoCT90nnnP4UXFKai7M41UIAK5wT+vpUsTHIG5V4JVm6ZHJH14qH50mZCdkgyrxv1BHXI+venoyiUo2ArnIGaZUldHtcUiyQRyhvldFYH2IyKd6E4xjIHofWsrwtcpdeHrFxJvZUETk9Qy8EfWtT+LHfr9KzPNas7BgbSOeetHVsE9elKRjPGPXFIS2MqOSfyFIQD1GR6LTuoPpimltp5xjgfjSA55AOM4+v8AjTAOmC2eSMA9qUKMknJzjJzSkFhgnj2puRuBB6jjmgCtBZpHcmeQ+dcZbbK//LMH+FR0UY9OverEmFhyfkwf4u1Oxz/Kg7sELwccGgYhUk47jtQw5HAKjt6U7Hzc4IxycdaYCCAuQ3r/AEoELtJ4PI65oqNgPvDvwSCev0opjG2MH2WxgtzLNOY0CmWY5d/dj3NWMHB54pC205IO3uR0FOyBwTyDipAQHOASCaFwAcetGOSevtSZyrH8s0ALhugwBjGAP1pMcjJPHzD/AD6UuQWwoJ/ClzjrxQAgZTjB7dvSl4A6dumaT16dfzoHXAxigBPvDg8Z5FL64HHI9KQ8AAAbuwHGaRWU84I5289/ce1Ah/foaRmAxxk9AfT60vc9PekHPOQeMZxQMAT/AHcH3o6gHn2puZN7gqgQKNrbvvHuCOwrN1nWrbSlZHBnvCMrbQkFvq2fuj60DSb0RY1S7tLK2S4vZTGqsGRQTudgOFA79enT1rzvWdWutYuA1yRHEp/d2q8hPc+p96W+vJ9QvGub9omlZgFCtkW6D+Eex6n1xVY/fYgBsfNkdMduKrY6adNR1Yi+UpUth2xyQcY+nvRFdNY30NxbFt8EgkAcdfX9CRUbvljgckc8cE+tVZ2ZHUFgxYjKnJO31AA/zmmka27ne28/hzxHMs82ILzH7yKWTymbjHzY4fGOD6Vo3OqaNoVmF8yCPAylvb4eSQ+wHf3JrzNrKSYNuhkx1GYifx6VDHD5arsRWVmGQgALY96LIj2KfXQu6heT6nqFxe3KhJJzjy0ORGoGFXPfA7+ppzRn+zbYyhsRSSpvHXkK3+NVFJUZVJETcdm/BJAOQCRwTircreZphV3OPtCuVHbKkUzTa1issm0MEDMAO/HH+NbvgqwttT1GVrkCWK3jEoQ8h2Jxz7CsJkUEY4AOCR2q34ev/wCxdUinJxCuUlUAfNGep+o60BJNxdtzf+I1zHe6poPh7DH7RP50qqcKVCuEUjuCQTj2FadppSQWYjUscD5ZOTwGxnP86g8d6el1deGtUt3xPaX8ZEw5URFWJBHvxg+prUieMwKwuPJ6IAzE7vc/n1pPZWOa/uJIzb63lhMbWyBMuMSA8qeoP8859af4liGs+Gpbny/9Ls2Y4TkHB+Ye4I5qxfzlIWRWGX+XBHBxyQMc55FXdBjB0+5ibiNndcYxjK/N9KkV7WkeSPIRgDhc5BHepUZCOGVQBxiq6KMKvPy5Ud+KVUUkgZ3cEEfw1odwl2rLgQEbs5P0/lVvVtQGpXMJW3a3hitkgVDIGHy+/vmqshMe7ccjrTHeISMMhT78cU7BdOx1WjQQReDdRuJ9srXkiQwqh3eUy8hm/unOce2PWse+URwW2R82584zyOOcfpVfTdQl06aZoVjlgnTZPE33ZAOh45DA9CKZczNOWkJXcwwAOAo9BStqQotSudH8P7Fb3XfOdcx2aiXBPWQkhfy5NO8ZyxS+ILj7OQ42KsvOMOAQR+Ax+NWvhfNHKurWqqwZpIpSxOD5eMbh7gjH41iz2twupy2DxSG6MrALjOcknP0xzmpe5nvUd+hR1hBNf3LyxKJJUiPmbmVojhWJAHBJ6HPFT32mXogM7WVzDaFQyy+XhRnoc9h9RV/w7BBqni2JZm32sQabpkOIwACR6EjP5Vautf1DVNWjaKVxC77YbZT8rqTghv72RnJPQU7jcnol0Nv4fXQl064tm2K0UvmAL1+fv7ciurOemMn3/nXEfDoIuoaksIHlBAqEc/KJGC8+mPzruOpBYd8DFS9zkq6SYg4AGCSetAyDjrj/ACKACOegHQdaNoKBWB9cZqTMB1A9e49aGJPJ5x29TQRng59evWlI+Yc9c8EdaYATzjqaacgFidy+np9KccZ4xzxTcZGCMDGF/wD1UAO5K5yPrR179OtJtz97nnigAHA6+tAC9GHJ+melNAyp4yOw6celB5GTgg9qRuCMJyCCOe9ADQg6gkE8nGQaKOg+9tXttOPwopjJQPU55zS855A+tIB3PUZ60cDOB15x61ICjDDg0HOcjr0zUMTsxm82J4dr4Vi+d64+8AOn0qRWUlsEcHB56UgFDA8cgj1HJHqKUccBeg7mk3DIAPBpDycY59PSmAuCBjJP1prORIgG7awx9D60yS4RbqGBlm8yUOVYISg2gZ3HoOvGevOKlIOeOaABs5wOMjijOeBgAHHNHQnggHrQo5z09e+aAFH4jvg0h+6e3vjNRwv5m5hjAJXj2NVNb1RNIsWuZF3scLHH/ffsB/M+1AJXdih4m1waYBa2xH2+YZGeVhU/xH1PoK4GTzYWkLs7HduaQnlm9Se5qTfJM0s07LNdXL5kdhk59vbt9BVK8YpFGqSEKWwSR93sXx/L6VaR2U4KOhO743H5SCeQBUEDzO0sa5cs7FQBn5OMcD0q1qMNpbX08On3P2q3AXy5e7Ejn8jV7w1rMWhtfH7M8s0ygIUcDbjPDe2eePSmW37t0jMtxLGJLlY5JLdcIZQuUVjjGD+XbFdf4OtbGfTGeJ8X5RluE4Mm/PX1xwMdq5K0spJYVk89YLducySbUkI7qoBLfhxVmFI7G9guLbVUiZDt84W7hkz2287wfqB60Mia5la51+luftd3YiRtyyKzMckjuQMnk54rnfGi28XiB1toFVtimZQ20B+fbrtxmrdv40kmUNPYQyXMRYRzRvtRscBihBYeuM/jXMz3Bleaa4l3O7FmduN560krChCSldigjc2wNszkg96tSqVsLjyxgMiORnp8/GPzrOGfK+VcnrnPFPiaSW5+zKwaeWJgqdc5GRjHuMU7GzRLYTQCdEvFkNvvHmCNtrsuDxn64OPak1KK3if/AEW5jukbJXKlGx6OCOD+hrp9U8HJY6NcXI1F/OhjMjCRAsZwMkcc/rXELNLPBHKrg71DHccbR2FCCElN3id7ol7Nq/hxtKhlt0v4CioJc/PGDkE/lt4qz9l1KGU/8S98fdby3Dq3uCTzz0rztvtEREsTutxH8ySINrK3Yj0NXdK8b+Ibe0jaWa2u5cEutzbeTlj6bOlHL2IlQb1hY7m2sNQZgFt2jAGGMrY6/meueRV7WL+18N6A3nyHzpFZIV6tNKR29uc57AV57d+O/FNwVEC6bYgqQTHE0jA+244H5ViXd5d3Vw13qM89xNjaXkcHA9AB90fQUcjEsM2/faLUAMUIQglz1OO9PGMk4HB6dqrszKAxJYYpRKmeCFzgDOen1pnQ0TbQ+AcZxiobuFdyEoCQvIxnFWoUB27juLA/lTJ0KgouWwCDnqRQnqTboUYJg+SMjaSCFHSpWeP+AjB6gjioUxGx3bQjHrnGT6U6HaFy/wDGMkH07VTQ72LkM0ttdQ3FrM8NzGTsmQ4PuPQj2PFa2peI9Yv7YwXN1GkTjbIIYvLZx/dJz0+mKwoSGAVdwz2I5FSRuCGabzNiggFVB57DntmpaE4qWrRf0nULexW+iulmX7TGipLAAWGCSUxkcHPX2ptveXJjmgS5eK2lcsyALuwf4dwGdvt0zmori0ig0u3na6R7qWTBgUcqMdf8+tNtV3TFTnJblTx2oJsndnc/DyHEWoP84AZIkPAyoBP5c12BYAA5AHXmsPwZHs8OW7IMGZ3kOe2SQPrwBW4oJUHJz7ms2cFR3kwJGOh+9t5pQPm3evr1+lIrdRz6GnAHqW6CggOvQ1GCEYsQcnnHpT25xjv6UinBIycdDz0pAAG0tg8HpikUAdTk9t3Wl53YwF9wev0oX7uRz70wEABZTngZxzwadxx7004K8HaOnoKXkN7kenAoACwVlBIHQD0PpSE7CAM9cA9aX5SOfug0p6deT3oGVbi5SB1WSKWQMCR5cRcDGOpA46/jz6UVZJOSFwfUZx+NFO4aCqMgHvjt2oUYOAeKAOhHTH3R0H/16TJ2kOMcc9x9M1IEcz7cEJMSOhRc4ycf1z9BSvKpleNGVmj2+YOeM+nuR0qTuMd/5VDPKkETzSA7VG9tq7s9hSAlDMdpC9R19PrSscdzj1pkG9YBuV93Xa7hmHsTTiNxBY9O1ADSwRWLvsVTk88dcD9TTxnI7Dpg9c0p9CM/Wgd+2Oo9aYDXLDb8pOWA+UZ/E+gpTnGCKawDAfe69M4B+tKyglic84zQAOdoJwoQAlmJxjvmvONX1M63qZnJIskUpboTjg9X+prb8eaoBAukQN884BuCp+5H2X2LfyrmLeURNh04XgYGVVR1H+eapI6KULLmKklzsEs6hnP8IIxuP+eOlR3UYS5MUk6TkqpMkJOF4zgeuOlXZolms2R1zIE+WVf4x2J9DiqdtbN5THIKoAWxyT1xx36VSN0R4/1gBGQOdzdB9T/KrWjGzXUYF1FQbXJJDHCs2DtDHspOM1Vchwg2cDn5v61fk02+ZGzbfOieYY1IMoX/AHc5/SgcrWsyGOG/luXub6aw86QBndbuMIv+yvPAGOwqa9jmt9MkeQbPMlMJyOmwbzj1ycflVGVo4jG0EkV8jMMhUOwdD83t1B+lbWueJo9Re4WWOVLb7OvkReUMxXA6891xkZ9O1O2om22rIyobf7A1i11Aot7kEIFky4GA3zAdMg+/4VXuYk+0sob5VJ5HReO1VFkXG4eYWAx0yFHYfStizNqukTZRTcMcDGQR0wf1P9aHoVrHUppGoK7BnAwSR19a2tA1XUNJsJZ7WwVrZrsG5vRGWQJwNnqMZ684/OsgEeac5C5GBnvXReHvE1rpegyaddW08jqZNm0Aq4Yk4OenU0iaibW1zofE93HqPgPULi0+aGaAr83VRu2tn3HPT0rzGCNRAq7OM7R0HHpir0Oo3S2l5ZWUmyxuWIktyfMO44yFPYk+lZryGOVldAJNxJHQr7YPNCVtB0qbjdEwG6Rw8hCqAQApO455B9MVVSInaS27BJyfU/4VNJlolLDIYBgTxuz6e1WTa3kVmk/2aVrZk3iRV3qADjkjofrTNbpdSs8oSKVZbdC7gCOQscxnPXA656YNV5OEZXViO4PH4YpRIrHHl74j0dR0HqaknEOc29yLgs/y7VJAT1b0PsOKYWsyIKXz5e7K8j6AU6KGYWkF0sS/ZJyyK27ncM8EdjweehpxSFZcETBMfN5WNy+h5649OM+orXi0XVLi1XYt1c6bB/pMXlSHyd2DyATzwT8vY0XCU0jMtHeaeOJGCO8ixBn4VST1PsOtR3q3CziJpFkTb8s6DB3g8qRn0wR9at6HCj6laqZI42EgZS33WbadiknpkkDJq1Fo+S8F1HPDKm8yK/LbsYGPT+opXsJySZjOkbAq5EgwMHB/DpUEEXlzlpFaQDgZOcVclt7m2tNNuruIQx30YaL5s7COqP6PjnFIp/usWBHGOBVXsUrMbvLhlKqFwc5HJHYfSlmZ453jk8tiFxHs5DLx1/OkPIQ4K/3v/rU8b0CuBu7ACkFrF4RRW4kOwBwBgknOPaolkBjO3uuT2561SjLsqhyzlTjJ71OpxFIQBkA/jxSsS42PYvDyBND05CuGW3TgntirxyDlR1/Cqum5/su0Gck28ePT7oq2crgH8z6VmeW9xAASSOTnI46UpUH5cfgKOuMjr1GaADnjGMcUhAc84HIHFIRwRyfpRuwDhTwO1JvAXt0yDnr+FMB2Ceh70p3A8DIpg4QL0PtS4XIIB4zz6Z9KAHHAGO1JkZ2k84zk0nPU8gUAY7Lk9fpQAEemNx59fxoHA4PXp7UEYxkde+elIdzZww69f89qBg+4/dGT9aKbgNjBAxn5T/niigBZIkniZH3AMBkqxBHuD2p/8S5boOh70ZOBxntjP6UEfKNwz9akBeQc9u+aQtgDPGKQhtyksQAfUY/H1pwJHQe1ACdOdwC5z9BTYhJ5f70oG3HBTJG3t17460rLuAGWBznB7+30pVyOMY+poAXqcetAz36nvSMeOOnt1oJwcAZ+nYUwFrD8Sa6umL5FuElv3UuqscLEP7zn+Q71oatqEOlafPe3AOxFyB3duir9Sa4Sw0O91Zmu71gftJMrlvmb2AB4+me3amkaU4p6y2KcsSxWkUrqskt0u+WUvuJfJyeOg9utUvtLxM+18EgggD+E9/auiufDU32dvsN0ZnUkeU8ewtjsCDj8xXLOfMhJ6n1PGKo6oWY8XJWCTk+WMEgd/wDGui+w2VpEI9Tt7qa+aMPKsMojWDI4XPc471zdgjXAsoUKqzyAEyHCjBzlj2HGBXbRJNqWq3N0ip5Usp2t5q5CgADIB/nQwqaM5C5QaXq0fllrmABJ4y64LoTnafcEEGurttHmvbtbyynR4ZZDMlwJAHXJzgjruHIrl/EEsc2qk20qzQ2sYtgV6Ocknb6gdM+tZ3mxhgvzJI3BBJUcU2rlODkk1ubXiya1m168azKmEMFZ0wFeQD5iPx/rWHeh3ZQ5wDuK4ON2OCcVeEcZsWdGHAGE7nPp9P61JZyWMOnzi4t4pLtgSsjbvMVdvyGPAxw2d2e1CBPlWnQo2bxGBlUDylJDcd8evei1DCBA2N4zuI789K1NX0y602GK4v4o0N0pZVDZYEYOCMcHmqMEoUrDJsVsbs9wfT6f1oGpcyugk+VM/mPenz2cyWttfusax3LOsewk8r1B9Kr3GXcYOSBkA9DjmqWu3U8doyxNILfBZfm24zgnAPAJ70JXLUW2kjXg8QWNpd6ZOYRJNYErNbxrtL9djgjq3P6Vq+Mlt9QgsNWht2iWeICeCZQssY/gZh156Z+lZekCbQ7W2EkMMepXcCzzyYyyZ5VARwBt6nvn2pdRunu4JTPIqJhfmVeXA7EgdOB1PUih76GbiuZOJg+Y6ysiyMwVflBOcL7E8D6VNo2vXejpMdOlOyYjzAytsY54OfUeopnliNWcLuEuyNSz4CcMTx+Ios7u4tmz9ltLzapUJcoSpBO3OM8461Z0SSa2uanh3RdOvtGe7vphJJulWVzKoW2UZI3IeWDc9KxWnS1dRtRAVVlRlIPPYY70ttZva2yeUUEysFUFeCCeOOw561Xt4993LNI265lQqFViVVc56dveiwoK7bb0J0uFdFMm4FztIJHy+3HT15rpPD/ii+0xfKhKT22SxikHPPcEciotE8F6lqxe7Ro7a1kO5HnJJbjAKgc7eOpxnNT6p4H1Wxi86FYbpkH/AC7Ah8f7p6/gTUtrYic6UvdbMdgj7mdAAWJYZ7Z6e9bVtrfk26QX9qmoRoMRyGYxzKOylh1A9+ccVgxSjdtkYNu/hI+bI9qkk3IgO87hwcdwT/jQOUE9GdDJ4pjlheF9CstpR7fdDOVwDnPBX8c+tcnMjSbo0kkiIAw69+cYHbt+tWgySH5CSRycc4PemTW8jTJtUsyfOSuRgj19j701oKMYw2BU2lQGDbOVz0NSSriHheQMZz0pqRghSTznPPWnuGKHnOe464pDvqJZxC51C3tpLlbWCfKvKcbRwSB1A5IA5NSajbJaXN3aJMtxHGxj8xcYbgen1xUZtgY04+Xpg9x71No9ob3VbGzVP9bMo4H8IO48fQUwk+t9D2aBFgtIY1+VURVXvgADFMtoI7ZHSMOd8jSHcxY7ieTk9PpU7DJ3Akc5wP6UZI46jNYnlAeCOB1xxQBkAke5B7UKuOOMelAJGB2/SmITLDcSeO3FJIUGGc4Cngk45PFKch1HBDeo9qXBP3sEY9KQCYAGMkDPJzzmlBycH/8AXSjIOOffHWkAwAMj3xQA0HnpgY9eKcAM4/GkHfPXHI7GgbgpODnHAzxTAQhUBYsQAc8nigcPkYBPXigZLcYPHIFHO3Hf1oGNJAGcqOTjJzRS5B4YDb1BNFAx4OcY7jNLnvnjFIDjp06++aXnJOcHtikIOpyRgdOvWheOccnrg0AbcDoKYu453KBycEc8dvxpAPPB9if1pq8qMghjng9aM7gNp+U98Z/OhR8m07sDuTk0AKO2TyKMknI4B9RSgn/9VR3LvFAzxJ5roNwTIG/HbJ4FMDifG1yb7U4tOxi2t2TcQ3DSt6nttB/Wtyyh+z5ijUxBfkjOcKccE1xcpE/758s0zs77u+STj8q1NP1i6t2RLuZnsmGGlkQbkPZsjqAeuao6XB8qSOmkkZCqxsWdsAliMgD19Oa8/wBfRYtf1SKHa0aTkkdMEgEj8zXc6hf2OlJ9pu5Yvs+0HaCGaY9QqjPP17V5vI00pkuX5nnZpX5/iY5x79qEVRWtyMMGkETMFJJCgDOSBk1s2+lXGoaRN9m0mG53uYYZSFX7PswWbccHJ4AGSM59KoWMVxdXa29su+VxlUOFz3OT0AHrWvceFNekUgQWzqM5jFyGz746Zqrmk2r72OYWUPsa3YGGT5gCMYxx36c0kCPI4SZWfHI5xjn1q5e21za3Ah1CFoZQDiNgV3DGMqehH0qKFpI2QNn5ckN9euaZtfTQkxLBEF6IOgHPHr9apguNrDhJuCp7gdxU4cliyvuZj1Pcn2psPntqNpbR28s1xOGKBB8qhRli3ZQB3JoRO25ratql3qzWsl35f+jxeV8p6nux9zgVd0N7azttQttSc2zyhJlaSM5mjA+4vrkg/wDfVU/C1xZw63DLdruj8sugVd3zdjjvUHiLVptZ1N3ZSCwxGuMhFB7n17/WkZ8t3yLYy4ZVcK+wqM7gN3IBPT8OlMvP9Q0CSLLg71jAzkD+eactu8YChshiTyw6Dt7VXvHlUZaP5DhWKtjAJ4/M01udK30JtN8RzSx21lqVrBNb24Ko/wAySopzwGBwQPRh9Ki8+43uZZBM/wBxTt8lWTOchSenHfmmPEpg3o0qMgwGPOPfB4JqB7adN2VEjxMVZpWyzyYzlj24YdB0q7JjSjfQ0WuIg8b3JjLMMBm42ZA59yOeKje6N1NaMLeKNY0AiRwwDgcEs3BIPPQ5BNVreESEQ3trEZnAl3KMqr42kjPt/Oo4LQLeTzO5JBIIJOQP7pGePXGBSSSE4otTSvKXjjgMEDjADu0jAjrtbA+gyOh71KXV7B4yWa4YMqKVG0DHAGCCOc5JpJIpkhhnMgRZRtWNow3T/wDWPyrQ0WCx+3tBqKwySyFI4xcyNHFyfmyV/i44yQOvekyG4pXPTvCuo22s6PFf2G4Q7BE0DcG3kQbWjI7Yx+PBFbA+Y5A47GvCNbsING8VarDpV7fxiMobea1u2Rh8oJViOHwTjnPHGar3viHVrm3htr3WLy5tiCGjJKeYpPAfaBn8etL2d9Uc31Xnd4vRmh4iu4LjxNqVxZENZPcbY3QZ3nGHIx23A896jRlLeWHWJHYL5jngf71ZlpdeeD5X7thhdkoCugPTAHT2rQ0mPTrlLyDVNXttMuIELpHc8GVue/cdOnPPtVWO1x5Y27D0AjeSP5fkP8LA4989xVxPtlopaMvHHcxlXwf9YnXB/T061kwMpNvJgoGADJ1IGO9aMUs24RueIwRGGUBsYAOT1PA4zUsiaEJxGpwoOcgdznrUMYZlJDMFIBLAZx61MzgbgMEnr7/WlbOBj7rfLQSLsGAgGEVeFz19q634a6c7z3OqSKBGmbeHjq3Vj+HA/OuNlHmxFSSQTjAJGc8da0fAHiSGw8SXVhq94sFvbxPb2ZeUKkarIQVaMdN2AQzfMTn1o5W07EVU3B2PXj6e/Y0p+vPrTJSqMm7ClmC5I6+1KHRiwRlchirbTkqe4Pp/9eszzRScKctj05pM/LnjOccfyoGOeQRn0HFAyCemeuaQC9gQD6YxSdGwM4/SlTCkgHnqeev4Ue+c49e1ACKrHOTg9AO1KvOB2BpB97oRjnr60EtxyAT2x3pgC8Hb1x156Um5cZDc9ue1KegwDkcYoPUtjjofYUDAA4xnof8AOaTIDcDjPFD7iAQu4nsT29aa7qsyI+7MmccZBwM/hQApDOOrKPoDRSDAblSRjoo5FFADkzsAOePWnbcNu7n8aam3HA25P404HOdoyOhpABA9cDOaXk4z296TlVGSOnOTQmdoJ5PegBR8uT68k0jZC5A3EfrS5IOfftSB137NwLY349RnGaAFPcCqerzfZtMunAbPllVGM5Y8AfXmrgIztByetcz4vuwZLazODg+bIufvc4QfzOfahFRV3YxJ7aO1QNIzKBGBHGSSzdQV6YHAJ/Gs65mxAEJcruIRW5cAY/SrtzcNGJy8xeTOwZbOARgj3GOefWsso9xcRrCHlmmwijOWLfjVI6o+ZX2RGXfFFEMc4wMfU98VBkxtsYhsDcWB45Nburw3emWsWn3lvbRZY3Cyrh3lH3dpPtnp9K5yYZlIHPc465HSqRrB8x1Wk2VsdH33KxrLIPNBb7xXONp9OhxSxIY4klUSRBW2lkb5h3xx7Yp3h4tqVkttbtGL63Lfu2O0yRk5BU+2SD7GtPTvD161yFutsMR/1irJueQDsuOg561LMJSs3djPF2LzwZb3twP38TxurMMMcttP5g5/KuEUNt2A4LfcJb9K6rxzqkF0INIsChtbaRWnkT5gpXhYx7jqfwFYHkIbLzFaEJGcbTIA4HqF/iH0prY0pe7DUqwqdzFjnnHHXP8AU1bv0NrHbxxXE4ubqD9+h+RPKccKrdTnGCOOlZEd8RcQMVBQfPnOOvANSyyCV3l2CIIoRY1UBpsH77c9ck81VjaUHfU0re1+0R7QpLb8YU42jpiobuEWs7QbRPI7iMIinLNngD3NS2k5ilZyN03Co6H5dwI5x3HGKij8z+1IL20YtJHIJY1Y8FlJ4qSdUyLVLW6sreO21mzltZZ1JjkEqyIfLBdgWXPUeuMYrIvg8epPbvvtkwrlCD8245Uk9gPT3FdTqc7XkUD+S8McSsoMzh2kLjGOgyFGQO/NZJUXcxLMZGfhnYku+0Y6noAB/SrTLpztqyDT5YZbponkCKql2Z8nBGccY5yRiqVzF5MkZQZeebGxixJLnoD+grWO5Eby33RE7th5Jbsc1W0O7ji1C2u9UtxJsuUcxbQyIo74PVh6+1NPqVfdoVmkmRIrhQgiGxvL4YjdkqT3PUZpl9aNMZXiLbiNqbpNu9QfutxyD69afrkUkerX8XmBIzMxQ7Scqx3Arnk5DA0y1EcarFGwbYBlGbcfoT1/Cl5hHa6Op8G6AdcZtQv5GSxQsihTtZiOvPYD1rS8b+GYodNF5pKEQQpiaDcXXYed6A55HUjoRzUngLV7eDw/JZS+b9os3LlACzSIzZ3e+C2D9K7eVooUPnMixjhtxwpB4x+OelZt2Zw1JyjU9D5z1MTR3UclsU3bPlyCF6jHTtjPPXmtLS1vIrm4ljm+zPPu/wBVySuQQCTn+hrW12xXS9Y1HTih2I2YZCxBVGGVIx6cr+FZkcoWMBlIJwMp2Ppj3rbmujtcuaKsR7Y2u5t6oVDE5Y8sepPvTRGZMPndIjfuyw3FR3H5VUtVaTUd05WWEW7k5U+Y8hIWMIw6cnJ/3fTNW9QLadLJbwn7RNDHmR1xseQdcHpjp3ptDSalZDLcMC/BdOSu88g554q7bKxiOwLtz8pBII/OsrSJpphulkLsHJbZjhzj5MjuAen0rYgCRAeWflIyD+PWplo7F1BYw/mKrgY2nk96nkO+LHHB52joaLeH7ROCAm4A7VY46jnH5UADJQ5+bsODUmI+0UG/tQcFPMUkt93AO7HHPQGuJhcI63MQ8u5mYXLvs+dpM7stnk4PHPpXbQ201wLqO3LiaKzuJ02nnKxnAH4kVxEAeSOGQtuSSJJVYLy4dQR/P9DW1LqVFXues/D7xhcaveT6Vr9yj3cpM9tKi+XvHVo8D06juQT6V30cdvbyXBiSON5CZ5dvBc4ALEdewGfavn7Q7+90i7hu9PKiVQcvKgKgDqCG6fUc4r2zw1qcGpaJZavdJaW9xcIIWdXyud3CBjyQTyB6msqseV3RwV4crutjZDBgPmyCO3oelOONvBOB1owBkBccelAJ5zx2ANZGA35iwGBx39fpRjGe+7r6CnAZOfX3oXG0Y5XHU9aBBz8pJ6H/ACKDyOuQD1FJEenHzYxx2pEKsMp26ccUAKTkHjK+9AOcdhjp3pQeeB/+uhv9njt7CgYgI3MMkEc4oBJz1C55ANJ1bHQn8qXofm49TQAzCBmYAnOOnNFBOeMsp9RxRTAdyqnj5h0H96nZXPzHk9QaavHck9Rj0/z2pwwQMcg8fWpAByvPY4oBPAPPHUUjYUE8gE5zSYZm4YBBg4HUnJ4PbFAC4A6Agjrg804jnPHHuaQ9OAMmlx37j3oATOATkZ7g1wPiSYtrl6ScjcsQ4ySFHIHoK748E4yO+fWuC1SKWTULwAKN17KAS+Dk44Pp046U0a0dzMY+Yskj8AnPAwCen+fSngTWklvdWTok8JDDPzZOOuO45xjtUd2pQlZMfKctnsMf1psV0pVGaQDbn5hwQSMDmmdFhNa1G41e7Sa8ZF2psREGFUd+vcmqKKEfeCpXqeM4FWQYGsPNniZ0LMs7CVl8rnMYABxyM8kHJBFVprWRDPFkB0XII4B9Dj3GDVFqyVhfM/0iNoJGR1JKur4YH6jpxUl3ql9cR+RPql5IHXlGmC59iwAP4Cs9I3R2jM6T4wRIiFMjGeQeh7EfrXfeFfDWjT6Fa3N3aw3090hkklmG7r/CoPQAjHHPFDshTcYJNnCK4RdoVUwMFTxg+1VyzJlGfzCpAZAeAfQ/4V13jvw5aabpsN9p4eFVkWKaMOSDuPDrnoQePofauOEMpl+YgIAcN0LZOf8AP1prU1pyU43RYsdOuNTuls9Nge4uHXef4VUZ6uT90Z49T2rb1Dwjd6QdPlubuzl+0zC3lBBQRnBbIJzlcKcjr0qtb3dxbaHLHaStELi8ImeIkNtWNdiZ7A5b8j71Z8LpZ3N/Jp2qvJ9mu0AjUyHAlByrDPRvQ/h3pXJnKW/REsPg6/u9Ja5tb+2csnmWyqxeOXnIORgDP5+tcxaPcG8QxSSxSw7t0WMEP0IPHA4rpr611TwK6NaXok0+4fy0LJ8m85OHToG4OGGM81g6nqb6jfJdTpGbpIFtpJdylpm3ElyV6DkADsB1poKblK/VE+pal9qnhkuDKfKUbM8Y424NZqNZOsjaZMdpbfKmPm3kc/4+9TrK7tLG0ju8i5eKIj94i8/Nn0/CqWU3y4d13kEFgc7ccEeoppGsYpaDb6adYJJY51gAB++MZPqQO1WYpgBGhiXeF+cg8RqBnIPc5/nVaSSSYeTHJIckYY4Ltnjj0+lVLq9ngkKQx8ZHykYMSjAPzfrj1qkr6GnJzKx0UuoLdPbvdrPNqKoIm81VVNgHybV65xjJqobiSMEysiqxbIkCjcWPYDBzmqEtxCv7xoJZJy4fLR73UqTt2LztJHH0NXofEGnXGlQWNrBD5ywSC/hms2NwZ/4MMwxt6dCCCKXKzNwcdkWNxgaG4DXljdR4eOaDDbSeo565HGD61o3niebVtDvdM11LK+srmHYZYwYZkbP3ipyvBxgjoawUgSOBW8vzXXkgucs/HQHoapXUstjeGARzrJjKglXUMeCuc8DGc88GklfYFTU99/6+Zv61dSajd/bJoxFmMRxopzsVRtH19zWRLE8bRsZxydxbrj0U04mTcCA8iopYuqM4QA4ySOgFS2EtzdwXkWlR3V3IsSiUW8SuhBIJByR25GM4xTSY0uVFJooVt4/7QSSaIkPOLc7N+D90HqO3NZhidVncwmFXO1B5ocxqT/EQACQOeBW5aSA53qwgbnzB1I+nHHFVSUVBKXAizuRQMbVxyc554zzVJvY1jOxV0+yFgs8tp5dylwVlKlipfHG8k8DgDiujtWLxmNgVx0XHQ1lM0bpvgdWBQgHkgnOeM8cj1q9b+blznoOAD1/Cpk76sieqLLosa7sttZuD6EH9OalRCpITIbGT3pur2N3a2Gn6jcTQi01HKxRREmQcZy2e3GMD1qWHlNjEhSMkZ6VBg3pc3PAtrLNrlxIi7litnUn/AGm4FeZWMLrpeny7mD20PktGf4gCcbvcdMj2r2v4eQfZ9ImvJsgTykrxz5a8fl1NeI2d/wDaGN1PviimZ5pFZsIitKQAoPQDK569a0p3d7E0m25W8v1NFU8yMZLDjBORn/69allczR6LcaZFNBHCZFlj8+Iy7GXoV5+U55z1yc5rNWL5MA9yOvWpVOVHUEgNyCCfp7VT1Kaue5aXew6jYQ3EcscplRd+09COuR1HPrVz9CK8q8Ea7/Y+ofZ5IUa3vZUEkxbBjPIGPXqMivVMbML0+lc7jY8+pBwdhQSffPb1pG/vADjpzQT8uTz34pD13ADJ/iA5+mKRAbeT3BHI/rThx9B2pr5VPlXcewpcYORg446ckUAAPopJ6/WkXJAyOT1BoPKjAO7HHpSnIPLcHnntQApHfHv1pmDjnrnHTtT1HY+nSo2bDBc5z1wRk+1AAVcsNpQHHOaKdIdpDDj+HjH9aKAFBwcPhT7UHryMmmJyqt8wHHXv7VJgglskE9QaQCjKjPfHWmkbUGANo9TSgYwB0NIfc8fWgB3frz9aQgL754z/AI0dWx90/wAxQeRz+hoAVQNw3HGDxiuAuJXuJbglGyJZGkIUAt8/GPXoBXfg7RvP8I3EA+lec6OHCRSCCeeI7nAVudxPykD0z29eaaNaXVmdZWtxf6ylpLcxP9pl/dmOMDyowuSCOjMMNV/xRoI0SOCVLl54pWMfzKqlW69vUZ+lZ4nk0/WLe8A8xopPMKjjI7qR2PJ4rqfGeoWOo+G1NndQTM00bIqkF8Z546jiqN22pRtsclYySRXELQT/AGaaUiMzNjaFJ6t1470t2WN/cB7kXEiMd0wORIfXNWNCgM90dgtWTAEyTEAeUeGYE9CvB45qiuwsip87ElR6uc4FBorXGGKXeAoZXEfmkY6xkZDEemORWx4U1DVLOXZplpcX1kXPm26KMIxGTtY8Kehx0NYUf7ySTyEaSURlmVASSF7/AEH9a3vBmt6fpllOlxKY50aW8jXcf325RnA/iIK4waYTT5Xpc1/EVzceKtPitvD9sZ4CVe5mdxH5TLyISD/Fnk+mB61xc1tcWkxt7uGSC4Uf6s8n6gjgj3FeraTHFb6ZZqu1fNjErk4G+R/mJOOrEk1H4gstKu7bdrEFu0SjHmynbs56BuvJ7ZqU+hhTrcj5baHkzXBtlf75gfb5sYwC2DwfqMnBrUsPDt3qrq1hLb3OnuRm48zY8YPXdH1DDpxweoNb3irQlsre3/sW1i8kusc0Uce+R933CHJ4Awc+xrkLWW80+RrjS7iS3kaMqSrY4zwD1GP5dqrpodKnzxvDc7j4kTBrDTdJgH+ky3cMpdxuEEaHJd/r90epJ9DXD6tFavcWrW5hkvT9oe5ePGMtMWiRiON4XIPtgVJoxhS4nF/e3KrODLdXTgyySEDG1fTIOB6DPrUVz9na6drOGSO3OXhWZsyHgHLHpyc8e1NaaCpx5PdKoikbbHJs8sYOBgnA7E96gjaN5GxONyhlRiucHJxnjGM9+takls+03LxMtrKzAyMu0buPwHGePcVmz3kUKp9pykxVnaI5IPHyoOOuM8+vSmtTeLvsRNDIVJE3kqX2SzJgSEYByCf888Vq6To7XVxIlnd2iNCDNJDv8ybaD18sHJGSefasZ1uZbKVoo1WXaoCFcruUcZAzwo9Mmr/wzGnv4vsrWeOSdnDvA5smhUumGAjwcqASzZfr35qraNl1E+RyT2N/WvhtNJYObW+Zrh8OfJcoccEgZ65IA6jANZer2kVnqOnyQadq9pZTWqzGKeKSRoZSTlGcAjKjjBz1zXq1lrulanf3VlZX0FxeWw/exxsCU5xyR71fja5VQHK7s4JBI4/rWfO9mecsRUi/fPEPMhmg220qveCURvBKp4QjJYnIx2AGDkmnzpEhkjgBWJihAkAVgwHzAbe2SfrXo3xBtvD8OmS3+s20YvGGy3mhQC4d+wUjlvfORivNCZ1iClD5hX5iMAH3B9Kpao6ac+dcyIV8wb47dzE4bJKMfmHb6nPUdKiSbW7cWyxalD5VvGscOy1iDKCTuYkqRnk4xinQ2r/aFllYvKgYLhfug9cDuTT7pvs+FiDMPLDOpQgpzjBH61SdtEbXvpuU7O2ntrlIUneaEuzK8hLNyckE9OuTxW7DZW81gMZW7j6NI2RKCeins3PT096p/aFhhRAsyMzEmRhgcnqB2x3NXJXWXb+7Rkz91ic/h6d6mTbJk2zLli83UktUlj3qufKyQFPdm9vStKyg2qwzyp5P9739SKgsLLzNSDxwoJpWCsGJAb2J+net5dJkntzdJMCqR/NgdMHp9cEUpPoTOSWhmG3QkBWmbG4ojsXWPJydo7ZPOBVmOKRotka73dlRADyWPAp4hGxWDkk/NuXpium8FaaJb1tQlUlLf5I8rwZCOSPoP1NTcxnOyudRDANK0pIsl4rW2YFCMh8Lk+/Y/nXgNrCU0eAMmYHB8skdeeQPpmvb/HmoTaX4O1e8tSPOSEqGP8G4hc/rXi0tmLD7PblFRGiRmUHdtXoOP72ADtyP1rSl3Jw2zb6v+vzG7ZPmUbWjwAGPUex9/erhfnLMXY4XLHJwBgDPsBUPliGAyB45gdqgqxGDnqykZ5GfxqYrz8uB6HH61bOjR6jnKvHtIUkdMGvWPAerf2hoMUcjlru1PlS7zktx8rfiP5GvJ40XcVwCRxwep/8ArV0/gG6W18URK+5DdRGD5TwT95cj8D9M1E1dGFaF4+h6mAVIyDjHX0NKrAqGzlcdu9NYISRnBPpTiTnoAe1YnCITwCOQe9AP3uAR1FDNycDIAzjPWhwSMdMc+tADA5DMCMD1z1pQwACngHAB6/hSg8/3uOtKAMAnqBzg8UAJnYOcAdB2/OkOAcuFyucn0+lKVcZ9/fpQh44zg9M84oAj2s2fvLg43A9fzopz9toO7viigB64XkDGeopRyMAgrTUYsCD24/8Ar0rcHgnP6YpAHRuec/rSnAwcd/TJoIOMA4I/Gg4I7Z7D3oAGIDZOOOOaQnC5Pb8cikRFRcKrdd3JyT70/JI6Dd1xQBU1csuk3hjzv8hyp99prldE02KXSWu72MsB8kEYJHzYAL8YP0HtXZTwpcxPFLnY+A+1iCR/SuH0rWv7JiutL1K3lliglZdyEZAz6Ht/jTRrC7TSMXUoTFcSQDJTh1zndg5/kQaqQxqWIdcSYxkYz7V0uop5l3b3C2wht2jKJGx3yDvlvTORgVk31uwto5RCIUJxjupzjr74pnTGWhQkhDKCo5PGMUTSyx+ZKGx5mGcoAq5XkcdsEZqQGQjaTngHPXH41Bqk0Zs5V3uVUb2Q5C8YLDd7j+dNFrV2LMH27SNZ07Wb+1uBDMTJ5u9QZCeqEDpkc4PUVivIDczvbwbYWYkR5wAM5JFexX9ja6zpT2k+Xt50BVl+8nQqV9x615frug6rpKXEs9p51nAFY3kWApUtt3BTzkZBI7DnJpxdyaNSMnrozd0HxqbeyhhvYVuYI/kEsR+cAdMg9SB9DWgPHNlcB47rTpltHUhXUrMeeOV/WvN5keFXdZX3xsEU4DAngHI6n86bb3chmlWSNURcYQqUYj2HIxiny9TR4aD1R6Rp8a6gkceiTS3Vsxw24FQJIyHj3buV5+UgDoeOlcU8hZPNWMK7DkJyoOTnnp1B574qMX8tvaSwweckdyAJgjFS4Gdqcdc5PQj3qOIF9xuhtPyKsYbIjA6dOM579gPei1hQp8rZb0mwe6hfzbmOCC3Uvc3tzgbFJwMAfkK27bSdEl0fVbrS7y5vmsgTNeTksqOuGKJFxwRkHA79TWDG7rCYnDPBM4crnHzqCAc+2T14zVrSJLvw/p+sRyrPO2pkRh7g/dUR4Lhgf7zAYxj070bjmm07Muapqk66DFFJGIggk5i+fe+AoZh6gEgYrA1S3WFCIZXFsjbELHG4ddrEdT1q5ePGLQLppu3EMe5zJggLxkY9OM59ves2aIzBYJgZIGbLIMlc9CQPcf1oiVTjYdptuXto5IYzaeXhYiJXKquTk8nJJ9RWjpWty2NvMlrEYLiXJMzMG/dEbSu0fe5yQcjBOeaxbyJvsq7/ADGEI2tsc7WXPHHr0qK7bYiqkErMyuACcOpXqo/lzxVWubOCnuc3oV3qPgzWvt2kBY4mZowZQJVlTgsrbcEgkDBHI/GvWIPiVqdzZRFdGtre4lYxgSzuwiO3Kufl5U8jk5z1ribSIG02x2skIOOJMKRyMdM44rQCxrbNGDJG5YlQjdMnJGfTmqnJSeq1LxCp1WnKN33G3cl7d3LTXlyL67XCyTTnGzJziPHCj2FAaVIEaaQAZIIB6jPYCoXSIohaWXMZOIl/iI7Y/LJqSSS5jjWS2ZY2U7mJOdoHtjrUkNaWROmXO2ELubgspzkn1p580WEjRGOTYVDRtzjcdvA69sntUVil1q14ITJbpI0bPvllWFIlUgHPp1HHWizcS3726j5kiDiULlHByMA9+R+FDRnbU1Gixp8I8iCN2ZwAhA8zHLbh1yM5yOvTtU+n6a8+mNeRlVVXKupIGzAHOPQk1SNquY5TCzrGysNwJVSBg8jsee9OE24v5TbQ5zsQkD1x7j0FQZvyLhhOn30XzI0qbSoB4bcOVP4HH41rXMqLp9vDOpIDsWijO1SBwCR2rnbdlZpizFp1+ZEwDke+fStW7uxcN5IcEQqEBX14PI/H60mZyTuh1v5s00UFu8YuJpBEkb4baWGN2PYDrXpNhaxWdrBa2w+SNdqn+8e5/E1wvgaLzdZkvGG2K3ic5I7tx/IE11Hi3V10XQ5rkAtNIPKt1HG6Rvu/Qd8+1J72OerdyUUebeMNc/t3xHcWy3Ei6XaMIo4tpCSuPvSns3I2jPoTXN3EjxyOZimCeN5+8TxxT1jPlPCgkZw6nzy/GB1AUepzkn8KsfYHtZkaaBhGwD+W4KiQHnOevPqK6FZHWkoaIrxAEjKLuHRup/A1OAc45PFNjj2R43HcO5Gc/lTlxkZJ59KRoOVSjsMAqRgHH8qnhk8maC4QHzopBIMdRtIPFRnO9NgG4dOe1SEgMuQzHHPH6UiGe2Wc8d7BBdQANDOgkUg9QRUyhVG0dBxj0rnvAl0114XtS7HEDPAWbjO08cDtg/pW/gfxYB7kGsXozzZKzaF5XdgdO+OtIDwrA49e9GA23bjnsTwRQ5wmSFBz60hC8DDMMetJjOMjOOQRxijk9GzkHnNITlDtXceh3cUAKVKjn1zSE8gbSegyD1p2W3gY+QKMEnnPvSID5h46jt1xQAyRBKRuP3c5IB60U5+PlVgoHc5ooGOBbJIUnHTJ7U7sMn/PvTVGTkcY79hTjgAEd+lIQL2z1PHvSHBYe/AHelwMjJJyO9IdvrxnB9qAHYzkDnNJnJOOnXpSZ3AgYI6j0NKfnXIPB/WgBEkVywB+78rcd643x7Yqk9rqCA7XbyZyn6H0z1A/CuyHPKgA9AT6VT1KyGo6fLYTqzGWNj5ijCqwPy9+P/1007FwlyyueapqXliaOWOaQyEAKp+Zwxwi4HU5A7j0ohv3fyTOoEikq4ddrqytyjA9MdKgkMsUUa7dtzbzYdWUFSVORz16joaqTNc3l1eXs0YW4uJmmZNxKrk/dyR0xgVdlY7VFMnhu5W85C6LI24ERkkFCenPfpSu4a2aF8lRuIRuVyRgnHrir2rmyn1HztMhMMDwqXjI24fnccfkMistk8yV/N37eq7TjP4/56UFKz1HaT4s1+w0saczRny02i4kjJZR22NnBGP7wyD61Rlvb2SC7iW8n8u+AF0jMW8/Hu2cZ9RinS7FlbftKfdcZ5Bzwce+KriBw+wpJMqJ5z7AxKqejcDgex9Ko2UY3vYfYxkuqPMY0kl+8x3BATy3HX1xVq/+x/2ldxafcm7tVYBJjwX4BOBjqDWcdRjhkjjf5m6gqMcdq6S11fTV8ANpUVq4vIGJGyPO4l8lwepbnpx3oYqnNH3rf13MEI4yYXAnClV3DgEnofQdKtkxxkCF22MNzYGORgkfTIq1f6Xc2Vla3V3HH5dwSqESBmyBn5scDI9zWc2GYlWwfcZwaW4KSlqjYvdNtreGN7xbq4d1+bYyxxozIHj2k8nryfwA71mLGsUhSIhiMBifbjBH1zU8mpXEljHazSI0ERGxHG4oF4Cqc8VXkuwstv5kaJ5SbcgcyDJI4746Z/CjUmKlazFlMZRWZW2qCCF43cdCO46cUkVv5siJFD5sjPgeUfnLY2qqnpjJyT6ZpshJ81thZ0YbYwcbySBge5z+lXtDvhpurWs0oMu0srFeGUEEFgD/ABKOfwoG7qN0P1LSba3sJpItUilx8sgRRFET0JDMQTjGMj2rmyJreBprie2uDKC8MkAciZGxhxnkHIKkHow967vVtMge2dzJp8trcAr5ryo8b8nPHbjtj6Vjym5kt5PKhMltJK0FlG0YfIQBicAZ3cE7ecbvwoi9CaVV211MLTrhFj8r5WYgHujA5BywP+zkEds1NH+7uYXnjTytmWhYcsRnPI7Yx0qzDaLcarJYvcRrLGWViCZAXCEruxzywwR2qlbyRzQWlxHbubeaNQ2fmUZH/wBfp7UzZtNuxJJciO2CNDI15Mf3KsAqKoHXd/ED+lQ27IUllgkWIRxoZRISSwJIBX6Ec+1Un05Xj32d1JHGMyqboO0YGfTOemTjtUsMsM+q7FuDL5kTR+ZBGHjaMYYdeDn6e1XZdCmlbQW6jtr27UhBFASd0r4cKCNoDDpkDJHFWrKTzYLQrbyx3W1t8IYtkcBQe2cDPUfSpJAqTRjPltg5XIwenzMOn4ds1QlubmOdhb3TxISDJGJiquw4HB4z2BPSktdBP3lZHSx6zc2+mRW8G3yvLbEhTko+M49aqW0pR42UsQULB/u9O496rWnm+ShZi5VdpLnJAHTPGPyq2HCKoLl4l+chsnc38R/+vUNGFkhtpvhfzADucquDjAGf5+tXZFjgs5Lh5leRh5pXBBJY/wD6s1XswC+64RkVySVjX5lU+me5p+qTBLUoVj3MFj2nB3gD5sfUdhzRuyXqzX+HOrW9lDqV9q0jWqeWrfOpwFDEds85IUAck5xWV4m1ibxBcm4/fW9hD8ttbu2Mnn94w/vEcew4rEdIIrS28jzkiXcyxGRmVucqWB7rkgZ5GTVOFJpd8crBkMzFQpP3TgjPvnOcVair3BU1zOZYSRpYrOKNI1eORkXnY7h24DE8AA5I+taAkjNq6SwSNeJKAt15xwqDhoynQjrgj1qgse1rafyowwjkRtynEwZsEODwwXkA9qkhOz5MnaBgH29KplctyR8gnGQM9vSmc7h0AOec04seM/e6Uu07SQBjupNSMRs7iBzt746VJuBTDFjJ0GOgHvTEyqhQSCODznNSJwGAPsB2oEzr/hreLFqd5pzu2Z4hKi9VJXhvxwR+VehsdvAGRmvKPBWU8VWDZVVO9GPrlTx+JFerO+1GYIzYHRBk/wD16ynucNdWkO7hccnuBSFSfQ/1NBVs/wA8dz9aTAUBSxwpzk96kxBgSMDCn9BSPyfX1GemaUZY46Hse9N+6wCknA+UHAz70API4KqCcetNZgQBxkdR1obGQZPlGQeuMUAsBgY4PXNACFmAAjZWA45zzRTkOM7MY9ziimAAglQPmPXPt/jTxwRyB+uaaAN3IA47nn8aMcEMCM9akBwBLVFbTx3ltHNCxeN/ukjB64OQfpUvJJ5z6DHSgknknnpnOOPWgBMDJIxkDAoHLZ+YdvTNLnAB5B7A0u75sZ4HGMUAH1xjFRTxR3CqkyCTbIrgHjDDkGpOvLcVBctCgaW7byoo8YkdgqsSDn8umPyoA5bxXokcc02r2q7lfBuou7Acbx+HX8652aJBakrICckDBzgkfKff3q1498V21/px0/R5riUyORO6REK8e3OMnsTge+KwNFga20O2eXzPJui00JeXccbiMA8cDHH6Vpyu12dtNS5byL0kQSxikkZPPCDgZyw79OAAc/nUBeNcPnovPvW9o2hrrWk3TQyMl5HIFVc4UgjgH6/0rm9rxyyxzRurrlWyOmPWki4tNtCXultHpKah9oiLNGs0tuFIZI3OFbPf39Miuw+FV1bzaJeWZSNb1JmNwitnejcK30xxjtWVoiyrZR3m0+Xve2QOAylVAyCO6nJHPpWRrUUuiaza6x4clFl5qsVhkG5Ny4DxP/eQgggjkde1P4tBv96nTb16f5EHjbQG0LUTaW777S5Rp7YEfNHtYZQnGMAHg1jpHNA4O6N8tuWUkgMuOmPX3Jq/ql9f6/qMdxrFyS8CsscKx+Wq5wThfwGSc57VWdmkJjmhPlICMRtk4BOCwxx6jrxV9LHVByUUpb9S/a2r3eoW1lFJsWaVQWcjCFuOR6cde/SuuuPBOh22BLr09tcgYzJcRAAn/YPT6ZrzyJpIRI8Tss0AV4ZAPMEcgOVLj0JqS60aDVdS1LULWK1u7i8lNzJZybfOjcj5lUNw65yV5zg4xRbzM5U238Vka+u6dceFEtbm6eHU9Pkc+XcxrhGI6RyYJAyM4IPPTrUT3P2iOOMIC0rtHCqsCFZmGAMe/qas+GNPv9F0PXH1mwuLfSZoAq2t4FjEszN8u0KeNqjqOuKwbeWFrK1ls5IZZWgNwBbkfcjbaWH91gwXrySTxRYSV21vbqX97M8glXy5I2BKKCu1g2CPpwRipdI09dSmZJoHeOaYGVk4KxBsFiTwAM5J4zUbHzLp/PZ5JbmUkvIMNljk8++TSWWoSW8V1BGnmRysVLEkH5T0PqOeVPGQPSl6A78rsNuLUWMa2skkFy9ufJNwkezzgvG/HYkYyfWtKy1u7F5Nm3txaPtyrMTKjjkFccDkDPOTk+lZDS7JFBjlyoCFQ33gcU6W7b7MqJbOZCS3mlgUK9senfk0WuPkurPU3PB1pJcalDcwmJYdPmSS7m8zaEOCzYB79TiqeuHTZNe1BrNi9hM6PH5OVC8HzcA/wk4I9DmsqF50hl+xXckQuMC4tyoXzQpPBIPP4+4p0lswQ3DavD9qkl2C1A5VBn52PABzgADOQaduouS022/IqxRl4nkmdgSxXa0gwyk5APcnHsK0IWAt4DFbAJGuxmI4djycn1I7DtVN/NhncSeWRIgCnaTjkhgG7ngY6Y71ftZoZ9NuhcXFwrM6y28TjCqynDOwPI+XihmktrkfmIUYmOMsrfcdSMg9wfTikmkR40Z4U8gucPnccY6Ef1610Wl+DdUvIFlaa3t8kf6wHzORnJUDCnHY81U13w5qWheRNcSQT27v5ZdGYeWxB2kg9ScY9jSuY+0g3ZPUxZJooo5C/YcZ6jjr9elaq28kFwbco6XKlkaMSb8kdcevvVW3czQSW6srFgyiCRPvttOMcZzweDW74Z8Q6db3V9e3yXFvLeBXtjKp8xyijeucZBZsnsSDmjUmba2RSjJxG+wtI8hiRcffYdcd+KxNSupmaVbhrUTxM5iXydxTnq57NwRx7+9RX2rzTXtzqBEUTNJIG81S6BWGMHkZwDjjvWdBAxuLhxIzPkRuASQCvP3Txnkn8auMLascY9WTSsJJQ0eDGzEgDPf3qeNSjENt2EbwVPT0Hr71XUMr7FDEKC5dmyWz1H4Z/IU+EsqEuGXY20Ec7j6/Tt+FUy7XLTSvI6k7mIUnGcnnk/rz+JpBgfKGx3NJgDlTxjPK4NKqgnIBJ7bjUhsPQfMVJGTxinhRk9ie3ali5XDKCvYnrUmDGNyquWBA3LupEsY6bcL8pPA46ZzT4xlB/COS1SRCN7gBW2RFuQ46D2rRlhiMaSqAJJQ2Il479QPTr+VJuxLdiLR5lg1bT5psKsdwjMSOnOAf1r2E8OcZx65rxg3axPHPcbWgt2DYPTaDk/XivY0dJkV0OUkUMjEYyDyDjtUTOXELVMeuH+Uv+JPNIMDJOeTxuPT6U7gbjtB+gpu3JyMe3H8qg5wLb2wGG4c5z/SlPTB5zz+H0puRkbuozjIpNo3Z2/NjIyfbtQApw+CMgY6AUMwKrk59fUU453ICOB78CmrlWLZJDHJJ9+9ACS4LfMAeATn6UU3aEONp4HA6nFFMZKhBVQCp7cU7opZu3NNjUhR8wz2I704gFjuBz/SpECn5iBjIOeT6077y/MOOhBpgJBjUKT1BYD7vHelBJ3ZXAJ/OgAYZA3DleaU/dOMYo5K4yRTQcHI59e/FACTSrBBJJIcJGhZjnHAHrXj2t6tc6xdfabptg24WJGwsfPHB68de/eur+IWtmOGTR7eVmdzuuWIx5aEArGD3z3715+zh92OvGK0hHqddCnZczImMf2eKOHAEMqykAFlO3uw788+mTVg3C2WrC284R2858zypnMgh5O6ONuygkHH+1UYPJyAV9PQf57VQubKJ7957hMK4EoIY4Y+ufXGc/StlZ7nUkup3Gm39xpc0ot0DRSgrNA4+Vx06jnoeorPmJknaWQ9SdwUk8Z6HPX0qt4c1BgkWk6nKIoDIltY3MvCyHHyrJjsfuqw6Ec1ev7doLgQXMJjlT5ZAT1bOeR/nNZNWdjLaRasb6O1s5Lac7IZJN6SLz5T4wQR6Ed+1VvFKo+n2FvFeQyyxyzT7rchxECoGCfUkE1BMFIYhAjZ4VBhfqPSqsygr8xVXPPBAP4UlvcqKSkpFW80t2tLGZ9StbPUbyLz4VkDFQgJClpPu5PpjjPNV7htQhmNrdjyZJVLRyKQ8bj+8jrkH3x0/GtcXUTWcdjqO8wK+be4SMObR+4K9TGw646HkVV1B0t7KS1t7h3jLCVpo4CsaMoOAN2Dz0Y44HrVp3Nozez/r+uxk3E5tJS52FXWNZUHzByWJV2HcqQeevPNXFeC6ikhIgmeVwVhRQW6443Dggng59arXcLXsaRlfPnhHmRDeI/JkGRgqSN/JHA7c0l4qNe26FfsUtvM0/wBiSZhGj7ArZ3cnPP6VVkx81/U6Twx4Ztrq5t4Hub2axkDBLeOU7YnBwz46Lg/KQOarz+FtXmksdE8mG1tZb1y1ykG0iBQC7Dn+8q4z/eq/4X1mz0zWDBcMDZbHiJj5XDEMWIwCDnaDjHI710nh+7S5+JGvvc3IeIWsEdlHnKBB/rCB03btpPfA9qi8k7nNOpUi2/K/9feY/i7wq2j2NlqVpcPKIsR3RYFi2eFdfQBjz9etctbSLAGV5eVPfqfYVsanqc1na6tYTTyvDdxSwqsrHPnh12nB6AgHn3FZFyoiIk/dMSPXgc45A6Y6++KS21NafNy2lqOgc7bichpcFEcRMpZWY4AAPXAyan1GFbDULmyuwhltjsIYhiDgHPHB4OcGligaN4LWycCY3aFWTAO92AVj64wOO1dprOieZe3K3d7LcajLGqyTMqxRAchcIOMe5OetF0iJ1EpeRxiRRWtpJbi0Mlw7KfPMw2xIDuyB1LN09MV0Xhi40SwlmOrywSCe1WRXkXKxjJDx45w3f1Iq9YafpU/hOOa507y76NWiuSoKNBMh+cMw5HcjjBGOK5iRJdOmlZDHLFExQSMm+KRSuVb05HPsaG76EX9omjO1WOIkz+ZbOoZ5R9lVhHFnOFTcMn5dvOOua0NASGXVbd7mFHtrOJZvKRcGVtwEan1LOcn/AHazs7IlwhJA5PqvXIrR0Jzp2qLJNG2UkSUoeu3OeffBz+NNs1l8Nj1iGFltWjnbc75MrjjLNyfw5x9BWR42hgu/Beoreh40jjEm0nlGUgryPfFbc97bW9p9rmuIkteD5ztheffvXAeMvEUGqQxW2nJJPaxyec8xJRHZfugc5xnn3IHFZxWpwU03JM560YxI/lyI6yFD867hgZOcHBBwcZ56mqRvfMkYbWykjRYZsA7cc47j0pLvzFj8xyis0QmXY+8sh4BI7cg9fQ1UCBmEUiyMCD5kbEtsBPQ9wo9K2S7nYo31Y1mhjufsYkLzbTOYTHgKuRg7u5JJ47Yp0qrNGyujgqeQ3BBHOR/Sp4Ld7mWaWHy2kRRGMsFEqnk+XnliPTqc8VDIrbwGbdsHDNjn04PfFVctaiJ5jQgb2YBuD14Pc+9KIsPkD51PIPWpYVcMSDg8dOlGS5C9ieh70myr2Iwuc4yTx97rmnxrlgCSAo6kcUuzrsIxjueQfWnIMrn5uDnr0FK4MciNnHHHzZ/xodckdwDz71J0RuSAeCSeopOGyE4B65oJGDIBY9PWnggKMlsnil4bC4Un6U12CkE4Iz0B6UhlmNBghlD9h1A9q9S8KXsl54csJ7iUS3Hl7XbuWBwQffgV5mbdkiBcZ3jzFKsCHx1wQe3cdRXe/D9mbw4m7fxPJk/jnj25qJbHLXV43OlAG444X0zR820EcZqNd3zlhj5iV29ce+e9PIxn0bnGeKg5Bc4YgnAPQY7+9M+dVAYA89/WnHJ43Dk5yR0o4GDl8MRj0H+FAApCnkMB02/X2pMN0ZQD7dOvagtyCSNnTIHf0PtSncrKM9OqrQMjVQ2SW+ozgA0USYI/hZc5O71/zmimBJw6sGXKkbSMdafgqoHQDv0pAxJU87eeQaUYIJ9vrUiANh+Tt749RSqSSc4AB7ikLAEhevrQBt6Dn6dB6UAIEGcqSMnr6GoNSnkttNu7iCNneGJnRRwSQM8VYx6jkDtSqRuG4jaeuRxQB4TJKZ98ryNI0pLmR2yXJ5JNUkOZmct0PPPtWlqKG3v7qEoEEc0ieWe3zHiqkkbAluisMgg8GuhHqREIIZiuAcevFNk2OwUja+R8+8hcf7Q7/WnqAMc/jUUpZv3SlSzE5z2A6kj9KaKKs9t59vcKGhkaNxLEJGZdx3FQU4zx17YFdFZeIpZorm11KYuyqHtbt2+ccgNC/qmBkHscjms23tpby4jggSSSRjsiQHksTnj8ahbT5TfxwhJZLnZIjwY8vy3XJbk8EYGfzFN2luS7PRmzBdw3UW6CUOjMU47EHBH5in3MaS2f2e4ji8kyM7BVxJLkAbWbrtH90YznmueW5EYEgIMxj3JI0YBAPKgY6qOPetGfWYFlnBknuIUji3MYf3gbbyvAw2D/ABDqCPSo5GnoJxfQlaGOS3eSzaMhAVjO75S3Zf6VdsZdLjhmtdUsdzTAos6KfMiz/EfZTg5HOMjmqNpcSSeWxm2IIxGF8oYcDoxz3HStHfaTzJdzhl8v7p3ZC+mSfyzSegpPozn7yCIQX7y21xd3NnDK8DWCK4MiYUsx/hQ5HPft0qK/git74wnZOwjjeXYSy7mGSBkk9vbjHGa2717UaiTYyKowqyqwUq+1ty5HQ7Tgg5659aLkNqYsYZEtLZbKPyo5twQzuw+631ILZ6AtVplKdrEUelapcWN1qKwO0BhZB5cLGRwFxkKoweOc57U2x1eRNVtNVtSGEbKG3LjhlClvxxnHetWbxfqNhYtpUNxbSxC0EayrHhoiQAUyDhiMnn2rjxKtrbi1LgbMCMc9sACkk2EVKafMjs/Gd9ZM99FpsNvN/aUizPdGRmYINrBVGMKcrgjI65rntzvHI4CssQUygHByT0UdyByfaqi3Yks8kjdgkjcBhRx398cCrS6gn2JLITRCKaVmmgIAwVQAjd1wQOx9jQlZDjBxVkWNP1WdWiMQSW7swZ7RCgCmTcOCT0yuRnOfSu7k1HSPEmpRSWmoC0vo0/eWso2SHHQBjx+Izx6V5UkiwhOIsg7txByQT+o7D8KDdKHlEKmRVfEbSZBYY6n37YHpQ4XCdDmd0eh6leXWkawG0m5dpZ7Ym4VWE4+QkrnOckL+g5qfwxpsV5by67rN+qxxuXKbhtUjjew6Aei449686tb+ONlcZCZADZ4YHrWihtlsJ3tZGyWCi3LYJXJIY/3up57UnCxnKk0rfidD4qvD4g1pFsIJmt4h5cLRLsMgUZYnPYE4H/16wLVXNutwvmlTMNuJVYE4O5SCN24EZz06it/wJpsc983mwu5EMTKAw+47H5s56cfrXOwXS6L4re3aVrhGkkgJ8wRthsruVv4SeOaEuiCPWEeh0FtKPEGmX8N22y6t9k1q0cZxtX5fLVRnAJIJYc8nJrHkto7uSXaziGGNZtsIB2ccgkDnnjnpxWhp0kOlanve6v8ATzBLJDJJs278qVbg9UDc5HPHHUVhahqFqJ5n06a9mSVUVlPyAKOq8cs2RktnGO3Wml2CMW37pPbW8BguHjijcx7vLHmjKbTlgCcZOGBPucDrUJXbJcI5WW5UBZG6lSDyFOeSSc859KS7vEkhM0Ml2LuQhZ4RGCvl5yzDHLHIHHP6VWup4mvpEt3V4FZz9oAZfNJ6jB6HoPwqrM0UJMld9k0qyojOWA3qo+Uqc/KR06496lGGbccDPGCMVRt3KvjdhVwcknA+taSoxbcxHQDg0noU48o+3AaR2bPzKQB2HuaURZQuMhRzz+XFKFBGQBwe/NIrN5e0E7QeBUkNhgrEc5AHftj1NN2HDMCRwNw9cDjP4Uu0gsGJAbt1H4+2KFdd22TYrAE49R9aBoaTkDHPc03zN0hQHJ6//rpWbKAt6459+30qZLgwwCIeUxG7O6IE5bAJJ9gOPTmgdg2kRjI+bgNzz9BT1tTPL9nUgg5DMDwMdwaZFukUsAe3BHOPU1dg/fRtDsVlOeBx/wDr/wAaRLdjMsZTCs1s4BjY7ii8bZF43D6iu9+G87M+rWytut45InQk5IyCGx7Ej9a4u4aBSGjjKy5OX3/wgc5XHXpznmul+FisuqamCflNumB15Dc/XrRLa5FfWDZ6OS23KZJ6kUZGRu+6envQRkA4IJ7HtSEcFcjkccdKyPOEA+VvpgZ4/Og8gZDZHOOuffFBBVAuCFzge59ae/XLHtQAwKwfJxg560KMHJ6t32/qaAMEKOFBwM8YpCQFyoxkZyRzigYEKpBJbnpjkUUgfA3bJCeg46CikA9B16kk8jGKdycYI+vrTYz8mSR6085ySFOD6UxCnd1wSc564/8A1UgDbiuTjtj+dGCCAckH/OaO/BPJpAHO7joRj6U7GRt6gjFIxbI24zn8qbvGcAsfXAz1oA8o8bxhPE9+pik2uyyAgbQflGT9KxUy37lehywboOnINdn8SImbV7U/u0R4PvDqx3Y5+mf51xkgWOZRHK8pH3wwwv4VrF3R6FJ3iiuyHfgZBB7DpQcGRiRj8Ov1qbAYbWGG67uxH+NN2tjjkjjpVmtxLS+bTrmC5jUtNDIHjUjO4g9OO39KNTuX1C7nuZ8ebPIXYgdz6eg9qBhXL/xYxnqcd8UyRGyc42Dp7/WhDsr3KzxExmJZGjHBOPb/ACfzoRAZX2iNY5WB2nIAAOQA3VQcYOOcHFWHA29tuOqnpzUJXH3DtbOQOufWqTKsJscXHziRJcKSoXjjtz2OauwrdtF84lkk2ksUXHy/TsOQKrbxgs46YG4joKdbXMkPmFGkUSxmFskE7cg8fkOnSkyXF9B00d7FpjXq2ywwxuqPNgeWGwQuR1PTB+ua56DU7ibVJ7kvHdsQwmSRSw9+nHpwa3IJGgljcu20MZDG43Ryknq6k4PtUVxH5t9NNIwWGRt/lou1QT12+g9qqLS3KgrX5kZ8lxLc7WcyZAWMFgM5AOAMdB2xTvMgQk3EUyq+IVnwGRGxnGe2QvfFWxbtGDFEEjhkbfs25Ycd29ev51YIQW3yzSLE6gSglgAM9/0obRbklojIupooUS3y7NKWYhoySmBzg9AOuMmq4umUOd/lrIVMbMpPzDsSAeSOo6VtiG5BmSJ4JRJDtBkyShxwy4AyR7/lWbPBfrtViWVQWbABLt0yRxjj09apNFQknoWnt2SETPKgyMogbJOR1b0OTis4lZEhUGSNg28Mp2kFTkHPrkAD61LFpNwyRkNKQQCfLBbcvoR3q8dEjmiaMxPAXyA7zmVSvBAwQMZ59DkDmhNLqO8Y7sgd/tFw7OoQySNmFUAIOc/KOg9/rTJiqPCRnnIxuIAyBgD/AGs/hWjqGmy2dxNDJcQzFLh0LAbWGwjIbvjkEc81W8iVo1lQlogMfOMknNSmiVJPUba3l1ZBZYJpopVTB+cIQeh4Hb2FNvG8x5nZ/MZuTvGScdT05qWS3VoW2kqgydw+Zhg9vb3p6R7sHb5Z6Mw+Y8dgaL9RaXuVrh3ldZr57mSGBNiLLJv6emcnvj8KvalozaXPaRTTR3H2i2S5R4FKphuy89iOTQLYKmY4dzgkD5/vN/QVui0F54NtxGAs+hlo5EJJ3wucjae+0k9fSk5ESna1jmoV6LAZEOCOCTv7k89OakWMl8KWyV+4o4BqcgKEU5LfNjucdhUhLE4Pyp0wppXG2QLGEO0li/BIz0GTjH61cVFGdhO08g45PFEcX7zJPBHLGphtWPduY8cZFS2Q2L90EEEHIBJppwCAqkA+hpSQGwSdmCffNMPKlgcg8Eg4xQTYRnxgYJwOG9KT5WUA844x/U09goRNh+bHzA9jQGyN2AQPvbTg0FEUxaPnGMLknOc01IZpV3KMEnGSAQD+PFWTAJ7WVUkCynaeB1OeR/SozqEsVhcaayxTWtyf3iN0QgZ3D36CgpbaEdvPLN8uCzqCML91u/A61p2l0D5Ec67kjPIyN2G6gAf1pYf7RhsYjFZ2VhaXEJI1Ce6G5gT/AM8+vvkDnpVMxrbXKi0lEyKuPM2bAzd8A84+tBMrSC5CSyu8ajIc7V38468+wAzmtv4exOPEiPDOEPlPlMH94pHT88H14rE+ys8UgIQ4+UAv2PX/AOvXReCdn/CT2nyjJjk6dvlpN6GdR+40elIGKgSEF+jYzjPfr2pQeSCAPTHH60AYyAcE9z1oPLAFsjGCByWFZHnDEAVjhePXtj0xTm+XhF3epx0PrilG4YwoLZ+UgfzoAAGAvOc4BoAGGBtCnB/z+VIc84+gAH+c0HLKeScenQ0IMcHAI5znPHpQAkvCrvAYe9FMb51BIXBxgdQPwooAlQqygoOvf/GnoP4hjPqajUjYMrtwPpUmeTg5z+FIQBRnIOe/PNHDEAYz6UmeBzkY+7QzBc5PUc//AK6AEl34/dhS3Xk+nbFOznA2gHhjznHrQAAgHOAOCecUu0MMZPtzQBxvj63kkmsJokJOGiZyeEzyB7E8/lXGuZNxZ8synAIU7QK9B8cN5en2zI6xuJshSAVPB+8D1FcBIzCNwSeSMLg4+vpxVx2Oyi/dIpkhcbl3hyc+qEY/MH61AsRd9saZOOmOTipxEwdAyhXcZG48Eev40h3xvmPKlG+VgMMP/r1RuimUOdwGVJPFOdWVQXOUYYB/XrVq6kFwN7RImFCt5YwGP97HrioUCPFi5DrEMgSImdrYJUH2J79qdykyiyDPA69cjimy7mxuZtvUAH+tTtyclckjH196ifOBjpj/ACKotELhtp2nA6U0jD4LYi6jKZ+tSSdMHaV9hUkeQPlVWAYHqcrincdyIxhgVwCCM7c8cdz6U+GJmO1kYAjBfAzg+lSRWvmnHTLZwOo/xqUqwIVz2yc96VyWxpiaNVVmZlK7evUehpAPuqpOOhHWpwRkbnBBPTHApNjO5AVQMZ5NK5FyKXI24IHJB3DP0x6VG8blMmSYEDs2O3pVjC8nGzHUH19qTyi6yDc2FBw3f6+1FxpkMIVZELtMsRBBAJVm/Ht9afbFkfYmc4yoLfKBkEf1FSCLChR1IAyT14qQp5cYMd6uXH+pEbEDB7noDRcGxWkSO4TzEgkmZlYF2yGHcEHrnFRXGJ5QZHWGVv8AllAm0Yz1/Adz6USgF4hGVY5O6QzBl9gBwalSJPMYF3UgZDhcn2Ge2aQtjPvI0C4nhnkTzFzMm3kHsVz0HfirzRRZmMaPFGo+UIFC59Sp/n1ppQeYjvFu2PvGTj69fYmpZnV2U28SpGgwvIL47k++MD9adxtkQUYIO8LglhnIJz/EfSui8Dog1e509mWf7faPG5AI7cDB9OawiEK7Szbie4AHHX+laGi3EVjqljfO2BC4Z8DLDOQQB34PWpexnPWLRhG0eykMcpJkiLRBi/XB2kgdunep1QH5iAZMDB56V0Hi2yNt4gvsH93IROrO2M7h0GOvTFYjIRjOTntTvctT5kmRoMDBYjGBj0p3zDJGDjse/wBKmiiMrrGiEsTwAeM1GP3brIcM6ZAB6fSgLjSpV8lRnHJPYetRPMpQAkZ6EGrf26TfEyxASK3DqOo9CDwaqmJyd5GS/Iz/AJ6UxrzGxIdmcHBPHofWpEKGMnDEYyCRjdzzxTV6ZK4Ht1P/ANar9nbPdSFVtppNnMiLxtpNg3Yryb7a3ieVCVY7g2eHUfyrUsrKO6mntgUbhsrIxXyyDn8enT3p2bFwsMVtLcRRgsYlDbUJ6gH0rNlnZHIDJI2wLE3DswxgA9//ANVLci/NsPbTbKwM8i2y/aJyrElske7d+nAHFOezOVwyO7DeMA5A9fQD/wCvWx4d0aS7Ed1qRENmjYYvwXOP17V0FwdMjWJbSBp0uJSJ7lY93yqMtgn8BxjAzScjOVVp23OattImayS+uU/0Vs7WBA3HBx74yOta3gDTxLPLqTIuxAYoSf738X+feq3iDVJ9euI7GzQrCzbY1Xgt7nHQY7V3Wn20VjZxWsDIBEoU7B1Pc/j70mzKpNqNn1J13cYxt9QetNCYUEc8Z69DR0Y7W5A6etHQOMjGepNQc4oH3yo2+6jrTMfN93twO9OU5IwenBHpSZJ5Y5xz+n60wBmG0Z55BJ3ChhliOCeOvpTsFV/vDvkc4poAVCA5AGefT396AELKgOQgTPGTxRQOSQGVSODkUUDFi5A2two4OOc08/KxJBzjrSR/Kp3AKQMcdRinry2SePakICM9vbPTilP0Awf84phAByPw4pd245OeByRwKBC4ODwOnXOKTOU74HORyfpS5I5Gcd+aQHJJDKVHG0CgDj/iHCzLps42KqF1LsuduQCPzxXIzF3BYJsUkuqKvAz04Nd349Yx6ChUf8vCE5GexrgozuBXAXByGxjt0P6Va2Oyi/dC4kNzNPIw2Mxzj+6enHtUQICHzUJXjjdgge3rSbjghyy5z/wI/wBM0iqXUEFDgEEAfdH+PeqN0iMvsjZmGSBux03ColiMjOYt8sjKXJxgBQMjj2GamdDGnmAlcdDkBgf7wHpSxgyh3TCrgAdtvrkH1NBSZUnYNKRADsGDgnJA+tMKFnDK2V7D0qedUXeoztyQMmmKBuG1QCOCSTk/X3qhpkYQsG3PnPQEd/Sljh64wT1xmnlAODyDzg0n95sDB4454ouA9PLC7QMZ4YE/n9KXG4qSMgDb7UnGNmO2Qc0q53HJPHcUCDaFOM849On+NLE3PBII6cVKoQxBnXqM4AwcZ6UKkYCtGTuAyVCjA+lK4rjDGJCNp8wDkcFTk80csrqrg8fdbgH3pxBAwwCk9OeT3ppLP8ioSwPOAeKBCREyIVGW2c7VHAHc1VvXht7O5lmeaIhP3ZiwPnLqAD6DrT7e3WZVjk2ZDfIHBHzj+vP61baEW6pI3kyKqhypIPf09aexSaiyJgC8cktrGkMpZkVMkAA4OD97Ge5pQluGZhlFOSNp3YHvmkS0u2kMVvG7bJmiQyNhhIeWTnnPGfqD60kcsUipKBGqn72c8n1xQDRI0QEoUsr7R8qq+QD6+lNaElSUxu56sBkDnH1pxkiDhEVQQMfKSdwzkd+KVHLlDFAoJ5PmuSPf2pCVx0X2SCCNY5ZmGDhEiAC+nXk88njpUbHeCbZzGMAYycZxycnnNRFZOMsFwcZBwAPTIo/eqTvwSfU5OPqKLDsdZ4pdr7StD1LHzSRNC5bClmHOcevDVyxdtwGDnIDfj3+lbmm4vfCV7axNM1zYzfakiVuWQjDcHsOc1lWiy3MpSNNpUHDNn7o5JJ9MVK0M4aJrsGcRndgZGMZ5pAA2Mg479hUkIikKl2kZTycDH4e1JIxBxhBj8BTKIJItjgsT0OCD2pC2FIBz0zjipo490u85KjOSRwvf8qRYd7YJwoz82OntTHcbEjSSseC2OnUL7n39q0rK/FsPIjYyTSEo7c5ORyM+4yMfliqp2pHshByBk4HT2+tDLiz88TGNgQyxqhywyVJ3jocjp+tLcl2Zet20+SwLRQG3nVgobeWD9c4Hbt1q1Fd6fEodNKjYjB/evwf+Aj6VmRkxnDgAjHy4z3703zTIXO4YJyxH930H+e1KxDjct6hf3Woki4fzI/4FUbVQegx0FSNezR2iwxOcbt525OccZxSApDCsaoobdveXrkY4UA9Bz+NQ/IMyLGskgfAYk44HQAUC02G+ZLBMxhd1lbhXjPOT29fSu+8KwQRae8qGaS5kCi5kmcuztt45PUYIxivPkia9vLO3jbbJczbAVO3b3J/KvW4kEaoAPugKCBjOBjPH0pS0MqzskhQCVGRuwOR/nvSAkAbgOnekIX5jg8noD6UHBVujDuB1qTmFUcZYHJ60dW4OABu54FAyfmG7kcE/54pR8vQjb6Yx+ZoGNIG4YI244we9ICRy2OPQf54pGI3BlIAI6dAKGwEAyWyOeefzoAa7hCANo453jIoppk2gZDYPOBz+lFAydfmIyRknNO6Hso5H1piY2D5QGzgAHp/n0qTG5jkZXGMUhBnIzkgHn1xTc7QcnJz3OKUkKQWIyfWnHG1hgY9aBDM5IKcgjjGKN43bTgEn5fc0qBQ21ckHjjtS9vmG329KBnN+Pwf7Cj4AAnQ7s9CM4OO9cC3zAyAAd8IDgZ7/AEr0Dx3Hu0Pzlba9vKkiMPXOP61wDXEom3l8TEdV4z65HQirjsdVD4RY9pXnG4c4Pp6ioJOu3naBn1xTk3ux2j7uSVJwffFNjAb+/wC2CME+mao3QYc7ORwPut3pHGAgVWXcMgFf8en0p7EoWUKVIByD2pJDlxvc4xgDnjucHtQMY4tRCpWV2uQRvjIChuDnBHPBxz3zVQtkHcOg9KuPbSfZ0nWPdDI5QsowisvY+/PtVS4Vk2eXCGBfEm1toQY689fwpopCSdeD+Hen+UQm44jJPHzDn8OtBc8FsdScg1PYyW8Qka4gErlMRqxwm/PV8EEgDoB1NA3cq7cZznj0HSn8nlVwMD8vWp5gEXejK+QHKruGzP8ADzycetRwYYjgDcccnAOfei4riwlw6BQQS2F6n2/yKWFCo5Qx4GF4wBz0GenSmqwAySByQBuwc5xx+VIrEhjl8Z6k+tAXLKKhQmVscZK7sBueg7k1ZV5RhopXjwcxKs/CkHp/s9aoxhgxYKzqPXgUquuG3qwYLtXHGD/UUiGi1ex6nPK73gu3Ul3dzHuBKjBO5R146+1U57Auuyzm89Su17ckZOevPb65pY4pDLGFinfIyqKxXOamO5gqpjdgdhn86Y9VsZl6bkpLJdu1wTuDsQCxIAABx3A79+vNJbeU0bGRD+5RlKM2052jaTkfie/05q+lq2CiAbY1PIwAmT/jj16YqQqkkUCzXMhEIIASEckszEk5yxyQOg4+lFzTnVjPhkjZsKY1baDnI29M5yP89qmhAlRnBViW+YD+IgY5p1tdR3TN9q3bQfMlIQRtIVOzywR2JGSfTnrilRoI4uBiQSkRy/MSV549x069cUCYvmJtz5Ugxk/KtR71YIG4IwOhyx96WNJGVWZXCcgs3Qt1xnpnA6UD5GIZgBQTY3fCSrPLe2EgYw3Vs4baMH5eQAeuPYViozoTLI7h5VwEU4+U9j/h7Vs+FVMWox3uVjSB1yzc7txxtHpn+lU9Tha21a8i6vHM6AE5yAePpxU9SE/eaK6CTlXbGRyfY+tNQjAXbnHQZ+6f604ksflwoGTgD9Oe3vT4yFkKRqCzc7Sfu+tMoktLYygKibpicqFPPB7itS/tYNLt0tZVE2oMwLHPyw+2e7evpVmzurTRrI3FvIJ9TlBVWxxCvZv97HasVlicefNcBfMXO4kkg56Hj7x9P1pbmV235EBUxHLEYPPI5z601VgSOaJIllEkgkZvM3Y4+7noOtSJIVi2JgDORu5IGcYA9feo3DJy28sRkgdM5pmg9FDjftwMj5c9PQH8qniPlSMwKEZB+YZBwc4PrzzTIoisTSOpVOgYjn1A+pphzM6RxRsWb+EAkj1pCLJke5uF8+cqsj5llIyf94gelWFWISTGGbdGuWjdvlL465H4Gs23Ekilrdo9g3EmTgNgE9evbjiuv8M6VHqNw2o3kSPErfug2DvbuWA7DHHvmh6Gc3yq7NHw5ootzHe3aSC5YZWM4ITPBP1Pp2Fb7F8qIyu30I7U9jhTluOnFD4OOTn1FQzjcnJ3YzIJH3A2Mjg07ceeoPUj0pDnOQCe+OmaUdCcdOmDyaBBkEFR/F0FRkOFkKbQSCwLcqD9Kc+N+QMkcBRxTnAdcNls8YBoGN/gUEFsgkA8c0j7SowAMDGepNO+7tz9316Y9s0m0BywwHxknrn/AApARJ8qD92CfQjBopysS7bdxxwdqknP+FFMCRTvGAOvt+lVna9/ti3ESxHTjG5mJJDiQY2Y9jzmp4uF28k9OT+tSKCV+UDHrSABx1Bx2ye9KD8wGRkZPFIWG7A3H5eeO1HZl29ORk0CHD7q9RTSejYz2JAzxQy4yFJ+YYzQBhVAy2MDJOTigDG8YwtL4bv0UqAqCQEgn7pzivMAxwpHOMAewr2cqkiOsiB42+V1YZBHpj0ryPXdNl0zUprZhuC5ZT0DKeRgf56VcH0OrDyWsSo2WOcY6kg85/HvSg9QAozzk8E01GU5C8j16g0RuNw3hWPTaRkZ+lUdI9QMqd6g5+UMOKd5iLGQFyQcc9qGBlX5UJHt14oj+ViemfUZP4+1AEeE3ZWNVbqajQBhgE/McY65FTbPnWMOMM2Fyw+b25p1jp66gZbfBMk2IVAHctySM5ICg9Pagd7aspqEw0m5jGcqTtO3PqD/AJFKrDcAR0Gd3Y1qXT3d5c3Ns084topGLRowKqBxjb0xWaQrSqiHCqMZ9z7ULUad9xXJJGzjPA+tNEci79uPMxyCcfjTwm0EyBdvJALcgfTtTchlIyCucimA3LtkkKSMEnbnNOyX/iCoM/eJANKoYL8rfL0xkVFNuAxklM8Adcd/xoAliJbJGeD8uHxzSHBVB1J/vDPXsSKRRAQT5swx8wB4zTUX5hvO9M7lCnac+ufUUAOVdikSIVUfKCeh9v8A61WAUWEggOvGVJ5+oHamGSWWbP2g72OSXJOW/vfX3p21iXMsr+zKQT1oExmUZfudOeQeKfvyzH94FUbRnqPajBByzIw74P8AT1pr5MbE7W44ySKQEZQeQ2xjG4TcuFzlvcGpXS4by/IiafzHCK2VB/LORUaRs6rs53DIz1NRlWXdIsjKw5+UYwPXPagaLKO6KkElwTDB8kSyPuSNSPm+XoDnvzmkkZH3eWuQCBvY4HXj6UyCABZnZ2VUTcjNEWDt6eg9ee1S7ZLlVSFT5bMrPk4Bx3A/rQD3uQBWQMgYl+SVLcBvUelbGvSQ3GoR3ULqftVuksihs/vMbW46jkVUt7ZpJDHCokZeSFOSoHqPb1robDSLW78OI7SRI8NyTNcAj/Vn34J4xgUm0ZSkk7s5rKgAHbjttB5P+HtQqAMJTxjpz098+vtVhzGiERsZTyT/AAqPc+tRSqpIGUlJYAqMhWPYge1BSZHJxIDucTK+SWA2rx0GO+e9J5pU4LqzONgGNxX6e9SCAhljBG8ggbVz839360bigmV1IVhtlwoDBlJIxxwM496YDA6gbZd+CCeF7joM1NBiKUrNEZJCpBCt2I9+hqOKCXeC6kEgcKRxn1qKWIRxO8zTiUnAHVQB3/PigNGWLaFWljcBWkY9CucgD/61TujRR/aUUrGxKht5AAPVSe49jTYpHMcLzKu3kiRhw/GMe+K67wjpcV1b/bbo/aRuMUSSJ8oweuO5570m7Gc5curMzRfDLagkd3cM0NmzE+UNwfAOMAnt7+ld5BGtvEsUCCOJVwqqOgp4PG0DaF9elBXDZ25APCn1qG7nJObluAAGdwC/0pGIUMSeB070qg7Pu89u9I7hIy7KcLzwCT+A60iA5LdwOhB70hTDYJw33sk9TTtuSVPTpyM03GBlVGQOgPamAMxRT/COfwoXaCxYkk/XkUu1fMUqBt6/hQQSwILHgge/uaBkF9HJLYzwwLEZirCIOSF3fw5I5A6dKkUMUj80ASYUMcHAbvj2zTsAhdjHbkflSEYU7QQ2OBk5PtQAOfkzJuyDjCnBopHwo4GW6DJ5x/8ArooGKOgPbPH0qRdw5O0e1MXrgHgDqP5U8LwMgg4xz2pCFBxknPPtnFCngAgqO3tRjpweO3vTV4bvjqe350AOzlAr88c9qGfAPX8KMLj/AOtQF3YzyKBCc5G4EnvXCfEKNRe2sqrIkrqVZtwIcDp9Dz+Vd6ByOuO3Ncj8Q4CYLKfkhXaI8cYIyP1FOO5rSdpo4JAVcKFyVOCpxjNSocZC8oPmXBz+Xv7UKRv2Day5zlecf596YVOSX3KMjtwMj1rQ7tx+Y8kQo6YGSWbqfUY/rSkOpIwAcY+X/PNMUlFGBzn6/h71MuWjBbIUAkc+/ekBHFGZHUKpn2nPlHOW46Z6/lTIVkixLDJKHA4ePqOOcUhY+fFx8pYbgD2z2q0Y55o3NrY3pgDn5kjLIMNgAtxzTAZNNGtlHbWyuwc+bPIw2lnz8qjnoBz7k+1WDaqdON04WNFGxFIJaUj7zfQcZPr0qq8MySRJJbzoXyyxyKVZvX8Kl1C6e8nEuGiRhhIg3EcajAUUhehQCttYFRx1YDnn3pfLAYjODyDkdOlSgZURsOMjaWOApPUmmguhJYoeflIbIwD1plXGxsTI67SxUANjoOv4AUFCVJaRIz/dUFmP5cCr+l2P2/VIbWAjJJdnYj5EGNz/AICtG10ywi0AatqDSTIu91jhXJKr7noTkY9vWlclzSOaEZ4IlPI7pUux41yZUbJ4UgkdP51fivY5ZVSWM26HC7ml8wKTwu7gYHuKilMUMr+VKTGD5U6YyUbuQD36EGncq7vYht1eMLI0bSJklgF+XOOhPWnnM0oREKrtHAJPOOeTRZxXTXJW23tMqk/K20tx/M1bVfPvbaGQtb+bIIcygkA44bPp2pCbICQVxHGoLcAZLGop7dJImUsVDD+I4HXpmpHl+fDnDoxViBkZBxx7cUxpmkhdOXVuc9h9e9AtSVwwUs5K/KFZdvAPTJqjMroGVmMbScYHO4Z/lWjpzNNtXc0CbgPNDlW3Z6/4e1KPJjlIySuTlwck+hNFwTsV7W23tGJyypI+AGb5S3HJHT866uD+ytFib7VGl5qIJRhj93H/ALIz1H51gw6s+zyYEt4pIkaUzOmXZQcfL2HJx9apM7TjzJy7zOW+ZyOx6gD+tDVyZRctzf1DWr+RW+X7LErBR5KiPd7Z+8y9Kw2MZieOVpEcMDGiHaoHcEdz0qNmXzRGuJblmCrG3HtnP14roJ4zpR1yWBCZtP8As9st11YPIMzMM9DyBn8KNhWUdEZTWdx9ka5VC9sOGdHVgpx09QfbFWLfTZrvT5r63mgZIvlkBmwYyOeSeB1HWpb+2aC+kt7WC6vZZIknaXG7BIyWbJx0OKsx32nx2Yaeyg+zgKhtlHzXEqjrJ2CLnOOck96QnJ2ujJ1Wxmt7lyZ/mb96E3YLbv4hjjv1HpUCSvayiWKRI2KlS390Ywe/f39aS9uZ7y5eW6uPNnwFDIflC/3VHQL06VM8MtrZW0qshMz/ACFMMUAB6+5P5Yqi+lmVk3EKWZBGx6k+/p2FOH+lTYJyi5MZAIjTueOeM/QVMtsz2rXTljGrLvQyAOwPUjI5Gfxra0DTJtS8+7zKbOQ722qBvA/hHv2/WhuwnJRVybw5oct/cC61CExW3UjoZT6bey98jrXcxRpDAkUKLFGqhUVRgAemPSorMlrGB9sy5UELN8zr9SepqfJ5/wAKzbucU5uTDGWG4A9QPenPgAdB3xTQQN2fu8cjt/jSkfPuGPXnmkQJwem339zSgABcAqMdO+PTNDEnIAYDrzSL3zyep96YCHJjwBkfXGRn+VOOcEHnnH1pANzE/Njsen4U1MYHGPUY46e9AAFwvXv3GKVnAIIDZ+mcDPU0DkYPDdMnrmkJwccYP6/5NAxcZyWIw3UevpTSp4JOAAeTz+NKC2DnaOOMd/Wmkbj0yPbv/jQAHkYVhjseT26UU0lVAAIVe2R1ooAnBU4xyMfTFC7sgA9CBz2pFXqyggnnGTjP0pxbr7jqKQCLnA6A56UA5I/n9KDnJHTqee1IDvXJGM4zmgQvAG/BznqetDZDjOSe2OozSrk8dPbrTI12IVXJyTyx6k9aAHHcVBTGenzdvrWf4hsl1LQ7y0A3EqSB0+Ycjn+taJwQCADxkc00p5sbpyNwKjPGcjt780DTs7nihkIXckMj7Rtw6bF/FjUsHBd5AVQk4Ct144x+nNFy4jZraYiSWNtgCDJOCRyPwoxg7d4XOBg+nUH6VsekKGI4Ge4+71Gf51NEP9HAU4dRghecVXcsfmZVbDYXJwCT6Y7+9Pj43fMQeBg84z/PmkBdurS40vUww+WeFlccZVv7rD1Bp39oSpYCyVg1qhLxCQksmeSuRjK5zjPP1qvFM6SyoiJLldjKx3ge+D0/DFTXskL8x25tsdtxZSMdg3PX3pE+pVmnkZDJJk5CRq2SNgUkgD8SeaYGVy7FAGABGDwMUlwEMzPCuOBtGSQPzo24Y4K8cArzmgvSxIdiMViJKDkHnGfX+dMkWMsoRWAIAYscgsep9qVslBheR2wc/Sl5CEcFWGTnr+FMk2/A1xb2eulZiimdfJjkxyGJBCg+h/LiqmrCKM6sv2iUzG6MccATEMcYfcSo7HcO9ULcbIC5kIbPygD5hj+IHtzUl9dSXc/mScyMBvderMB1Pue/09zSsLl9644DN5I8KqVYEDzUGJUIxhh0qijs8EYldWlGAzgbd2O/PtxQbSUL5w3CNTtiBODu64Udfc1ZkOnXFsDcS3VrelmWcQxhkcE/eX0I9O9BeiKtheCKRp0jVyd8QV+MYyuf581rWt8sUTJM3m/MZAMAKWIw2R6Y4H0rNkeJ2git49qQwpAiEfM+By5HPJOSetbug6A9yftWqSPaWMf/AC0kXaZPYA9vfFDJqOO7E02e0uLi3iuLeEQxo4nZo/mkGMgk57eop9ybKB5Y44yQVwFb7wXbnoeh6H2zVLVZII7qU6eJI7c/LFubJI7sfr6VRaR2WMTOyv8AdLMRg89vTtk0rEKN9SbzovtHLkWLKXKNnfnBwFHrnAyTjFNKLcwRiYKkMakgCXBbI5Y+p+X8Bx3qCRI0kKK6ygk/MjZDe2fSlDKi/wCqUlSSVkXIJxVF27EhEiMCxIjkG0op4Zcjggds4NRpETKqsvzKRu3rx15B/wD11MYWaCKRw4eUHBZdysAcHH+NM85IGSUOg2Ekpt3D8QfzpATtEjwYWJVcMX81FIcrnjbn7uDjI7jFJeSSXpknkDrdbESdkbEcqDhS6f3h61aN9d3CQw3BZkYBkUnDbhwDgY5+tQlGIfaigI/8UnIPQgevXr2xQSmxzahdh/MW6kjlC+UJF+R9vp9OBVdbRgPNdJpInOElAK7sHkZPpU6yYcxWlw/lByHuguQoIw2B3H61IkATSEuTPmaSU4QHeykcA4zwx9T0FAbECw/absLFPGjODjLDGB2DHrx+dJBbi+S7nDfuoI1LnG3I4AUDtn0+pppHmRIHmSJ8NuU5UH3zjLH0AqaNwVWMrIqDlgvJLAcMc/5FAbD7W0muLiKKKJZC7BY1ZSUAPQn2969LsLZLGyht41wkaBeDxnv1965bwhbPcXL3n7xYVHlfOd3mEZwPQADHHrXYdAAckjOMioZy1pXdhSeF3YYmgEEEdCRntj60nyj7h+btRjJwPukZBHf/AOvSMReMZ3c+1A6sMfw9egHpS5GT2I79qQgZ2nke9ACOOjAY74x/nNBY4PTgZ+nNL0BwDy3TNIx+cAbuTjn/AD0pgRRXHmSyQ7ZQ8eMsYyFbP909D+FTZX+HoOQvbFNYcfMT9fT2pF3K7EqByeh+9/n0pADgthQfXHAz+BPSlwNpIyGB6560dBt65OAf6e1B4AzgcnIxTGGMLuXHPJyeKb+8IYrgnGOmMenHalAI37gcHAzn/PFJuJBZgSOpJ6UABjHAcAnH8R6n1opgQBAqNs5JJx3ooGSJySF+7nr13GpOmM5K4HGP1NJGMjjHI4IHIpctu9MHnucUhCMxI+XgnuTTuM9TzxgjpRxtxgc/hikYZT+JQCMD/PagAJBG0A9M5BoJwVHc9OgJoPA75x07Yo/TPIPegQmCMn5ue3p70cFQ2CR157UoYnBOMH7vt7UA55GCT6joKBnkXxDgWy+JWjmPIS8srhyCAFaQ7V49zjpVVlUqnmIGMTYAC4QYHJA7HPeuu8fzomraeLq2WSDyJsTlgCr5X5Ceu0g5+tc9BEJJpDIUTcoMbkk7QP4cd/TnNa3ukd8JXhEpBAHMjFC/JBHRQew9KtRxyG4jJZEkUrlmXhcdGbHanW8ETCSS58xYEIR5I0zgnpx6Z79u9QLH8rAyBscYLZz64I70DvcsXFxJsSJrZY3Tc6zxNywZsnOOG79ccY4qmLhIplmiLxXEb+bGSQQrDp/k8VKImcoCkYaTiNvMwD7jt6cU+RJIo2W5gRdg4EiAEnoQWH44oGmkVZ2jDgxSpICMk7SuCTk4B/nT9gTGNxx6DgUr+SmwT2imIg/NH8rHP6YBqERkofmfcG4Xbz+BoKHrLuI46jjjoacGyBzntx0HrSSIoVGLyNI4yAeAMcYx3p8kf+korkIxPK9APcn0oEX9Ps/NhkuHZILWFh5kkhyAT0XA6tjoBViRbKYgSC72g/f2If0H+NRRQyPNDbNIFVcsuWG0e+RxyeM+9UireXJLI5XDbeT1PUj2/lUme7NE6ZpxkbbqUcYOMebbOp/Sp9P0jSY5HOpXrvGMBFSJkDH685/DFZDPkA5dmUghueB6fT3psrl5M5B3jopOB7AdaNQs31OrOt6dpmU0XTY4nAw0sowce/8AF+Zrn7+6ub24kuJjLLJgEtJwAOwA6AfSqkChrVY1j+VSB8oz9Oc5/CkKM0LkFVEZCktJ8+ScfdPLY/SiwRikxspC53EEuMMSBjHXj/OeKYUCdoyzHgkHKipEhZwQscm8dDGeh/2v89KszWUruEQxyyON/wC6beRxnnb0+lO5V7FFcmRd6l1dsBccuf7v1+lOmVYC3mmMSqcbc8H6+lXpbWS3mi82SVLjYHV4Rkk/3V98cH0qtexbLox7z5ynhFIlPr1Gc0Ancknu5Ht4t674lBRVbkBepC+gzzUsdksv2cSOqwyJ+6iWLfI7cY2Kv3vqcVGlsYmjMvmQTo/+tZg+4HBGQ2dqj/Zx6YrYMEZj3pttnRDNFsygk3EgbR3B6duDzSehLaWxiOlxNPNBBbo7xnMnljjg4yzZ5Oepp9xZQQXSLNO0siqC7g/Kwxyvtzxj86mthNYS3FvZzxyFl2vLCnPBztA7Y6ZqxFb2/wDZ9u8amed5G3RKhSMADG1ufvc5/GmNysNW2EssLTQxx2qh2QmYAEKeQ3qB04GearzRxRQw3MUbRLNESrS4Ys+cYjA7+x5q08SW4lEtzbKbM7irgyDJOAgVRhm9TVeDEMkcwO4EbDIg2kFh8wA/wpXJI2h8wtOHBIIDFh8seR/e7nINbHh3TW1B5GuQFtIgGLP93IOeeh6c56Uabo1xqAcqCqniN5B8uM9W9D7Cu1t7OGK3MJjiKyD96oXCyHGCSD1FJszqVLKyJoEjEUf2fHlgfKB057j1z609sdlA/HtQgCRgKuEUbRgY/ChclflIBJzkc1JzCjpknHHOccUBQe2R3pBnbuGCc889RSjDDpgD9KBC/LvHYjnikb7wXnAGSP6+9IDhMnG0HOf60EcAHPHNAAAGY5yQRSE4PIxg9fUeopVztI3HAH5f5FG7AOOQeRz0pgLtG7tj0zimORnBPOfTp70445JYkfTBoJ5yTwTjHpz/AJ5oAAQMr93t70u4/wATZXpgD2pmMfMOoGcN/n60Fu4wfrjNAw3bgFAGDzg9QP8AP86JOOV6gj/P8qU8knAOOh9fekbnldo7Y7gUAJ8wACrgdc45/WimucY3ZJx127sUUwJNuMgtuBzwTn6n/wCtT87l4/LP9aaFCD5VXHUZ7f8A16exyVzkc9qkBGKsDkBgR6Ug9z7+mKVm+YY5wcHPU0DBXIAx160AMY/OONyk9c04jKg8EDpzjNKMbjxj+tGAIvl7HtQAY+bqOfWjBbBYfN3I7e9LgZx34GfasXxc97HockmmytHKrKzug+YR5+baPXH5UDiruxyXji5t7zXbR388S6W0gWGRQ0DllG2Xj+MDoT0rPFtK8YleZAqcblIdgSc4KjnnrwKsyXbRXStp1z/aUMqr5q3aAKzHqDnnrjpVI3tpcxvdadbD/QrlrS+spG3fZZVPGCDnY2OCD7da0V7HbFNJJEOWSQtHIGGMb4HzuXoSAetSSRCSBLuO7hPIV1wFZOoywH0HIqSOxlu1eRV8kMjzxMAdrqOq5HTHv/OqjxYRZWaT2kxhWPofQ+1Moc0Ztrho7sPE+N4dFDA9wRnqPpU++1eMgSPEyn5njQ7Ze4BTPFRQXFxHCIX8q4g5JgmH3MdCrZBHXtVqeR5ZkvZmt0tpGCLbiN2wuOnY49waQMz3BSRk8xVXjIHQH1+n0psEbu7BHDKM5O8A47kZ64q9eRpcBm0wSrBCnmMMcKx4KAnnnryT0OKRLe4uJyRvlcpvdAo3L6jBwPfHWi476EziU2qw3DpawJl43lDHeWAz0BAOMHNRzhjL5cgt16HdH0weAQPQ1c01ZIpkZJns4JF3kSSKpbHrGfvKfYU3yL2aw+2WItZLcS48u1BEgZSeSmOB1pEFWFpBGuxIZoC4QqcqC3oWGACeoOarsjO+FV2JGN33j+datjcvb+eyw/b3mTyirhhHgc5IIwfTPBFQ3UdlJtltvtdnHtEjwNEZAR0yjA4Iz69KYJ6lSGRlja3VGbAyWJBKkD0+narFtHbtcpHfSLGFXcjRzA8kfKSOoyc9OlXI2fUHWS4dY7RFJ+2XlnFjI+nJ9O9QX2mCGW3t7i73yuvmW5SEJbyIep3DkfUigLrZmevlbiQQ20nBjRs9OCfep7smaEmK1XKIoLGQhnIz821up561Z02Aq7XBKSyRAqEtrkK/oH7Ar69/apNKt7Sa+RLe3Mjyy7B5x3/Zxjg5Hf3Jz6UA2V5bv7RYy2v2+VrVQhHmkLvJHPy9Bzxgg1ZtNR1CaeSO2aO3glXLvFCqIgA+8G4AbjA+vSqis9ncqkpgkaORtyKQwkBOGXpjnrk8+9SXMZNw8CRNbIZAPKu5xuiJONp9skYNIGkPNncxotwPLmlmAl3s/mlhgfeXrnnpToI7xYDaLaRQL5qtkRbZA3VQCSOPbPSqZCwTvZiAPfpJs81DuBz94YPU9MGtxL8aZE8DmUXKIGDSIXUyZ4HHBPXJ6ckUCdxLfTYGd59RdfPJ3um/JyMgnLdOR7kdhWZqeoefbpDmRolciNsnBQ9ueeDUOIrq53zTSByWYRsoZn7/ACknA+hrRgFtMJxp6ytC0e91KqjRBcZLu2QVz6YoFtqxkUUk0UL3F68bIQsTyKY41TOCd4HpwBnJwaiNpNBKYr6J7iE7kXaynb3DLjOD7n1qS5dpbk6fbSXDzPEZSXbZEEG3LBTjbjeo9+tN/s5pmSDyXS4ZghHTefUN3DZzmi4Jk2lRWGJ1ungt7V04l35kB/hCt0BzzjHpXQ2egNNHGt0WjtgS/khvmYnuT2HsOam0bQ5IRbzal5TSxqwWBQCiEnOfc4x+Oa3fv7d2cj3walswnU10I1jjht9sICRKMBVXFSE7xliT3GOMUE4yGI28nI4xSA/Pjncxzn1/wpGIowGI5AA4xSEHaD0I9e1K+1WAbkYPIppAIGeR79fw96AHAnk9Pb0pG4UrggY5AP8AKgN+7Bxzjo3X/wCsaCAN2enoTQAK/JBJ4PJI6+tL8wydpyT2PFJ6bQRxwCOfwoTGWHPHfHUf4UAA+ZcN35we34Uj5LKEAzwMmlLKWwCc7cg0Y5G08++enpTAFJ5IZiBx+FUddvZNP0a9vYLV7ya3jZ0gQ4MmOqj3/rV8dsE8DofT0pq7ck52sOM+tA00ndlW1vbef7IY5CstxAJ44nQrIU4zkdsZAI7GrJVR8oGRuOR6d6Vjh3yOnX0P1pjFdwUdAOMHt1zQA9RlRlhnrkDn600gPt46E4B6GnKBu56Y5IP6UhjAZsYXcMYA6elADGClsklfxFFI24n5VLA85A5ooAnAG3cCGA9qPmC5J4B6+tNTBcEN0HAxxnqeacGJHynK460gDd3BAJ4GemP/ANVDYA4PbvycU7p1yfbv/wDqpMHON3A745oAacFCASBwcDtz0pxyWABwD3/z0oDYAPO3+dB4Oc/MOfXj3oECnIyGyc4GaRs7Cfu8DnFLkfxAg8nnrijHPPQ8YFAHnnjG6A12dUXmMINoxjgdT+JrD0jw1pFpJqOqWV7NanUY9t3YMnmB5d4dZEPYfeHPTJrZ1ODVbXWr+KBY3lvcxeYVGNrHjA7HHaqckKW80QuBMbKNzHNHHw4Cj/PNaJtKyO+DtFJMqwQmVzGdxmzsCsSM/h37YrQeyJsrK4X7Ss0g5V42CABiNjN03fXsaoZIiDYfYrExh/mfYT79SBWgtzZFwjC8e3lTZJGz7vPkXowOTg5wd3bpSHK5XSKVvtcdmHglUNusVbO0Yw/U8gDGR1HFV5Z3eKM2QuoyIfLdmcEOVOAR6jBxTo7W8MDTRwv5cLbZXx/ePUt3Hv0p0GRHZf2hbw/ZnSQRM8Ybac+gI6NzTGQyD98hJeJ0fD5Y7+AMMAePxzxUgs/OvVhlxBI7cS3DFs8cb8ZyenIP1qW0gEpkitY1u5owJNyqSsY6ZOeeuOAKY8d1BKJC8lvM+RlWwXBODyO/agL9Cxd3F3a3bRalsM9qUKx7AwXA+XY45HY4796WcRm886K+YXRRTJIhP71evzFQD2IORkVFeRSTSJO9w8sJiSJkYkyJtY49nznGevA6VeSxvFjKq8DRXSB4xsEpcgdR6NgYJ96VyHZEPmT3F2Z7yO9WJ0VtiPvIyeNuc5GOgxn1qrdZMW6cskoztmMZj3IOBnsSe9S3bLZSRn7JFGRtaRBu2dOGQk5HoR605J4poHkjtLo20Y3XCxzkqPmHXOeD6dc0AVpZZJZ4RGHDKiqvm4IXaOcE8Dvii1ubeMBTaJcKVAVJ3L7PUjGOvtWk6RW00yx28cyFCxlgZ0HlnnaucgHpkjmqVnHseGaOFbiESAtEvHb7pxz+JoC6sOuRYzSGS5Vo5G2skVqoxg/XhcDHy+pphuJ2R0ja4js85KIdqgE9OeoyOuTWtPY29vYS+fHC10UkdGSQttJI2qzdGIFU7NoUljlaG5nZYyIiYwQpxgfKPvKMnOTznvRcSehRRAIyxkjCcKyLKN5PYe/4cVoabcR2kZnunlBAKW8RySxb7zAY6ZAHtTCZrO6kaK4tplt4Dse1hRVh3HH3ccYyemcVVVfMuD5s0sweMyGeM52naflbIz169MZzQPc3dY1CeGWJf3D3YLky7gxMZGFBxg55rJaOKC6+zy3AukaIl3TJCP8A3QTwT7ipLGwZrZYLSKOS5bDzs/KRqPuAP0UZ57k4xiriQ6akgi03drt2g/e7ZhHbxH3YdT6Lkn6UiVZaIgsbRLW9S5RZZYtyiUZHzIeg8vBHUZ9fWlsoLnWbuWRVNukMu2XyFyBJ164AHA5ySATW3qNxNppjGn6GbvVpP41XZbQnGMFycAAYAwOcGmx+HrrVGifxJqS3qRsXWG3Qxw59NoPzYPOTmj1J51u/6+RleIvsFp5za3Z2P2u5fzYdPgkZpZuMZdv7vOSAMcd66nw3K91pNvJNp5sdvywxOdxCjgE55B9qs2mmWVncyz2trGlxLy8wGXYDoM9cDsOlXHAU5JH0x3pN3MpTTVkKTgAgn1JNJxuGDg57f1pSflAXqOMdaRWy20H5hxkjkfhSMhcgEkEEdee1NHC4AJA65pQMHCgZHOKXIIzwBQAhAIBboeT6jmlQZG3t3puMjA5wecnqPWnf3sHHGRQA0HKkZIHqPSl6EdiemfSgjI5UHnOCfamkfMqofl5znnFADgRu6A+vFIRzyMg9cd6DkduTzSA4wB1HGaAA43fKDksM8cEUkbFgPl4fPPT8aUklj1wfzpxyFyn3sYyf6mmAz7pcqBkY/AijbubnBYcr3xSsAcHORjtyKApIGATyeDxxQAYG0FSBng0EZHykDv0pFI+YDDYOPmBHTrQGVx944POBk0AAKsq5GAeM/wCFNG7dkrgHoOCB6mpGx8xzgYyCO34U1MhVJAQAcD1oGDsFOTkjp0yR6dKKAoVgQRkj+LJz+NFIBUztyp2jGefX1NOXC9ST9aRSMY5JzgE047sFhgYHHH4UABXhsDnocdKQnLDGARx7fnQxwQzFhjnIFBP4DtnjFAAScg4/r+FI2RkjgHH554p2Sx78dQKTBCsVAAJ6DvQICdo6bRjueh70oz0OQuMY/wAKF5VgBwTjB6CgAAle3T3/ADoA5jxnbX1y9k9tGrpDueN1JD+Z0wpHTI71yEMk91OIZRdB41wwjABIzjB9OepNdV4+ilZLaeGYgQbi0ay7H5wN+M8jHFcvDNaXSm4vVuGtjvjuLqAkqmDgdB0yRkDP58Va2Oyl8BNfafHHYRXy3DS73ZArMJVTA5yRwBnPFLcyS31pFEkEUtzI25XRdjSICBtA7gD/ADxSg2W22uWCQxNIxlaJi2xeNvyHa2M89O3vTrYXYECwz+ZDvZoJTHmNiASG3dxwQfT0oKJ4NbVWM8EF5bvGoUhVLRlgcfNnpkfgapRytbW0LJGYVljKyK4ytww43beoJyeehxUlq72kphgkkkSN0xDgotwmG3rg85BJ49OnarPhaGO7uJ5ZfLa4hkRovMyBt5IVQ33ccjHPWjYHZJsuO9yl1p1lBbx2M/kpvbIBRSMEtjr+NZ62JN2kQd5NpCScghGH3iSPYZz19ale6hg1m5vLHyru3ucxqZGf9yx/un69MdKmWMX8UKQPLHqVvO8sVtN8vnjAyM9+4yeTmkTsU4418qPefLhlkaKMLHvGcjkg8AEckirNogj0rygksflXkgyj9FYAn04z2NUb4M1nJ5FrDbI7MmxSz7drZKEnO3t07CmXt5HdNcPtaK3ddyxseXk6kZA+bnGPpTHa5t3159sjvbNMl0O7MrgxqG6oN3JyccjpWVc4sdWRHTDMvJSbKE5I7ADjgH86rzTRxLIJhKtxGFd41HMvuvygqRxweKlN/ayoGjeaGRXM0gu4wyv0BYLj7x9sUWGo2JbcXaWeyGe4Ftbwloz5oHlKW5L46c5IzV2DUpotDih06VIb2WRd0y4GecH5TnsBz05rAM32GYXuYYHLkosjlyn++uMnI/hxjnrVVdTAmllWFIi0bRFEyN4bO44H3eCD/KnYfs3I3bm6ui0VpfRW2IiZPKaMb2+bBGV5zyT2wKoLdRRJKyN5qoWxISfLk6AJuJ+bHXAGOKxtQ1Eyop86YJsEYJYruAH97O7HtmpLfVb+6ZBp0V1dyxYVVitspGoH8Jxj6nk0+UtUnY0baWBDFLqM0LxguPLB+cryDvA6knHHQe9RprE0JAtLcLmPaGc5yD1PpyOCDToPCGv30KuYEtSD8onk2ke/GTW9YfDqJlD61fzTHn9zBmNef9o8n68Ue6txOVKO7MbTdWGq30Gl3ItriV5f3doGJhUgfMzKv3uD3OB3rvtJ068S3ePVnszGkgeCK1i2LEB0y3cn8BVzS9LsNKgMOnWlvbxdxGmCfqep/Grp5VSCc+/es2+xyVKqk/dVkIFDIUAAQ+39KZHGiOdpCjHKcYB9fxqTDc4Jx2powcAjPHJxjNIxEkdY1LYcqWwdoJOTx2p24KcEZ44A55pzDnIPAppwArKxxj65oAUEHHGADnjmkX72RnBPI6cUo47jOMdcY+tAPzYB5PoP5UABJUZ4U96Q53ZGCMc//WpMllO7AA565NSHnnIDenagBi7V27sDjINIvXGfm7YNOAAzjIGc0n3UBQYbvj/69AB0OeDj060i/KBg8HBGexpQ3zYPXjj09/pSdgSAADk55/H60wGjPzBnLbudvTAPanuSMHC8gfn6UnOeOfqev1o2qoyqjPWkApBZiVIIJ78im8DAUqcdc9qkwMDZjnnPQ0zngNt6ZYDsKYEVwsrbWiEfmf7ecbe+Md8dKeScgE53dcd/88U45UYGDnvnnFAJyBnkfjx/SgBCw3MG+bGAefX/AOvTiuQT1AOD/wDWqIOu5Rv4yQcnpxz9aeOTk84PQelAAGHJyM7ee4/GjJCjIDEc+9KW5A3ckZBx17ZzSHOcHPsSetAyOTB4B/75HT86KecFBuOR2LY5ooAfnKgoB65pQOQcDHWmKQSHySenpTj8q4XHHPNIB3JBAxn68fnTSQVyuSO2Tgg0o+/g7cfyFJ8272HUetAhxPyjJwD0ycnNNIyNqkFTzwcY+lKDuyc7QOmeKAwLYABx34/KgBSQFDEE56Zo3Z4wADwBSKGGcYA9vX+lOBJXAUDPQdKAPOPiFb3n9uLcR2d5LbLarumhj3qh3HI7knHNYcOu5Ro7e8cRsFAhaTAUDkcenfGBXsQ4wVIyBwAcVXurK0uI9lxaQTqezxA5/E1XN3OiNdJJNHnF1qsdyYrmWWX7WAwmljABcEDbnAwcc4z9DWNd3UlxNv3yswYtuUKCRng/LwOPTvXpV14R0G5JL6esbcgtCzRn9Dj9Kot4C0gsDC97FjPyrMT+eQeaaaNI1qaOPl1RBdwSbGlEOJWW5cuDIT94Y5GRjI9qyLfULa+v7oB1up7eQR3DhSpEhBPG7oB075r0YeBNMAKi4vQpwSA4+90z0/Slk8A6CIY0jtpYrpCf9KRyJXz13now9iOKalEtV6S7nHWt5bLG0dzHEAeGkBbehHfb93Ht3phvWaC1ZGkWdNpJdwzo2OsZ7LwPpzXWjwDZliP7SuyueiqnI9On601fAEDXRa41S8e3HPlBEU9Om/qcfSi6F7Wn3OWXXbmzM8kDsjSkH5ccepAx9445brVzQvElhp2Xa1a/1i7vEhtbK3xuIKk5GeBgbiTx9K6iy8EaAoRpbKWR1Ur+/mZt3uQDj3rbsNM06xYtY2VrbvtHzRRgHH160rxInWptWSPL5rbXbi7eWDRdTtsOzRpGu3YpP3Q2eeMVZtvC2v3MymS3jtU3K26aYdOvQZ5Br1XGVwnUdMdqM5O0Z246ev40ucn6y+iR5zD4C1GWcm7v7YHqZNjSvJk9ycf1BrRtvh7p0cIF3e31yx6spERJz2wOK7Q7lxjLf3Rnv70mP4eAScn6UczJeIqPqZNr4b0a1YtDplruPWSRd5J/H+dbC/JGEACgDovQfhSEEAcZPSnfLgY6DpxU7mLk5biHnhgCffv70Abcnkk9c+/alLYTnjPQ9RSYyxPOOOD6+tAhpBKkAgkkfSnf7LdM9ulBIxljjGeopGGQQcjoM4oAUnLAc4A6+lL83UAMR1piYYfINuM8ev8A9an4GCQMmgBkjLEjsxGwDPygkinjk9+R97OaY77cs5wqjk5pR97k5IPX0oAarb2cFCoGByODxzj1p3zdW4PbvSfQHd3A9aUn5ARk4PPFAABzyqkk49KGzu4IGDkkdqUAZzwfw600nEeV27zwCeR9DigBxIUjluOvNNJbI3HqOuOvvTsneSMD0z/jScAZG0g8YPAoAQqpO4qN2MehHtTjwMjCnHQfypuMFl2/LnA4yfwpSdxyBk9CVNADVOedpwT696CS3KgE9aX5iGAy3HB6Ume5IK9hTAcwJ2gn5ug570gCElgOP8img7ACQT3oYEvggELggkY59BQA4DcuRj8emaQksvO4Z9vzpHABGD36dsf1+tJzsIJJNAACARnBYfmKcVyuOn44/Kg/dIwNmOw5pq/dwrEjoo6mgBd27h8+ymh+AFGPfj+lKjjBwCO44/Dmjg5GOvHJoGMYAKMkhvXZniinARhQruyge/JooC44fxAsQehHpTgoYbs8D074pkDFlQk4BB4HSnH7jAjOM4pAADAdS31PWgYLHBzjrxTuqHtgDpQyApn0OaBDCSMjHOB94/pTvYZ69+n0pqsd23oNxH5VIo3IT356UAM5AU88HkZ6/wCNKd2Msc5460BQCAOAccUqoC5HTnH9aABdoYnA9OOmaR2xjOSSdvCn5fc+1ICWiRuhY84+tLK3JXAx1oAU++QfXNIAdpXoOacCd4Ge1NzulKH7u3+poAVwxAxnHXA6/nQpHQFgD7fzqMMSpPQggA1IFDE5yPoce9AAOAWY4XOQOOPejByRzj0FAO4c45PNIrbiAwByCaAFxjGDkjpSYy2SPYg96UjGcdPSkBO0evr+NAAQ3rgdR60pwCACeTnrTX+6x78/jxQ3y428ZUfzFACnkMwwT646U0fewSm3r7inE4Ld8N3po5YDoM4/CgBzjjGc5/lQPlALkA9evemhsjdxkGn7RhCOuOtADRlsNjHHIFOAbAGSD2zTVO5C2PypMlm29APSgBSM4OSAevfilcEAMv3R6HnP+FNkJXbgnJI5/GkZiJcDj5sZoAVMBeDye2M0u3j5QCp5BzT9oBCjp0pkh2shFACLuB6AYPpRgHj05Iz0pejY9etBG5mLc4bA/KgAPUMBk+3vQeDkkDA4INIxyfwP9KcqjGRxkjPvQALyGLHk+nUim4wG2kBRx0zinKB5Z7e1NYlS2Oy5FACjAXBGCOCc9R/9em4UHzON3TPc80RDESEZ6A4z69qfKoVlAHBJHNACeWAWDDg9c007sqQwGDyCOMegpyqNyqeeOp601uQR7f1pgKOpPocDHGKQDIyVBXt3/KgfPErHgkHOKXblV5I5A4oAYgJXaSQPUd/alwwHA5Pb/PSlVQCfbFNRiXAJznv+FAACpkwN271IxTgADnLKcHJ96ahLK5PrQygydxtBbjvx3/OgA534Xd9MEUuzB3gct13UMNiYB6gk+/NMPJbsBzj1oAkycgAA579KbuYAYySOnFK427QOh49aXOd31Ix9KBjQ4A3Ek9sAUUoCy4EiggDiigWh/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On microscopic section, a polyp exhibits slightly dilated endometrial glands embedded in a markedly fibrous stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16839=[""].join("\n");
var outline_f16_28_16839=null;
var title_f16_28_16840="Placement of inferior vena cava filters and their complications";
var content_f16_28_16840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placement of inferior vena cava filters and their complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/28/16840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16840/contributors\">",
"     Peter F Fedullo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/28/16840/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16840/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16840/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16840/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/28/16840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16840/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/28/16840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical interruption of the inferior vena cava (IVC) to prevent pulmonary embolization was first suggested by Trousseau in 1868 and subsequently performed by Bottini in 1893 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In 1959, Moretz first described external clipping of the inferior vena caval by means of a clip that created a single slitlike channel [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/3\">",
"     3",
"    </a>",
"    ]. This development was followed by the introduction of the serrated Miles and Adams and DeWeese devices that created four channels within the IVC [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transvenous interruption of the vena cava, eliminating the need for general anesthesia and a laparotomy, became clinically feasible in 1967 with the introduction of the Mobin-Uddin filter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Due to the unacceptably high incidence of IVC occlusion associated with use of this device, the Kimray-Greenfield filter, introduced into clinical practice soon thereafter, became the preferred device for transvenous caval interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications for and complications of IVC filters are presented here. Other treatment of deep venous thrombosis and acute pulmonary embolism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only widely accepted and validated indications for IVC filter placement in patients with thromboembolism are listed below. These are discussed in more detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"     \"Anticoagulation in acute pulmonary embolism\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absolute contraindication to therapeutic anticoagulation",
"     </li>",
"     <li>",
"      Failure of anticoagulation when there is acute proximal venous thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other situations in which the placement of an IVC filter is controversial include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A compromised pulmonary vascular bed due to an embolic event, such that another embolic event would be poorly tolerated. Examples include acute hemodynamically massive pulmonary embolism and chronic thromboembolic pulmonary hypertension",
"     </li>",
"     <li>",
"      Proximal venous thrombosis in a patient with poor cardiopulmonary reserve",
"     </li>",
"     <li>",
"      Venous thromboembolism in a patient who has a high risk of bleeding",
"     </li>",
"     <li>",
"      Whether IVC filters should be routinely utilized in patients with anatomically or hemodynamically massive pulmonary embolism is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/9\">",
"       9",
"      </a>",
"      ]. The primary goal of therapy in massive embolism is relief of pulmonary vascular obstruction, but prevention of recurrence is an important secondary consideration. Several factors should be considered prior to placing a filter for this indication:",
"     </li>",
"     <li>",
"      Filter placement in a patient who has experienced complete embolization of lower extremity thrombus exposes the patient to risk without expectation of benefit",
"     </li>",
"     <li>",
"      The site of origin of the embolic event must be such that the filter will provide a beneficial effect. Infrarenal caval filter placement will not be of prophylactic value if the emboli originated in the renal veins, a cardiac chamber, or the upper extremity veins",
"     </li>",
"     <li>",
"      The insertion site may bleed, which can complicate primary anticoagulant or thrombolytic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the increased ease of percutaneous filter placement and the introduction of retrievable devices, IVC filters are increasingly utilized for prophylaxis in patients with a high risk of developing venous thrombosis. Prophylactic filter placement has been used as an alternative to pharmacologic or mechanical prophylaxis (ie, sequential compression devices) in patients with traumatic injuries and in those undergoing spinal, neurosurgical, or bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/10\">",
"     10",
"    </a>",
"    ]. Several series have reported that \"prophylactic\" filter placement is becoming more common than insertion for \"therapeutic\" purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/11-17\">",
"     11-17",
"    </a>",
"    ]. As an example, in a study of the use of vena cava filters from the Nationwide Inpatient Sample (NIS), prophylactic vena cava filter placement increased at a significantly higher rate (157 versus 42 percent) compared with placement associated with deep vein thrombosis or pulmonary embolus over the seven-year period studied (1998 to 2005) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/15\">",
"     15",
"    </a>",
"    ]. The evidence that filter placement reduces the risk of pulmonary embolism or death in these populations is inconclusive. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Effectiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVC filters are inserted percutaneously via a femoral or jugular approach and are usually positioned below the renal veins. Some have suggested that an internal jugular vein approach may be preferred to decrease the risk for subsequent femoral vein thrombosis that could be related to femoral vein injury at the time of placement, particularly in patients receiving prophylactic filters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suprarenal filter placement has proven to be safe, when necessary. Indications for placement of a suprarenal filter include renal vein thrombosis, IVC thrombus extending above the renal veins, and thrombus in the infrarenal IVC that does not provide sufficient room for the filter to be placed above the thrombus and below the renal veins.",
"   </p>",
"   <p>",
"    Vena cava filters have been used in patients who have an upper extremity deep venous thrombosis and a contraindication to systemic anticoagulation, although experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Filters are not a routine part of the management of upper extremity deep venous thrombosis, which is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=see_link\">",
"     \"Primary (spontaneous) upper extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IVC filters are placed with either fluoroscopy or ultrasound guidance. Fluoroscopy requires transportation of the patient to the radiology department and uses intravenous contrast media, which may not be optimal in critically ill patients.",
"   </p>",
"   <p>",
"    Bedside placement of IVC filters with ultrasound (transabdominal, intravascular) has been performed with high rates of success without significant increases in complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. Intravascular ultrasound guidance is advantageous in patients with significant abdominal wounds, those who require turning precautions (eg, spinal injury), and the morbidly obese [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/23,24,26\">",
"     23,24,26",
"    </a>",
"    ]. Additional training is needed to master ultrasound-guided techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/22,25\">",
"     22,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF FILTERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of percutaneous IVC filters have been developed since the introduction of the original Greenfield filter (",
"    <a class=\"graphic graphic_figure graphicRef69737 \" href=\"UTD.htm?4/48/4868\">",
"     figure 1",
"    </a>",
"    ). The newer devices are designed to optimize flow dynamics, maximize clot-trapping capacity, expedite ease of insertion and allow for future removal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/1,2,28,29\">",
"     1,2,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non-retrievable filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several IVC non-retrievable filters are available for use (",
"    <a class=\"graphic graphic_table graphicRef51423 \" href=\"UTD.htm?16/8/16525\">",
"     table 1",
"    </a>",
"    ). Beyond differences in design and material, each differs in terms of the diameter of the introducer system. Another design feature involves the maximal IVC diameter that can be accommodated by the device. Of the currently available filters, only the Bird's nest filter can be seated in an IVC with a diameter greater than 30 mm. The placement of bilateral retrievable filters into each of the common iliac veins is an alternative strategy for patients with an inferior vena cava too large to accommodate non-Bird&rsquo;s-nest filters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Retrievable filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of retrievable filters have also been developed (",
"    <a class=\"graphic graphic_table graphicRef51423 \" href=\"UTD.htm?16/8/16525\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/31-38\">",
"     31-38",
"    </a>",
"    ]. Manufacturer recommendations for timing of filter retrieval vary; retrieval success decreases as duration of placement increases; however, filter retrieval following a prolonged duration of time has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The success of late filter retrieval is dependent upon the degree of strut epithelialization that has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although filter retrieval is achieved in &gt;90 percent of attempts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/36,41-46\">",
"     36,41-46",
"    </a>",
"    ], removal of the filter can be technically challenging and potentially unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/32,47,48\">",
"     32,47,48",
"    </a>",
"    ]. Reasons for failed attempts include excessive tissue ingrowth, thrombus within the filter, and filter tilt. A period of anticoagulation may hasten resolution of the thrombus, allowing for subsequent filter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In spite of a high rate of technical success when filter retrieval is attempted, a high percentage of patients are not scheduled for filter retrieval for a variety of reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The Food and Drug Administration in the United States has expressed concern over the relative infrequency with which retrievable filters are removed and has recommended that &ldquo;implanting physicians and clinicians responsible for the ongoing care of patients with retrievable IVC filters consider removing the filter as soon as protection is no longer needed&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In case series, up to 20 percent of patients were lost to follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/50,53\">",
"     50,53",
"    </a>",
"    ]. Even when posthospital care can be tracked and there is an opportunity for removal, most patients do not have their filters removed primarily because of continued care in an extended care facility or an ongoing indication for the filter.",
"   </p>",
"   <p>",
"    Several studies have found an increased effectiveness of systematic patient follow-up to assure removal of retrievable filters at the appropriate interval after placement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. With such a program in place, up to 75 percent of retrievable filters are successfully removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the obvious theoretical benefit, carefully controlled trials that demonstrate the ability of IVC filters to decrease recurrence rates or mortality from pulmonary embolism have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/1,2,57\">",
"     1,2,57",
"    </a>",
"    ]. A systematic review of retrievable inferior vena cava filters estimated an incidence of pulmonary embolism following filter placement of 1.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/51\">",
"     51",
"    </a>",
"    ]. However, this number combines data from diverse studies; in some, pulmonary embolism was specifically sought, in others only clinically documented pulmonary emboli were reported. A large number of reports on individual filters have been published; however, they often lack clearly defined end points and objective criteria for pulmonary embolism recurrence and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/58\">",
"     58",
"    </a>",
"    ]. Furthermore, with only rare exceptions, these studies do not allow a valid comparison among the different filter types, in terms of both efficacy and complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/59\">",
"     59",
"    </a>",
"    ]. While the data suggest that recurrent embolism is unusual following filter insertion (2 to 4 percent in most series), strong scientific evidence that IVC filters prevent death from pulmonary embolism is not currently available [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the largest trial to date examining the effectiveness of IVC filters, 400 patients with proximal deep venous thrombosis were randomly assigned to either standard anticoagulation alone or anticoagulation plus insertion of a Vena Tech, Greenfield, Bird's Nest, or Cardial IVC filter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/60\">",
"     60",
"    </a>",
"    ]. During the first 12 days after randomization, significantly fewer patients in the IVC filter group suffered pulmonary embolism (1 versus 5 percent). However, after a two-year follow up period, there were no significant differences in survival or symptomatic pulmonary embolism between the two groups, and a significantly higher rate of recurrent deep venous thrombosis was observed among patients who had received an IVC filter (21 versus 12 percent).",
"   </p>",
"   <p>",
"    After eight years of follow-up, a second report on this population was published [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/61\">",
"     61",
"    </a>",
"    ]. Although the overall incidence of venous thromboembolism was similar among patients with and without IVC filters (36 versus 35 percent respectively), patients with filters were more likely to experience DVT (35 versus 27 percent) but less likely to experience a symptomatic pulmonary embolism (6 versus 15 percent). The overall mortality and incidence of postthrombotic syndrome was similar in both groups.",
"   </p>",
"   <p>",
"    Together, these studies suggest that the addition of IVC filter placement to standard anticoagulation results in a reduction in the risk of subsequent pulmonary embolism; however, filter placement increases the incidence of DVT. Filter placement does not appear to increase the overall risk of venous thromboembolism, postthrombotic syndrome, or mortality. Of note, neither these studies nor any others have compared the efficacy of anticoagulation with IVC filter placement in the absence of anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality from filter placement appears to be quite low, regardless of which filter is used. As examples, three deaths (0.12 percent) were reported in a review of 2557 patients undergoing filter insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/2\">",
"     2",
"    </a>",
"    ], and a second series of 1765 insertions had a major complication rate of 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/62\">",
"     62",
"    </a>",
"    ]. Complications of IVC filters include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/51,63-65\">",
"     51,63-65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Local complications (eg, hematoma) related to the insertion process",
"     </li>",
"     <li>",
"      Deep venous thrombosis at the site of insertion",
"     </li>",
"     <li>",
"      Filter migration",
"     </li>",
"     <li>",
"      Filter erosion through the IVC wall [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/66-68\">",
"       66-68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Filter fracture and fragment embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/64,69-72\">",
"       64,69-72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      IVC",
"      <span class=\"nowrap\">",
"       thrombosis/obstruction",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of clinically important complications appear to involve both acute and chronic venous thrombosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute thrombosis &ndash; Acute insertion site thrombosis has been reported in up to 40 percent of patients undergoing filter placement and appears to be more common when using both a femoral approach and a large introducer [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/18,75\">",
"       18,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic thrombosis &ndash; One trial randomly assigned 400 patients to receive an IVC filter plus anticoagulation or anticoagulation alone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. Recurrent deep vein thrombosis was more common in the group that received an IVC filter, both two years (21 versus 12 percent) and eight years (36 versus 28 percent) after insertion. IVC obstruction has been reported in 5 to 18 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accidental entrapment of j-tipped guidewires during central venous catheter insertion [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/76-79\">",
"       76-79",
"      </a>",
"      ], filter migration [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/80-83\">",
"       80-83",
"      </a>",
"      ] and filter embolization [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/84\">",
"       84",
"      </a>",
"      ], are rare complications following IVC filter placement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether concomitant anticoagulant therapy should be utilized following filter placement is unknown. Although filter placement protects the pulmonary vascular bed, it does nothing to lessen the thrombotic predisposition or to decrease the incidence of lower extremity venous thrombosis. Small thrombi are capable of passing through patent filters or through collaterals around obstructed filters; furthermore, direct thrombus extension can occur through the filter itself.",
"   </p>",
"   <p>",
"    Because patients with IVC filters are at risk for IVC thrombosis, insertion site thrombosis, and recurrence of the initial thromboembolic event, continued use of anticoagulants when there are no contraindications is prudent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/2,85\">",
"     2,85",
"    </a>",
"    ]. Although caval obstruction can be asymptomatic, it often results in lower extremity edema, increases the risk of other sequelae of venous insufficiency (eg, stasis ulcers), and results in development of collateral vessels that may serve as a route for recurrent embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16840/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the relative paucity of data on the performance of inferior vena cava (IVC) filters, we routinely employ these devices in the treatment of venous thromboembolic disease when a patient is not a candidate for anticoagulant therapy or has failed anticoagulant therapy. These devices may also be useful in patients with a limited ability to tolerate subsequent pulmonary emboli (eg, patients with acute hemodynamically massive pulmonary embolism or chronic thromboembolic pulmonary hypertension) because they offer superior short-term protection compared with anticoagulation alone. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic IVC filter placement is an option for selected patients at high risk for venous thromboembolism for whom pharmacologic or mechanical prophylaxis is contraindicated or has proven ineffective. Although outcome data on the use of prophylactic IVC filters are mixed, high-risk populations that may benefit include high-risk spine surgery, major trauma, and patients undergoing bariatric procedures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In spite of a high rate of technical success when removal of a retrievable filter is attempted, a high percentage of patients are not scheduled for filter retrieval for a variety of reasons. Even when there is an opportunity, most patients do not have their filters removed primarily because of continued care in an extended care facility or an ongoing indication for the filter. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Retrievable filters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There currently are insufficient data to compare the safety and efficacy of specific types of IVC filters. Until there is more clinical experience with temporary or retrievable filters, clinicians should consider the decision to place a filter irrevocable and, given the absence of long-term follow-up studies, one that requires careful consideration. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/1\">",
"      Streiff MB. Vena caval filters: a comprehensive review. Blood 2000; 95:3669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/2\">",
"      Becker DM, Philbrick JT, Selby JB. Inferior vena cava filters. Indications, safety, effectiveness. Arch Intern Med 1992; 152:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/3\">",
"      MORETZ WH, RHODE CM, SHEPHERD MH. Prevention of pulmonary emboli by partial occlusion of the inferior vena cava. Am Surg 1959; 25:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/4\">",
"      Goldhaber SZ, Buring JE, Lipnick RJ, et al. Interruption of the inferior vena cava by clip or filter. Am J Med 1984; 76:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/5\">",
"      Mobin-Uddin, K, Smith, PE, Martinez, LD, et al. A vena cava filter for the prevention of pulmonary embolism. Surg Forum 1967; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/6\">",
"      Mobin-Uddin K, Callard GM, Bolooki H, et al. Transvenous caval interruption with umbrella filter. N Engl J Med 1972; 286:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/7\">",
"      Greenfield LJ, McCurdy JR, Brown PP, Elkins RC. A new intracaval filter permitting continued flow and resolution of emboli. Surgery 1973; 73:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/8\">",
"      Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004; 164:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/9\">",
"      Tapson VF, Witty LA. Massive pulmonary embolism. Diagnostic and therapeutic strategies. Clin Chest Med 1995; 16:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/10\">",
"      Ozturk C, Ganiyusufoglu K, Alanay A, et al. Efficacy of prophylactic placement of inferior vena cava filter in patients undergoing spinal surgery. Spine (Phila Pa 1976) 2010; 35:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/11\">",
"      Pais SO, Tobin KD, Austin CB, Queral L. Percutaneous insertion of the Greenfield inferior vena cava filter: experience with ninety-six patients. J Vasc Surg 1988; 8:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/12\">",
"      Roehm JO Jr, Johnsrude IS, Barth MH, Gianturco C. The bird's nest inferior vena cava filter: progress report. Radiology 1988; 168:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/13\">",
"      Knudson MM, Ikossi DG, Khaw L, et al. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg 2004; 240:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/14\">",
"      Spencer FA, Bates SM, Goldberg RJ, et al. A population-based study of inferior vena cava filters in patients with acute venous thromboembolism. Arch Intern Med 2010; 170:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/15\">",
"      Moore PS, Andrews JS, Craven TE, et al. Trends in vena caval interruption. J Vasc Surg 2010; 52:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/16\">",
"      Duszak R Jr, Parker L, Levin DC, Rao VM. Placement and removal of inferior vena cava filters: national trends in the medicare population. J Am Coll Radiol 2011; 8:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/17\">",
"      Stein PD, Matta F, Hull RD. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011; 124:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/18\">",
"      Gorman PH, Qadri SF, Rao-Patel A. Prophylactic inferior vena cava (IVC) filter placement may increase the relative risk of deep venous thrombosis after acute spinal cord injury. J Trauma 2009; 66:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/19\">",
"      Richard H 3rd, Widlus DM, Scalea TM. Inferior vena cava filters in trauma: balancing pulmonary embolism prevention with the risk of deep venous thrombosis. J Trauma 2010; 69:1003; author reply 1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/20\">",
"      Ascher E, Hingorani A, Tsemekhin B, et al. Lessons learned from a 6-year clinical experience with superior vena cava Greenfield filters. J Vasc Surg 2000; 32:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/21\">",
"      Watanabe S, Shimokawa S, Shibuya H, et al. Superior vena caval placement of a temporary filter: a case report. Vasc Surg 2001; 35:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/22\">",
"      Haley M, Christmas B, Sing RF. Bedside insertion of inferior vena cava filters by a medical intensivist: preliminary results. J Intensive Care Med 2009; 24:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/23\">",
"      Kardys CM, Stoner MC, Manwaring ML, et al. The use of intravascular ultrasound imaging to improve use of inferior vena cava filters in a high-risk bariatric population. J Vasc Surg 2007; 46:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/24\">",
"      Chiou AC. Intravascular ultrasound-guided bedside placement of inferior vena cava filters. Semin Vasc Surg 2006; 19:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/25\">",
"      Uppal B, Flinn WR, Benjamin ME. The bedside insertion of inferior vena cava filters using ultrasound guidance. Perspect Vasc Surg Endovasc Ther 2007; 19:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/26\">",
"      Killingsworth CD, Taylor SM, Patterson MA, et al. Prospective implementation of an algorithm for bedside intravascular ultrasound-guided filter placement in critically ill patients. J Vasc Surg 2010; 51:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/27\">",
"      Kassavin DS, Constantinopoulos G. The transition to IVUS-guided IVC filter deployment in the nontrauma patient. Vasc Endovascular Surg 2011; 45:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/28\">",
"      Kinney TB. Update on inferior vena cava filters. J Vasc Interv Radiol 2003; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/29\">",
"      Kercher K, Sing RF. Overview of current inferior vena cava filters. Am Surg 2003; 69:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/30\">",
"      Van Ha TG, Dillon P, Funaki B, et al. Use of retrievable filters in alternative common iliac vein location in high-risk surgical patients. J Vasc Interv Radiol 2011; 22:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/31\">",
"      Ku GH, Billett HH. Long lives, short indications. The case for removable inferior cava filters. Thromb Haemost 2005; 93:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/32\">",
"      Millward SF, Oliva VL, Bell SD, et al. G&uuml;nther Tulip Retrievable Vena Cava Filter: results from the Registry of the Canadian Interventional Radiology Association. J Vasc Interv Radiol 2001; 12:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/33\">",
"      Yamagami T, Kato T, Iida S, et al. Retrievable vena cava filter placement during treatment for deep venous thrombosis. Br J Radiol 2003; 76:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/34\">",
"      Asch MR. Initial experience in humans with a new retrievable inferior vena cava filter. Radiology 2002; 225:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/35\">",
"      Ishikawa T, Okabe T, Ogawa K, et al. Usefulness of a second temporary vena cava filter for preventing acute pulmonary thromboembolism. Circ J 2003; 67:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/36\">",
"      Stein PD, Alnas M, Skaf E, et al. Outcome and complications of retrievable inferior vena cava filters. Am J Cardiol 2004; 94:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/37\">",
"      Hoff WS, Hoey BA, Wainwright GA, et al. Early experience with retrievable inferior vena cava filters in high-risk trauma patients. J Am Coll Surg 2004; 199:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/38\">",
"      Mismetti P, Rivron-Guillot K, Quenet S, et al. A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. Chest 2007; 131:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/39\">",
"      Lynch FC. Removal of a G&uuml;nther Tulip filter after 3,006 days. J Vasc Interv Radiol 2011; 22:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/40\">",
"      Garcia-Godoy F, Collins T, Sacks D, et al. Retrieval of inferior vena cava filters after prolonged indwelling time. Arch Intern Med 2011; 171:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/41\">",
"      Given MF, McDonald BC, Brookfield P, et al. Retrievable Gunther Tulip inferior vena cava filter: experience in 317 patients. J Med Imaging Radiat Oncol 2008; 52:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/42\">",
"      Cantwell CP, Pennypacker J, Singh H, et al. Comparison of the recovery and G2 filter as retrievable inferior vena cava filters. J Vasc Interv Radiol 2009; 20:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/43\">",
"      Johnson MS, Nemcek AA Jr, Benenati JF, et al. The safety and effectiveness of the retrievable option inferior vena cava filter: a United States prospective multicenter clinical study. J Vasc Interv Radiol 2010; 21:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/44\">",
"      Lyon SM, Riojas GE, Uberoi R, et al. Short- and long-term retrievability of the Celect vena cava filter: results from a multi-institutional registry. J Vasc Interv Radiol 2009; 20:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/45\">",
"      Hiromatsu S, Nata S, Ohno T, et al. Non-permanent inferior vena cava filters for prophylaxis and treatment of lower limb venous thromboembolism. Vasc Endovascular Surg 2010; 44:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/46\">",
"      Zhu X, Tam MD, Bartholomew J, et al. Retrievability and device-related complications of the G2 filter: a retrospective study of 139 filter retrievals. J Vasc Interv Radiol 2011; 22:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/47\">",
"      Lorch H, Welger D, Wagner V, et al. Current practice of temporary vena cava filter insertion: a multicenter registry. J Vasc Interv Radiol 2000; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/48\">",
"      Imberti D, Bianchi M, Farina A, et al. Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. J Thromb Haemost 2005; 3:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/49\">",
"      Teo TK, Angle JF, Shipp JI, et al. Incidence and management of inferior vena cava filter thrombus detected at time of filter retrieval. J Vasc Interv Radiol 2011; 22:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/50\">",
"      Helling TS, Kaswan S, Miller SL, Tretter JF. Practice patterns in the use of retrievable inferior vena cava filters in a trauma population: a single-center experience. J Trauma 2009; 67:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/51\">",
"      Angel LF, Tapson V, Galgon RE, et al. Systematic review of the use of retrievable inferior vena cava filters. J Vasc Interv Radiol 2011; 22:1522.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm221676.htm (Accessed on March 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/53\">",
"      Lynch FC. A method for following patients with retrievable inferior vena cava filters: results and lessons learned from the first 1,100 patients. J Vasc Interv Radiol 2011; 22:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/54\">",
"      Irwin E, Byrnes M, Schultz S, et al. A systematic method for follow-up improves removal rates for retrievable inferior vena cava filters in a trauma patient population. J Trauma 2010; 69:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/55\">",
"      Minocha J, Idakoji I, Riaz A, et al. Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic. J Vasc Interv Radiol 2010; 21:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/56\">",
"      Rogers FB, Shackford SR, Miller JA, et al. Improved recovery of prophylactic inferior vena cava filters in trauma patients: the results of a dedicated filter registry and critical pathway for filter removal. J Trauma Acute Care Surg 2012; 72:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/57\">",
"      Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest 2002; 122:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/58\">",
"      Vena Caval Filter Consensus Conference. Recommended reporting standards for vena caval filter placement and patient follow-up. J Vasc Interv Radiol 2003; 14:S427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/59\">",
"      Ferris EJ, McCowan TC, Carver DK, McFarland DR. Percutaneous inferior vena caval filters: follow-up of seven designs in 320 patients. Radiology 1993; 188:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/60\">",
"      Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Pr&eacute;vention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/61\">",
"      PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/62\">",
"      Athanasoulis CA, Kaufman JA, Halpern EF, et al. Inferior vena caval filters: review of a 26-year single-center clinical experience. Radiology 2000; 216:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/63\">",
"      Joels CS, Sing RF, Heniford BT. Complications of inferior vena cava filters. Am Surg 2003; 69:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/64\">",
"      Nicholson W, Nicholson WJ, Tolerico P, et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med 2010; 170:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/65\">",
"      Nazzal M, Chan E, Nazzal M, et al. Complications related to inferior vena cava filters: a single-center experience. Ann Vasc Surg 2010; 24:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/66\">",
"      Yeung LY, Hastings GS, Alexander JQ. Endovascular retrieval of inferior vena cava filter penetrating into aorta: an unusual presentation of abdominal pain. Vasc Endovascular Surg 2010; 44:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/67\">",
"      Becher RD, Corriere MA, Edwards MS, Godshall CJ. Late erosion of a prophylactic Celect IVC filter into the aorta, right renal artery, and duodenal wall. J Vasc Surg 2010; 52:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/68\">",
"      Sparrow P. Double whammy: inferior vena cava filter-related perforation and thrombosis of the inferior vena cava and aorta. Circulation 2011; 123:e245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/69\">",
"      Tam MD, Spain J, Lieber M, et al. Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications. J Vasc Interv Radiol 2012; 23:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/70\">",
"      Johnson MS. Vena cava filter fracture: unplanned obsolescence. J Vasc Interv Radiol 2012; 23:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/71\">",
"      Dinglasan LA, Trerotola SO, Shlansky-Goldberg RD, et al. Removal of fractured inferior vena cava filters: feasibility and outcomes. J Vasc Interv Radiol 2012; 23:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/72\">",
"      Vijay K, Hughes JA, Burdette AS, et al. Fractured Bard Recovery, G2, and G2 express inferior vena cava filters: incidence, clinical consequences, and outcomes of removal attempts. J Vasc Interv Radiol 2012; 23:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/73\">",
"      Usoh F, Hingorani A, Ascher E, et al. Prospective randomized study comparing the clinical outcomes between inferior vena cava Greenfield and TrapEase filters. J Vasc Surg 2010; 52:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/74\">",
"      Hajduk B, Tomkowski WZ, Malek G, Davidson BL. Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: a prospective, observational cohort study. Chest 2010; 137:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/75\">",
"      Blebea J, Wilson R, Waybill P, et al. Deep venous thrombosis after percutaneous insertion of vena caval filters. J Vasc Surg 1999; 30:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/76\">",
"      Duong MH, Jensen WA, Kirsch CM, et al. An unusual complication during central venous catheter placement. J Clin Anesth 2001; 13:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/77\">",
"      Vinces FY, Robb TV, Alapati K, et al. J-tip spring guidewire entrapment by an inferior vena cava filter. J Am Osteopath Assoc 2004; 104:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/78\">",
"      Wholey M, Toursarkissian B, Velez G, et al. Technique for retrieval of a guidewire lodged in a vena cava filter. Vasc Endovascular Surg 2002; 36:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/79\">",
"      Stavropoulos SW, Itkin M, Trerotola SO. In vitro study of guide wire entrapment in currently available inferior vena cava filters. J Vasc Interv Radiol 2003; 14:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/80\">",
"      Porcellini M, Stassano P, Musumeci A, Bracale G. Intracardiac migration of nitinol TrapEase vena cava filter and paradoxical embolism. Eur J Cardiothorac Surg 2002; 22:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/81\">",
"      Arjomand H, Surabhi S, Wolf NM. Right ventricular foreign body: percutaneous transvenous retrieval of a Greenfield filter from the right ventricle--a case report. Angiology 2003; 54:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/82\">",
"      Bochenek KM, Aruny JE, Tal MG. Right atrial migration and percutaneous retrieval of a G&uuml;nther Tulip inferior vena cava filter. J Vasc Interv Radiol 2003; 14:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/83\">",
"      Yegul TN, Bonilla SM, Goodwin SC, et al. Retrieval of a Greenfield IVC filter displaced to the right brachiocephalic vein. Cardiovasc Intervent Radiol 2000; 23:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/84\">",
"      Rogers NA, Nguyen L, Minniefield NE, et al. Fracture and embolization of an inferior vena cava filter strut leading to cardiac tamponade. Circulation 2009; 119:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/85\">",
"      British Committee for Standards in Haematology Writing Group, Baglin TP, Brush J, Streiff M. Guidelines on use of vena cava filters. Br J Haematol 2006; 134:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16840/abstract/86\">",
"      Raju S, Hollis K, Neglen P. Obstructive lesions of the inferior vena cava: clinical features and endovenous treatment. J Vasc Surg 2006; 44:820.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8212 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16840=[""].join("\n");
var outline_f16_28_16840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF FILTERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non-retrievable filters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Retrievable filters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8212\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8212|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/48/4868\" title=\"figure 1\">",
"      Vena cava filter models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8212|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/8/16525\" title=\"table 1\">",
"      Types of inferior vena cava filters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=related_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27754?source=related_link\">",
"      Primary (spontaneous) upper extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_28_16841="PCLBCL- LT Bcl-2 staining";
var content_f16_28_16841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous diffuse large B-cell lymphoma, leg type Bcl-2 protein expression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Primary cutaneous diffuse large B-cell lymphoma, leg type commonly demonstrates strong expression of Bcl-2 protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16841=[""].join("\n");
var outline_f16_28_16841=null;
var title_f16_28_16842="Infectious complications in liver transplantation";
var content_f16_28_16842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infectious complications in liver transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Nina M Clark, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Scott J Cotler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/28/16842/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/28/16842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the past decade, survival rates after liver transplantation have steadily improved, with one-year survival exceeding 85 percent. The improved survival has been attributed to a number of factors including new and more conservative use of immunosuppressive agents, improved diagnostic methods for identifying and preventing infections, and better surgical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific factors (preoperative and postoperative) that increase the risk for infection in liver transplant patients will be reviewed here. The most common pathogens responsible for infection at three key time points (the first month after transplant, months one through six, and after the initial six months) will also be discussed. Other issues related to liver transplantation and infections in solid organ transplant recipients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in liver transplantation, morbidity and mortality due to infectious complications remain major problems. In many centers, infection is the most frequent cause of death following liver transplantation even though deaths related to infectious diseases in nontransplant settings have steadily decreased. In an autopsy series, for example, infections were the cause of death in 64 percent of 321 transplant patients who died between 1982 and 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/2\">",
"     2",
"    </a>",
"    ]. The most common types of infection were bacterial (48 percent), fungal (22 percent), and viral (12 percent). In another report, up to two-thirds of all liver transplant patients had at least one episode of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3\">",
"     3",
"    </a>",
"    ]. Other series have observed infection rates of 1 to 2.5 episodes per patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Infection is the most common cause of fever in liver transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several principles of infection in solid organ transplant recipients are important to recognize [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms of infection are often attenuated in the setting of immunosuppression.",
"     </li>",
"     <li>",
"      The variety of possible pathogens is quite broad but is influenced by the timing of infection in relation to transplantation.",
"     </li>",
"     <li>",
"      Antimicrobial agents used to treat infections can have important drug interactions with immunosuppressive medications.",
"     </li>",
"     <li>",
"      Infection may be more severe and progress more rapidly compared to immunocompetent hosts.",
"     </li>",
"     <li>",
"      Infection risk is determined by a patient's \"net state of immunosuppression\" [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"       8",
"      </a>",
"      ], a balance contributed to by factors such as the dose, type, and duration of immunosuppressive therapy, the presence of indwelling devices such as catheters, nutritional status, metabolic conditions, certain immunomodulating viral infections, graft function, and underlying diseases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link&amp;anchor=H14#H14\">",
"       \"Infection in the solid organ transplant recipient\", section on 'Net state of immunosuppression'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of risk factors for infection before transplantation permits the optimal use of strategies for preventing infections in the post-transplant setting. Although the ability to accurately predict a patient's risk of infection after transplantation remains limited, there are some risk factors that can be modified, when recognized, such as the cytomegalovirus serostatus of the transplant donor and recipient. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Herpesviruses'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One important risk factor is the presence of a latent or unrecognized infection in either the transplant donor or recipient. Such infections may reactivate and cause significant morbidity after the introduction of immunosuppressive therapy. As a result, potential transplant donors and recipients are routinely screened for infections such as those due to cytomegalovirus and other herpesviruses, tuberculosis, hepatitis B and C, syphilis, and human immunodeficiency virus (",
"    <a class=\"graphic graphic_table graphicRef59792 \" href=\"UTD.htm?31/17/32028\">",
"     table 1",
"    </a>",
"    ). This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pre-transplant colonization of liver transplant recipients with organisms such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) can lead to post-transplant infection with these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, MRSA and VRE colonization are not contraindications to transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various other risk factors for infection after liver transplantation have been reported. Many are related to surgical complications of the transplant operation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, in a series of 101 patients, risk factors for infection included a prolonged operative time (&gt;12 hours) and reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/12\">",
"     12",
"    </a>",
"    ]. Two pre-transplant variables were predictive of infection; a serum alanine aminotransferase concentration above 60",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    was associated with an increased risk of all types of infection, and a T",
"    <span class=\"nowrap\">",
"     helper/suppressor",
"    </span>",
"    ratio &le;2.8 was associated with an increased risk of viral and fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other reports, the risk of bacterial infections was increased in patients who had undergone Roux-en-Y biliary anastomosis rather than choledochocholedochostomy, had multiple abdominal surgeries, or had cytomegalovirus (CMV) infection in the postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. Similar risk factors have been identified for post-transplant fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3,14-16\">",
"     3,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV infection increases the risk of other infections, which may in part be due to the immunomodulatory effects of this virus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3,8,13\">",
"     3,8,13",
"    </a>",
"    ]. Patients who develop rejection or who have poor graft function after transplant are also at increased risk of infection because they receive a more aggressive immunosuppressive regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to screening potential liver donors and recipients for infection as noted above, there are three general approaches to the prevention of infections in liver transplant patients. The first involves vaccination, the second involves the universal administration of prophylactic antimicrobials to patients at increased risk for specific infections, and the third involves preemptive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"     8",
"    </a>",
"    ]. These strategies are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients awaiting liver transplantation should receive appropriate vaccinations before transplantation since anti-rejection immunosuppressive medications may prevent optimal responses to vaccination post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/17\">",
"     17",
"    </a>",
"    ]. Although efficacy is decreased after transplantation, certain vaccines such as pneumococcal and influenza vaccines should be repeated after transplantation in an attempt to lower the risk for these diseases. As a general rule, live vaccines should be avoided in transplant recipients due to the risk of disseminated disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"     \"Immunizations for patients with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibacterial and PCP prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of surgical site infection (SSI) is higher in liver transplant recipients compared to other solid organ transplant types and can cause considerable morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/18\">",
"     18",
"    </a>",
"    ]. Antibiotics are administered at transplantation in an attempt to prevent SSIs including wound and intraabdominal infection, although they do not provide complete protection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/19\">",
"     19",
"    </a>",
"    ]. Skin and intestinal flora are common SSI pathogens and it is important to recognize local epidemiologic patterns and recent colonizing or infecting organisms in the transplant recipient and donor when choosing antibiotics for prophylaxis. The use of antibacterial agents around the time of transplantation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link&amp;anchor=H7#H7\">",
"     \"Prophylaxis of infections in solid organ transplantation\", section on 'Antibacterial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients without sulfonamide allergy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    is generally administered after liver transplantation for 3 to 12 months, primarily to reduce the risk of Pneumocystis jirovecii (carinii) pneumonia (PCP), but it also helps to prevent infections with Listeria monocytogenes, Nocardia asteroides, Toxoplasma gondii, and many common urinary, respiratory, and gastrointestinal bacterial pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8,20,21\">",
"     8,20,21",
"    </a>",
"    ]. One single strength tablet is taken daily or one double strength tablet is taken three times weekly. Routine use of trimethoprim-sulfamethoxazole prophylaxis has virtually eliminated PCP infection in the post-transplant setting in comparison to a 10 to 12 percent incidence in earlier series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who are intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , second-line PCP prophylaxis agents can be used, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/5/11350?source=see_link\">",
"     atovaquone",
"    </a>",
"    . However, these medications do not provide the broad-spectrum activity that trimethoprim-sulfamethoxazole does against pathogens other than PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    is allergy. Myelosuppression can also occur, but it is uncommon at the doses used for prophylaxis. Oral trimethoprim-sulfamethoxazole in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can affect tubular secretion of creatinine and increase serum creatinine levels without necessarily decreasing renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/23\">",
"     23",
"    </a>",
"    ]. In higher doses (such as those needed to treat PCP), it can also exacerbate the nephrotoxicity of cyclosporine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     \"Cyclosporine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Herpesviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus remains the most important viral infection in liver transplant recipients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    have been incorporated into strategies designed to prevent CMV disease in patients at risk of CMV reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. As a result, the incidence of CMV disease in the post-transplant setting has declined [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Herpesviruses including herpes simplex (HSV) types 1 and 2, varicella-zoster virus (VZV), and cytomegalovirus can be significant pathogens after transplantation. Without prophylaxis, approximately 50 percent of patients with HSV will have a recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/29\">",
"     29",
"    </a>",
"    ]. Antiviral agents used to prevent CMV infection also have activity against HSV and VZV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prophylactic and preemptive CMV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at greatest risk of CMV infection are those without preexisting immunity. As a result, liver transplant recipients who are seronegative for CMV and receive an organ from a CMV seropositive donor",
"    <span class=\"nowrap\">",
"     (D+/R-)",
"    </span>",
"    develop CMV reactivation at a high rate, while CMV seropositive recipients (R+) have a modest risk of reactivation and CMV",
"    <span class=\"nowrap\">",
"     D-/R-",
"    </span>",
"    recipients have the lowest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Cytomegalovirus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    CMV not only has direct effects on tissues that it infects but also has indirect effects resulting from its ability to modulate the immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/30\">",
"     30",
"    </a>",
"    ]. CMV infection is associated with an increased risk of bacteremia and invasive fungal infections and an almost fourfold increase in the risk of death within one year of transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. In addition, CMV infection has been associated with an accelerated course of hepatitis C virus recurrence and allograft loss after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Thus, strategies to reduce the risk of CMV reactivation can also reduce the risk of related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have described varied approaches to prevention including prophylaxis and preemptive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. CMV prophylaxis refers to giving an anti-CMV drug to those at increased risk of CMV reactivation (eg, CMV",
"    <span class=\"nowrap\">",
"     D+/R-,",
"    </span>",
"    <span class=\"nowrap\">",
"     D+/R+,",
"    </span>",
"    <span class=\"nowrap\">",
"     D-/R+),",
"    </span>",
"    while preemptive therapy refers to giving an anti-CMV drug only when there is evidence of CMV replication (eg, by CMV antigenemia or PCR of the serum). Both strategies reduce the risk of CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    , a valyl-ester prodrug of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , has a bioavailability of nearly 70 percent (compared to 7 percent for oral ganciclovir) and at doses of 900 mg daily produces serum ganciclovir levels that are similar to that measured with intravenous administration of ganciclovir administered at 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily. Thus, many transplant physicians prefer valganciclovir over oral ganciclovir for the prevention of CMV reactivation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link&amp;anchor=H5#H5\">",
"     \"Cytomegalovirus infection in renal transplant recipients\", section on 'Valganciclovir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has been approved by the US Food and Drug Administration for the prevention of CMV reactivation in renal, lung, and pancreas transplant recipients, it was not approved for liver transplant recipients because a clinical trial showed an increased incidence of CMV disease compared with those who received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    in patients who had undergone liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Despite concerns raised by this trial, valganciclovir is used widely among liver transplant recipients because its bioavailability and ease of administration make it a more attractive option than oral and intravenous formulations of ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Universal CMV prophylaxis has additional benefits since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    are active against other herpesviruses including varicella-zoster (VZV), HSV, and Epstein-Barr virus (EBV) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"     8",
"    </a>",
"    ]. The use of CMV prophylaxis also reduces the risk of other infections and complications by reducing infections that occur more commonly in patients with CMV reactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/40\">",
"     40",
"    </a>",
"    ]. As an example, in a retrospective study of 192 liver transplant recipients, there was a significant reduction of bacteremia in patients who had received greater than 14 days of CMV prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, CMV prophylaxis reduced the risk of biopsy proven rejection in liver transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend CMV prophylaxis in all CMV",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    liver transplant recipients due to the high rate of CMV infection and disease in this group. It is also reasonable to use CMV prophylaxis in CMV R+ individuals, although preemptive therapy (monitoring CMV PCR or antigenemia and initiating therapy if positive) is an acceptable alternative. These recommendations are in accordance with the 2009 American Society of Transplantation guidelines and the 2010 International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The choice of drug and duration of prophylaxis vary among transplant centers, but most centers use antiviral CMV prophylaxis for three to six months after transplant, and during intensification of immunosuppression for rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"     8",
"    </a>",
"    ]. Approaches for the prevention of CMV disease in other types of solid organ transplantation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who do not receive CMV prophylaxis, an antiviral with activity against HSV and VZV (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ) should be given during the first three to six months after transplantation and during periods of intensified immunosuppression (treatment of graft rejection) or other \"stresses\" (concomitant infection or surgery).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fungal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida is the predominant fungal infection encountered after liver transplantation, with a shift towards infection due to non-albicans Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/46\">",
"     46",
"    </a>",
"    ]. The role of prophylaxis for fungal infections in liver transplantation has not been well studied, although it is used commonly.",
"   </p>",
"   <p>",
"    The 2009 Infectious Diseases Society of America guidelines for the management of candidiasis recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 to 400 mg [3 to 6",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily) OR",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily) for at least 7 to 14 days as postoperative antifungal prophylaxis for liver transplant recipients at high risk of invasive fungal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients considered to be at high risk include those with the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative renal failure",
"     </li>",
"     <li>",
"      Fulminant hepatic failure",
"     </li>",
"     <li>",
"      Prolonged preoperative hospitalization (particularly in intensive care)",
"     </li>",
"     <li>",
"      Use of preoperative broad-spectrum antibiotics",
"     </li>",
"     <li>",
"      Large transfusion requirements",
"     </li>",
"     <li>",
"      Early retransplantation or complications requiring return to the operating room",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An observational, single center study found that prophylactic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    products (amphotericin B deoxycholate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    ) in high risk patients as defined above significantly reduced the incidence of fungal infections and reduced overall costs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/48\">",
"     48",
"    </a>",
"    ]. However, this study has been criticized because a number of Candida \"infections\" that were diagnosed in the no-prophylaxis group likely represented colonization rather than true infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/49\">",
"     49",
"    </a>",
"    ]. A meta-analysis of 10 randomized trials of antifungal prophylaxis in 1106 liver transplant recipients revealed that antifungal prophylaxis did not reduce total mortality, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis decreased invasive fungal infections by 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A better understanding of the optimal selection of patients at increased risk of fungal infection, antifungal agent, dose, and length of treatment will require additional studies. The use of antibacterial agents around the time of transplantation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link&amp;anchor=H8#H8\">",
"     \"Prophylaxis of infections in solid organ transplantation\", section on 'Antifungal prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of seven studies estimated that, compared with the general population, liver transplant recipients have an 18-fold increase in the prevalence of active Myobacterium tuberculosis infection and a fourfold increase in the case-fatality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/51\">",
"     51",
"    </a>",
"    ]. Although it is optimal to treat latent TB prior to transplantation, it is challenging in liver transplant candidates who may not tolerate the potential hepatotoxicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . Treatment prior to transplantation can be attempted with very close monitoring of liver function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/52-54\">",
"     52-54",
"    </a>",
"    ], but some experts favor beginning therapy after transplantation once liver function has normalized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link&amp;anchor=H14#H14\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\", section on 'Treatment of latent TB'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=see_link\">",
"     \"Treatment of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TIME COURSE OF INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infection and types of infections encountered differ based upon the timing after transplantation, although with changes in immunosuppressive agents over time and the institution of prophylaxis for various infections, the timeline of infection has been altered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, most postoperative infections can be grouped into three major periods: transplant to one month, one month to six months, and after six months (",
"    <a class=\"graphic graphic_figure graphicRef58770 \" href=\"UTD.htm?21/33/22035\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link&amp;anchor=H3#H3\">",
"     \"Infection in the solid organ transplant recipient\", section on 'Risk of infection following transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transplant to one month",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections occurring immediately following transplantation are similar to those seen in immunocompetent hosts following surgery. Bacterial infections predominate; they usually have a nosocomial source such as indwelling stents, central vascular access sites, and external drainage catheters, or are related to foreign bodies, necrotic tissue, or prolonged endobronchial intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two major sites of infection during this time period are the abdomen and the lungs, both of which may be associated with bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/12,55\">",
"     12,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal abscesses and infections of the peritoneum can result from operative complications including biliary leaks, with the predominant pathogens being enteric organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intrahepatic abscesses are often associated with hepatic artery thrombosis.",
"     </li>",
"     <li>",
"      Cholangitis may occur after T-tube obstruction.",
"     </li>",
"     <li>",
"      Wound infections are common [",
"      <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3,19\">",
"       3,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=see_link\">",
"       \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nosocomial pneumonias are particularly common in patients who require prolonged mechanical ventilation. Pseudomonas aeruginosa and Enterobacter species may be recovered from bronchoalveolar lavage specimens. Other common bacterial pathogens associated with pneumonia include Staphylococcus aureus, Klebsiella pneumonia, Stenotrophomonas maltophilia, and Citrobacter freundii [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clostridium difficile colitis can also occur, particularly in the early period following transplantation and in patients requiring prolonged hospitalization. In fact, liver transplantation has been identified as a significant risk factor for C. difficile acquisition in the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of C. difficile colitis was noted to be 8 percent in a series of 467 liver transplant recipients followed from 5 to 1999 days after transplantation, with more than half of these cases occurring in the first month post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/57\">",
"     57",
"    </a>",
"    ]. The intense immunosuppression and frequent exposure to antimicrobial agents that occur shortly after transplantation likely contribute to the increased risk for C. difficile infection in this period. Gastric acid suppression, hypogammaglobulinemia, intraabdominal hemorrhage, systemic infection, and biliary complications may be additional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. However, it has not been demonstrated that organ transplant recipients with C. difficile infection are necessarily at higher risk for severe disease or death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/57,60\">",
"     57,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection is often suspected when patients develop a fever. However, fever is not always present and when present it may also be due to noninfectious causes, such as malignancy, rejection, transfusion reactions, medications, or adrenal insufficiency. In the series mentioned above, noninfectious etiologies accounted for 22 percent of febrile episodes in liver transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a bacterial infection is suspected in a liver transplant recipient, empiric broad-spectrum antibiotics should be initiated until the specific bacterium and its sensitivities can be identified. Antibiotic regimens used for empiric therapy in the early post-transplantation period should include coverage for gram-positive cocci, gram-negative bacilli and anaerobes, with selection of agents that cover resistant organisms that have already been documented in the patient while awaiting microbiological test results. In addition, it is important to consider local hospital epidemiology and resistance patterns in the selection of empiric antimicrobial coverage.",
"   </p>",
"   <p>",
"    Aminoglycosides are usually avoided in solid organ transplant recipients due to their nephrotoxicity, particularly in combination with calcineurin inhibitors. In recent years, there has been a shift toward a higher proportion of infections with gram-negative organisms. An analysis of 233 patients transplanted between 1989 and 2003 found that gram-negative infections accounted for 52 percent of bacteremias from 1998 to 2003, compared to 25 percent of bacteremias from 1989 to 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/55\">",
"     55",
"    </a>",
"    ]. The three most common organisms isolated in bacteremic patients were methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, and Pseudomonas aeruginosa.",
"   </p>",
"   <p>",
"    Candida is also an important pathogen during the first month after transplantation. The bloodstream, surgical wounds, and the urinary tract are common sites for primary infection, which may then disseminate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/46\">",
"     46",
"    </a>",
"    ]. Candida infections may also manifest as esophagitis and superficial infections of the skin (folliculitis) or oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=see_link\">",
"     \"Biology of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Candidemia should be treated aggressively since fungemia is associated with high mortality. In addition, as noted above, a greater proportion of invasive Candida infections among liver transplant recipients in recent years have been due to non-albicans Candida spp, a finding that has significant implications for outcome and treatment as these organisms have been associated with higher mortality and may be less susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    than C. albicans [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H230581572#H230581572\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Empiric antifungal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Except for HSV and unusual situations like donor transmitted viral illnesses such as that due to West Nile virus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/61\">",
"     61",
"    </a>",
"    ], viral infections are uncommon during the first month following transplantation. Without prophylaxis, reactivation of HSV occurs in approximately 50 percent of patients who are seropositive prior to transplant, usually as genital or oral ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     One to six months",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opportunistic infections tend to occur one to six months after transplant due to the cumulative effect of relatively high-dose immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV is one of the most common pathogens causing disease during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/30\">",
"     30",
"    </a>",
"    ]. In the absence of prophylaxis, CMV reactivation occurs in approximately 50 to 60 percent of patients; 20 to 30 percent of these will develop CMV-related disease such as pneumonitis, enteritis, or hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3\">",
"     3",
"    </a>",
"    ]. As noted above, the timeline of infections following transplantation has been altered due to prophylactic therapies. In many cases, primary CMV infection is merely delayed rather than prevented and often occurs after prophylaxis has been stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver transplant recipients who were initially seronegative for CMV but received a graft from a CMV positive donor are at greatest risk for CMV disease, similar to the observations with other organ transplants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    .) Approximately 40 to 60 percent of healthy adults are seropositive for CMV and, following liver transplantation, these patients can experience reactivation of latent virus leading to CMV disease. OKT3, antithymocyte globulin, and retransplantation are additional risk factors for CMV reactivation in the post-transplant period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. The lowest risk is present in a seronegative recipient who receives a liver from a seronegative donor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/24,29\">",
"     24,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CMV disease can present with a variety of symptoms, the most common of which are fever, leukopenia, thrombocytopenia, malaise, and arthralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/64\">",
"     64",
"    </a>",
"    ]. Less frequent manifestations include pneumonia, gastroenteritis, hepatitis, and retinitis.",
"   </p>",
"   <p>",
"    CMV may also affect the allograft. CMV hepatitis may be difficult to distinguish from graft rejection, which is also common during this period. A liver biopsy is helpful in this setting. Findings on liver biopsy suggesting CMV disease include the presence of viral inclusions associated with a mononuclear cell infiltrate and microabscesses. Although somewhat controversial, CMV has also been implicated as a risk factor for ductopenic (ie, chronic) rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of the various methods that have been developed to diagnose CMV infection (serologic testing, histopathology, and shell vial assays), assays that allow for rapid identification and quantification of CMV have proven to be most valuable in the post-transplant setting. These include the CMV antigenemia test and the polymerase chain reaction (PCR) of the blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CMV antigenemia assay incorporates antibodies directed at the pp65 matrix protein of the CMV virus. This test can be obtained relatively quickly, and immunostaining of the antibodies permits quantification of the virus. The CMV PCR is done by DNA amplification and is the most sensitive assay. The PCR test also allows for the quantification of viral load. In one study, renal transplant recipients with symptomatic CMV infection had higher CMV DNA loads than those without CMV disease; patients with primary CMV infection or reinfection also had higher peak viral loads than those with endogenous reactivation of CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/66\">",
"     66",
"    </a>",
"    ]. In another study, the initial CMV viral load and the rate of increase of virus in the blood correlated with the risk of developing CMV disease in liver, renal, and bone marrow transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Either CMV PCR or the CMV antigenemia assay should be used if tissue is not available and CMV infection is suspected. They also allow for the monitoring of viral loads once anti-CMV therapy is instituted. Patients with \"compartmentalized\" CMV (eg, enteritis or retinitis) may not have detectable CMV viremia and therefore additional diagnostic procedures may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8,68\">",
"     8,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV, EBV, respiratory syncytial virus (RSV), human herpesvirus 6 (HHV-6), influenza, and adenovirus may also occur during the period of one to six months following transplant. Of these, EBV is the most important because of its potential to cause post-transplant lymphoproliferative disease (PTLD). Respiratory viruses (such as RSV, parainfluenza, influenza and adenovirus) were uncommon in one prospective series in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EBV replication can be detected in approximately 20 to 30 percent of transplant recipients and in approximately 80 percent of patients receiving antithymocyte globulin and high doses of immunosuppressants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/20\">",
"     20",
"    </a>",
"    ]. EBV infection has a wide range of clinical manifestations including a benign mononucleosis-like syndrome, but the most serious complication of EBV is PTLD, which is associated with a mortality of 40 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"     8",
"    </a>",
"    ]. A major risk factor for PTLD is primary EBV infection after transplant, which occurs when an EBV seronegative recipient receives an organ from a seropositive donor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HHV-6, the cause of roseola infantum in childhood, has become appreciated as a potential viral pathogen in several series of liver transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/7,70,71\">",
"     7,70,71",
"    </a>",
"    ]. The virus, like other herpesviruses, remains latent after initial infection and can reactivate during times of immunosuppression. Detection of HHV-6 post-transplant has been associated with fever, rash, cytopenias, interstitial pneumonitis, and hepatitis. However, it remains unclear whether HHV-6 causes these syndromes by directly damaging tissues or via immunomodulatory effects that enhance CMV reactivation, infection by other pathogens, or allograft dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In one report, two patients with HHV-6 infection, without concomitant CMV infection, had significant graft dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10265?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Aspergillus species",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most fungal infections following liver transplantation are caused by Candida spp., but Aspergillus infections can also occur. In one series, Aspergillus accounted for about 15 to 20 percent of all fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/73\">",
"     73",
"    </a>",
"    ]. A shift in the timing of onset of invasive aspergillosis (IA) in liver transplant recipients has been observed; a study comparing cohorts of patients with IA between 1990 and 1995 and between 1998 and 2001 found that 55 percent of infections in the later cohort compared to 23 percent of those in the earlier cohort occurred at least 90 days after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/74\">",
"     74",
"    </a>",
"    ]. One potential explanation is that CMV prophylaxis may lead to a delay in IA infections, since CMV reactivation is a risk factor for invasive fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common site of aspergillosis is the lung, although it may disseminate to other sites including the central nervous system (CNS). It is the most common cause of CNS infection in liver transplant recipients, accounting for 55 percent of brain abscesses in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/76\">",
"     76",
"    </a>",
"    ]. Mortality of aspergillosis in early series of liver transplant recipients approached 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/77\">",
"     77",
"    </a>",
"    ], but more recent data suggest the outcomes may be improving [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other opportunistic pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection due to Nocardia, Listeria, Cryptococcus, and Mycobacterium tuberculosis can be seen during this time period. The risk for tuberculosis among solid organ transplant recipients is much higher than that of the general population and the post-transplant incidence ranges worldwide from 0.3 to 15 percent, depending upon the country [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/78\">",
"     78",
"    </a>",
"    ]. The disease is presumed to be largely related to reactivation of latent infection, although new infections may also occur in transplant recipients residing in endemic countries. Tuberculosis can have serious consequences when it occurs in the post-transplant setting. Disseminated infection is common in transplant recipients and is associated with a high mortality rate (29 percent in a review of 499 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     After six months",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opportunistic infections are uncommon beyond six months post-transplant in patients who have good graft function since immunosuppression has generally been tapered to a maintenance regimen. These patients usually develop the same types of community-acquired infections seen in the general population, although at an increased rate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"     8",
"    </a>",
"    ]. Transplant recipients may be more susceptible to some pathogens such as Legionella [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/79\">",
"     79",
"    </a>",
"    ], and may experience more severe manifestations of certain infections such as West Nile virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, patients with impaired graft function or those receiving higher levels of immunosuppressive medications are at risk for the infections typically encountered during the period of one to six months after transplant. One of these is Cryptococcus neoformans, which usually causes meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients on chronic immunosuppression often initially have only subtle findings of infection due to attenuation of inflammatory responses by immunosuppressants, but this may be followed by a precipitous decline in status and severe manifestations of infection. Respiratory infections due to pathogens such as Streptococcus pneumoniae and Haemophilus influenzae can be life-threatening if not promptly treated.",
"   </p>",
"   <p>",
"    Chronic or recurrent viral infections including those due to EBV, CMV, hepatitis B (HBV), hepatitis C (HCV), and human herpesviruses-6 and -7 also can lead to complications in the late post-transplant period. As an example, CMV infection can be persistent or occur following prophylaxis discontinuation or following treatment for allograft rejection, with manifestations as described above. In addition, the immunomodulatory effects of CMV and other viruses may increase the risk of opportunistic infections such as PCP and invasive aspergillosis. As mentioned above, CMV infection has also been associated with ductopenic rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic viral infections can also produce damage to the liver allograft (HBV and HCV) or cause secondary tumors during this period, including post-transplant lymphoproliferative disease due to EBV, and hepatocellular carcinoma due to HBV or HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .) Patients who have chronic rejection are more susceptible to chronic viral infections, possibly from the increased immunosuppressive regimens.",
"   </p>",
"   <p>",
"    The endemic fungi, including Histoplasma capsulatum (most often occurring in the Ohio River Valley), Coccidioides immitis (most often occurring in the southwestern United States), and Blastomyces dermatitidis, may also be seen in the late post-transplant period. In one series, the median time to symptoms from histoplasmosis was 11 months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/81\">",
"     81",
"    </a>",
"    ]. Endemic fungal infections may represent reactivation of disease or new infection. Listeriosis has been noted in patients on chronic immunosuppression. It is usually associated with meningitis but can also cause hepatitis and bacteremia. Transmission of Listeria is usually through contaminated dairy products. The stable low incidence of Listeria can be partially attributed to some protection from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis for PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/28/16842/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=see_link\">",
"     \"Treatment, prognosis, and prevention of Listeria monocytogenes infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite advances in liver transplantation, morbidity and mortality due to infectious complications remains a major problem. In many centers, infection is the most frequent cause of death following liver transplantation even though deaths related to infectious diseases in nontransplant settings have steadily decreased. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification of risk factors for infection before transplantation permits the optimal use of strategies for preventing infections in the post-transplant setting. However, there is currently no single test that can accurately predict a patient's risk of infection after transplantation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to screening potential liver donors and recipients for infection, there are three general approaches to the prevention of infections in liver transplant patients. The first involves vaccination, the second involves the administration of prophylactic antimicrobials to patients at increased risk for specific infections, and the third involves preemptive therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (TMP-SMX) be administered after liver transplantation to reduce the risk of Pneumocystis jiroveci (carinii) pneumonia (PCP). It is generally administered for 3 to 12 months. In addition to preventing PCP, TMP-SMX also prevents infections with other sensitive organisms including Listeria monocytogenes, Nocardia asteroides, Toxoplasma gondii, and many common urinary, respiratory, and gastrointestinal bacterial pathogens. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antibacterial and PCP prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytomegalovirus remains the most important viral infection in liver transplant recipients.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      have been incorporated into strategies designed to prevent CMV disease in patients at risk of CMV reactivation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Herpesviruses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antiviral prophylaxis in all CMV",
"      <span class=\"nowrap\">",
"       donor-seropositive/recipient-seronegative",
"      </span>",
"      <span class=\"nowrap\">",
"       (D+/R-)",
"      </span>",
"      solid organ transplant recipients. It is also reasonable to use CMV prophylaxis in CMV R+ individuals, although preemptive therapy (monitoring CMV PCR or antigenemia and initiating therapy if positive) is an acceptable alternative. The choice of drug and duration of prophylaxis vary among transplant centers, but most centers use antiviral CMV prophylaxis for three to six months after transplant, and during intensification of immunosuppression for rejection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Herpesviruses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not receive CMV prophylaxis, we recommend that an antiviral with activity against HSV and VZV (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"       famciclovir",
"      </a>",
"      ) be given during the first three to six months after transplantation and during periods of intensified immunosuppression (treatment of graft rejection) or other \"stresses\" (concomitant infection or surgery). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prophylactic and preemptive CMV therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of infection and types of infections differ based upon the time after transplantation, although with changes in immunosuppressive agents over time and the institution of prophylaxis for various infections, the timeline of infection has been altered to some extent. Nevertheless, most postoperative infections can be grouped into three major periods: transplant to one month, one month to six months, and after six months. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Time course of infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections occurring immediately following transplantation are similar to those seen in immunocompetent hosts following surgery, such as wound infections and infections resulting from technical issues. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Transplant to one month'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opportunistic infections tend to occur one to six months after transplant due to the cumulative effect of relatively high-dose immunosuppression. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'One to six months'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opportunistic infections are uncommon beyond six months post-transplant in patients who have good graft function since immunosuppression has generally been tapered. These patients usually develop the same types of community-acquired infections seen in the general population, although at an increased rate. An exception is certain viral infections; CMV infection may occur in the setting of recently discontinued CMV prophylaxis, and hepatitis B and hepatitis C infections may also reactivate during this period. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'After six months'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/1\">",
"      Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996; 22:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/2\">",
"      Torbenson M, Wang J, Nichols L, et al. Causes of death in autopsied liver transplantation patients. Mod Pathol 1998; 11:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/3\">",
"      Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/4\">",
"      Colonna JO 2nd, Winston DJ, Brill JE, et al. Infectious complications in liver transplantation. Arch Surg 1988; 123:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/5\">",
"      Kim YJ, Kim SI, Wie SH, et al. Infectious complications in living-donor liver transplant recipients: a 9-year single-center experience. Transpl Infect Dis 2008; 10:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/6\">",
"      Singh N, Wagener MM, Gayowski T. Seasonal pattern of early mortality and infectious complications in liver transplant recipients. Liver Transpl 2001; 7:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/7\">",
"      Chang FY, Singh N, Gayowski T, et al. Fever in liver transplant recipients: changing spectrum of etiologic agents. Clin Infect Dis 1998; 26:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/8\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/9\">",
"      McNeil SA, Malani PN, Chenoweth CE, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006; 42:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/10\">",
"      Russell DL, Flood A, Zaroda TE, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008; 8:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/11\">",
"      Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002; 35:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/12\">",
"      Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/13\">",
"      Paya CV, Wiesner RH, Hermans PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/14\">",
"      Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/15\">",
"      Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/16\">",
"      Gladdy RA, Richardson SE, Davies HD, Superina RA. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg 1999; 5:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/17\">",
"      Duchini A, Hendry RM, Nyberg LM, et al. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 2001; 7:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/18\">",
"      San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007; 7:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/19\">",
"      Garc&iacute;a Prado ME, Matia EC, Ciuro FP, et al. Surgical site infection in liver transplant recipients: impact of the type of perioperative prophylaxis. Transplantation 2008; 85:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/20\">",
"      Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/21\">",
"      Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995; 9:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/22\">",
"      Martin SI, Fishman JA, AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/23\">",
"      Lake KD. Management of drug interactions with cyclosporine. Pharmacotherapy 1991; 11:110S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/24\">",
"      Stratta RJ, Shaefer MS, Markin RS, et al. Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 1989; 124:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/25\">",
"      Martin M, Ma&ntilde;ez R, Linden P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994; 58:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/26\">",
"      Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/27\">",
"      Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997; 350:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/28\">",
"      Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/29\">",
"      Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/30\">",
"      Razonable RR. Cytomegalovirus infection after liver transplantation. Liver Transpl 2010; 16:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/31\">",
"      Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/32\">",
"      George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/33\">",
"      Falagas ME, Snydman DR, Griffith J, et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 1997; 126:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/34\">",
"      Humar A, Washburn K, Freeman R, et al. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 2007; 13:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/35\">",
"      Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/36\">",
"      Singh N, Yu VL, Mieles L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/37\">",
"      Singh N, Paterson DL, Gayowski T, et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 2000; 70:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/38\">",
"      Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/39\">",
"      Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/40\">",
"      Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/41\">",
"      Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2006; :CD005133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/42\">",
"      Levitsky J, Singh N, Wagener MM, et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/43\">",
"      Slifkin M, Ruthazer R, Freeman R, et al. Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation. Liver Transpl 2005; 11:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/44\">",
"      Humar A, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/45\">",
"      Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/46\">",
"      Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 2003; 75:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/47\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/48\">",
"      Reed A, Herndon JB, Ersoz N, et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 2007; 13:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/49\">",
"      Huprikar S. Reply: Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 2008; 14:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/50\">",
"      Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006; 25:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/51\">",
"      Holty JE, Gould MK, Meinke L, et al. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009; 15:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/52\">",
"      Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007; 83:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/53\">",
"      Subramanian A, Dorman S, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/54\">",
"      Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002; 74:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/55\">",
"      Singh N, Wagener MM, Obman A, et al. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004; 10:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/56\">",
"      Samore MH, DeGirolami PC, Tlucko A, et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/57\">",
"      Albright JB, Bonatti H, Mendez J, et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int 2007; 20:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/58\">",
"      Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/59\">",
"      Doron S, Ruthazer R, Werner BG, et al. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation 2006; 81:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/60\">",
"      Gellad ZF, Alexander BD, Liu JK, et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis 2007; 9:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/61\">",
"      Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/62\">",
"      Breinig MK, Zitelli B, Starzl TE, Ho M. Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation. J Infect Dis 1987; 156:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/63\">",
"      Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/64\">",
"      Dominguez EA. Long-term infectious complications of liver transplantation. Semin Liver Dis 1995; 15:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/65\">",
"      O'Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988; 2:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/66\">",
"      Hassan-Walker AF, Kidd IM, Sabin C, et al. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/67\">",
"      Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/68\">",
"      Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14:4849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/69\">",
"      Singhal S, Muir DA, Ratcliffe DA, et al. Respiratory viruses in adult liver transplant recipients. Transplantation 1999; 68:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/70\">",
"      Lautenschlager I, H&ouml;ckerstedt K, Linnavuori K, Taskinen E. Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998; 26:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/71\">",
"      Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002; 8:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/72\">",
"      Kusne S, Blair JE. Viral and fungal infections after liver transplantation--part II. Liver Transpl 2006; 12:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/73\">",
"      Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/74\">",
"      Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/75\">",
"      Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003; 3:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/76\">",
"      Bonham CA, Dominguez EA, Fukui MB, et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation 1998; 66:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/77\">",
"      Rossi G, Tortorano AM, Viviani MA, et al. Aspergillus fumigatus infections in liver transplant patients. Transplant Proc 1989; 21:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/78\">",
"      Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/79\">",
"      Singh N, Muder RR, Yu VL, Gayowski T. Legionella infection in liver transplant recipients: implications for management. Transplantation 1993; 56:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/80\">",
"      Kumar D, Prasad GV, Zaltzman J, et al. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004; 77:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/81\">",
"      Freifeld AG, Iwen PC, Lesiak BL, et al. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005; 7:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/28/16842/abstract/82\">",
"      Peetermans WE, Endtz HP, Janssens AR, van den Broek PJ. Recurrent Listeria monocytogenes bacteraemia in a liver transplant patient. Infection 1990; 18:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4588 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-DD2D800F1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16842=[""].join("\n");
var outline_f16_28_16842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibacterial and PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Herpesviruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prophylactic and preemptive CMV therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fungal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TIME COURSE OF INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transplant to one month",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      One to six months",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Aspergillus species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other opportunistic pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      After six months",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/4588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/4588|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/33/22035\" title=\"figure 1\">",
"      Infection timeline SOT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/4588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/17/32028\" title=\"table 1\">",
"      Pretransplant lab evaluation SOT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37176?source=related_link\">",
"      Biology of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10265?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=related_link\">",
"      Cyclosporine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9432?source=related_link\">",
"      Treatment of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/46/745?source=related_link\">",
"      Treatment, prognosis, and prevention of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_28_16843="Genetic syndromes CNS tumors";
var content_f16_28_16843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic syndromes associated with nervous system tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inheritance",
"       </td>",
"       <td class=\"subtitle1\">",
"        CNS tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NF I",
"       </td>",
"       <td>",
"        17q1",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Glioma, meningiomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NF II",
"       </td>",
"       <td>",
"        22q",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Acoustic neuroma, optic glioma, meningioma, ependymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberous sclerosis",
"       </td>",
"       <td>",
"        9q32-34",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Ependymoma, astrocytoma, ganglioneuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Von Hippel-Lindau",
"       </td>",
"       <td>",
"        3p25-26 3p13, 14",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Hemangioblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sturge-Weber disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        AD",
"       </td>",
"       <td>",
"        Chorid plexus papilloma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NF: neurofibromatosis;&nbsp;AD: autosomal dominant.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16843=[""].join("\n");
var outline_f16_28_16843=null;
var title_f16_28_16844="Tests for anaphylaxis mediators";
var content_f16_28_16844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Available tests for the evaluation of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Availability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total tryptase (serum/plasma)",
"       </td>",
"       <td>",
"        <p>",
"         Mature + pro forms of &alpha;/&beta;-tryptases.",
"        </p>",
"        <p>",
"         Maximal elevation above baseline 15 to 60 minutes after onset of anaphylaxis; declines to baseline with a t",
"         <sub>",
"          1/2",
"         </sub>",
"         of ~2 hours.",
"        </p>",
"        <p>",
"         Comparing acute and baseline levels improves sensitivity and specificity.",
"        </p>",
"       </td>",
"       <td>",
"        Thermo Fisher Scientific Inc. (many commercial labs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mature tryptase (serum/plasma)",
"       </td>",
"       <td>",
"        <p>",
"         Mature tryptase.",
"        </p>",
"        <p>",
"         Peaks 15 to 60 minutes after the onset of anaphylaxis and then declines with a t",
"         <sub>",
"          1/2",
"         </sub>",
"         of ~2 hours.",
"        </p>",
"       </td>",
"       <td>",
"        Virginia Commonwealth University*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histamine (plasma)",
"       </td>",
"       <td>",
"        <p>",
"         Peaks 5 to 10 minutes after symptom onset and declines to baseline by 15 to 30 minutes.",
"        </p>",
"        <p>",
"         Histamine may be released",
"         <em>",
"          ex vivo",
"         </em>",
"         by passing basophils in blood through a small-bore needle under vacuum or when blood clots.",
"        </p>",
"       </td>",
"       <td>",
"        Most commercial labs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histamine (24 hour urine)",
"       </td>",
"       <td>",
"        May be elevated in urine collected up to 24 hours after symptom onset, but histamine-containing foods and histamine-producing mucosal bacteria may be problematic.",
"       </td>",
"       <td>",
"        Most commercial labs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N-methylhistamine (24 hour urine)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Some commercial labs (Mayo Clinic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N-methylimidazole acetic acid (24 hour urine)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Research labs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-beta-prostaglandin F-2-alpha (24 hour urine)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Research labs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Available in author's laboratory (LBS).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16844=[""].join("\n");
var outline_f16_28_16844=null;
var title_f16_28_16845="Open globe rapid overview";
var content_f16_28_16845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of open globe injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        May accompany multiple trauma or serious head injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Open globe laceration is considered a tetanus prone wound",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Open globe rupture may be occult",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Inspection (with penlight or preferably a slit lamp):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Obvious corneal or scleral laceration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Volume loss to eye",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Uveal (iris or ciliary body) prolapse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Other iris abnormalities (peaked pupil or eccentric pupil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; 360 degree, bullous subconjunctival hemorrhage (posterior rupture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Intraocular or protruding foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Decreased visual acuity by Snellen or handheld chart, assess counting fingers, hand motion or light perception if unable to see chart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Relative afferent pupillary defect by swinging penlight technique*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immediate ophthalmology consultation for comprehensive eye examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CT scan: non-contrast 1 to 2 mm cuts axial and coronal through the orbits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other studies based on presence and degree of traumatic injury to other anatomical regions (eg, head, thorax, abdomen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Initial treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure nothing by mouth (NPO)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess and treat life-threatening injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid high dose ketamine if rapid sequence induction (RSI) is required",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If RSI is necessary, rocuronium is preferred to succinylcholine for muscle relaxation, although succinylcholine may be used with dexmedetomidine premedication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do not remove any protruding foreign bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoid eye manipulation that will increase intraocular pressure (eg, lid retraction, intraocular pressure measurement, ocular ultrasound)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Place eye shield after initial eye examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Put patient on bed rest with head of bed elevated to 30 degrees if hemodynamic condition allows",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treat nausea and vomiting aggressively (eg, ondansetron 0.15 mg/kg per dose: Maximum dose 12 mg, intravenously)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide sedation, as needed (eg, lorazepam 0.05 mg/kg, maximum dose: 2 mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Provide analgesia (eg, IV fentanyl [1 mcg/kg per dose, maximum initial dose: 100 mcg] or morphine [0.1 mg/kg per dose, maximum initial dose: 10 mg])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Do NOT give any eye drops (eg, fluorescein, tetracaine, cycloplegics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Begin IV antibiotics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Vancomycin (15 mg/kg IV, maximum dose: 1.5 grams)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Ceftazidime (50 mg/kg IV, maximum dose: 2 grams)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Fluoroquinolone for penicillin allergic patients (eg, Ciprofloxacin 10 mg/kg IV, maximum dose: 400 mg, Use with caution in patients under 18 years of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure definitive management by an ophthalmologist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urgent surgical repair, ideally within 24 hours of injury",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * See \"Open globe injuries: Emergent evaluation and initial management, section on Reletive afferent pupillary defect\".",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16845=[""].join("\n");
var outline_f16_28_16845=null;
var title_f16_28_16846="Ovarian volume related to age";
var content_f16_28_16846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Ovarian volume related to age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 374px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 95% upper confidence limit (mean + 1.96 x SD) shows the upper range into which individual normal ovarian volume measurements will fall. Mean values are indicated by solid green circles. Bars indicate mean + 1.96 x SD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Pavlik EJ, DePriest PD, Gallion HH, et al. Ovarian volume related to age. Gynecologic Oncology 2000; 77: 410. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16846=[""].join("\n");
var outline_f16_28_16846=null;
var title_f16_28_16847="Bunion PI";
var content_f16_28_16847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bunion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 569px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A bunion is a bony, often painful bump on the outer edge of the big toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_28_16847=[""].join("\n");
var outline_f16_28_16847=null;
             